Ever 2018 Eupo 2018

European Association for Vision and Eye Research European University Professors of Ophthalmology EVER 2018 Annual Congress October 4-6, 2018 EUPO 2018 Course on Retina, Intraocular Inflammation & Uveitis October 3-4, 2018

Programme book

Nice, France

www.ever.be www.eupo.eu European Association for Vision and Eye Research

EVER

20October 17-1919 in Nice, France

www.ever.be 1 Table of contents

Word from the president ...... 2 About EVER ...... 3 EVER Membership...... 4 Speakers’ affiliation to scientific sections...... 5 Composition of the board 2018 ...... 8 Venue...... 10 Congress information ...... 11 Programme information...... 15 Grants and prizes ...... 16 Floorplan ...... 18 Partners of EVER ...... 20 About the programme book ...... 22 Scientific sections 2018 ...... 23 Courses ...... 25 Thursday, October 4 Welcome by EVER 2018 President, Alain BRON...... 28 EVER-Acta lecture by Gisèle SOUBRANE...... 28 First morning session...... 29 EVER lecture...... 32 Second morning session...... 33 Noon session...... 36 Keynote lecture: Rajandra APTE...... 37 First afternoon session...... 38 Poster session...... 41 Second afternoon session...... 49 Evening session...... 52 Friday, October 5 First morning session...... 54 Keynote lecture by Leonard LEVIN...... 57 Second morning session...... 58 European Ophthalmology Heritage lecture by Jean-Jacques DE LAEY...... 61 Noon session...... 62 First afternoon session...... 65 Poster session...... 68 Section Business Meetings...... 77 Second afternoon session...... 78 Keynote lecture: Christine CURCIO...... 81 Evening session...... 82 General Assembly...... 85 Saturday, October 6 First morning session...... 88 Ophthalmic Research Lecture by Francesca M CORDEIRO...... 91 Poster session...... 92 Second morning session...... 101 Noon session...... 105 First afternoon session...... 108 Second afternoon session...... 112 Prize Award Ceremony & Closing Remarks...... 116 EUPO Course, Wednesday October 3 and Thursday October 4 EUPO programme...... 117

19 Presenting First authors...... 126 All authors...... 131 Authors by country...... 147 Sponsors...... 148

Word from the President

Dear Friends for EVER,

It is a great privilege to be the current President of EVER. The executive committee, the EVER board and the logistic staff are working hard to maintain the quality and the attractiveness of this unique meeting in Europe. EVER is a subtle combination of basic and clinical research that is able to satisfy the expectations of both clinicians and researchers, which remains a challenge and one of our greatest ambitions. Listening to your feedback, attendees, speakers and pharma partners included, we have prepared with the commitment of our Program Secretary, Francesca Cordeiro, a new and con- densed format for 2018. We do sincerely hope that this alchemy will produce a fruitful and successful meeting for most of you. I am very heartened by the enthusiasm and the achievements of the young generation to EVER, and I greatly appreciate their contribution. Now we have Gauti Johannesson, representing this new generation and sitting in our EVER board. This year we will have the EUPO course on retina and vitreous diseases during our EVER meeting, another opportunity to welcome our young colleagues. You are kindly invited to participate to the EVER 2018 meeting from Thursday October 4th to Satur- day October 6th in the exceptional venue of Nice. Scientific curiosity, complicity and friendship are the three reasons to attend and learn together.

Alain Bron President EVER 2018 3

About EVER

The European Association for Vision and Eye ophthalmology and the visual sciences. It provides Research, EVER, is a non-profit organisation. an umbrella for other ophthalmological societies to The aims of the association are to encourage re- meet during its annual congress and is an excellent search and the dissemination of knowledge con- place for networking. cerning the eye and vision by means of meetings, publications and exchange of information. EVER is the leading ophthalmological research www.ever.be association in Europe which covers all areas of 4

EVER Membership

EVER currently has members from 50 countries all Elections 2018 over the world and represented by 11 scientific sections. Membership is open to individuals of Cast your vote for the elections of any nationality, engaging in or with an interest in ophthalmic and vision research. Applications for • Chair of section LC: membership - available on www.ever.be - may be Andrzej Grzybowski and Roy Quinlan submitted at any time, membership is on calendar year basis and starts on January 1. Every member • Chair of section RV: must select one of the 11 scientific sections that Aude Ambresin, Deyar Abd Alkader Ibrahim best represents his or her primary area of interest. and Francine Behar-Cohen

They will be elected by online voting. Voting will The benefits of EVER membership are: close on Thursday, October 4, midnight. The result of the elections will be announced • significantly reduced registration fees for annual meeting at the General Assembly on Friday, October 5, 19:15 - 19:45. • submission of abstracts at annual meeting

• organizing Special Interest Symposia (SIS) Website: www.ever.be and Courses On this website, you can • free electronic subscription to the EVER journal, Acta Ophthalmologica (IF 3.324) • obtain up-to-date information about the scientific programme and the EVER 2018 • voting rights for the election of the Board meeting and view the status (session, hour, Members place) of your presentation

• travel supports and poster prizes • pay on-line and print your invoice

• quarterly E-Newsletter • access general information about EVER

• access Acta Ophthalmologica, the EVER journal

• cast your vote for officers

• print CME certificate after each congress you attended 5

Speakers’ affiliation to scientific sections

ACB Anatomy / Cell Biology COS Cornea / Ocular Surface EOVS Electrophysiology, physiological Optics, Vision Sciences G Glaucoma IM Immunology / Microbiology LC Lens / Cataract MBGE Molecular Biology / Genetics / Epidemiology NSPH Neuro-ophthalmology / Strabismology / Paediatric / History PBP Physiology / Biochemistry / Pharmacology PO Pathology / Oncology RV Retina / Vitreous

RV 17%

G 14%

COS 12%

ACB 9%

IM 9%

NSPH 9%

MBGE 8%

PBP 8%

PO 7%

EOVS 4%

LC 4% Download the EVER 2018 Congress App to enhance your congress experience

All congress information in a nutshell:

Information about EVER - Browse sessions by day, type, section, ... - Visit the exhibitors and sponsors - My congress bag: create your personal agenda - Receive the latest news - Make notes - Rate sessions - etc. 7

EVER - European Association for Vision and Eye Research www.ever.be

EVER is the leading ophthalmological research association in Europe which covers all areas of ophthalmology and the visual sciences. One of the main activities of EVER is the organizing of a high quality research meeting every year at a location chosen for its access and congress facilities. EVER collaborates closely with other societies in organising joint meetings during EVER.

EVER - EVER Foundation EVER f f www.ever-f.eu

In 2010, the EVER Foundation was created to raise money to organize EVER f Research Fellowships to offer to young ophthalmologists or young vision scientists, especially from Eastern Europe or from developing countries outside Europe, the opportunity to gain experience in laboratory techniques and scientific research in leading European Departments for Vision and Eye Research. The duration of the fellowship is limited to 6 months.

Acta Ophthalmologica - EVER’s journal eu.wiley.com

Acta Ophthalmologica is the official scientific publication of the European Association for Vision and Eye Research. Acta Ophthalmologica publishes clinical and experimental original articles, reviews, editorials, educational photo essays (Diagnosis and Therapy in Ophthalmology), case reports and case series, letters to the editor and doctoral theses. (IF 3.324) 8

Composition of the board 2018

Executive committee

Alain BRON Thomas FUCHSLUGER Steffen HEEGAARD Francesca CORDEIRO President Secretary General/ Vice President Treasurer Programme Secretary

Rafael I. BARRAQUER Peter WIEDEMANN Andrew DICK Harminder DUA President Elect Vice President Elect Past President EVER f liaison

EVER office by Mecodi

Marlene VERLAECKT Lies VAN EYCKEN Mieke AKKERS Executive Officer Executive Assistant Executive Assistant

Kapucijnenvoer 33, 3000 Leuven, Belgium - [email protected]

www.mecodi.eu

Website and onsite support

COVR - IT solutions for scientific and medical associations www.covr.be 9

Composition of the board 2018

Section chairs

ACB COS EOVS G

Kai KAARNIRANTA Nora SZENTMARY Miguel CASTELO-BRANCO Sayeh POURJAVAN Anatomy / Cell Biology Cornea / Ocular Surface Electrophysiology, physiological Glaucoma Optics, Vision Sciences

IM LC MBGE NSPH

Piergiorgio NERI Rafael I. BARRAQUER Jochen GRAW Dominique BREMOND-GIGNAC Immunology / Microbiology Lens / Cataract Molecular Biology / Genetics / Neuro-ophthalmology / Epidemiology Strabismology / Paediatric / History

PBP PO RV

Manuel Vidal Sanz Frédéric MOURIAUX Peter WIEDEMANN Physiology / Biochemistry / Pathology / Oncology Retina / Vitreous Pharmacology

EVER representatives in Acta Board Aki KAWASAKI & Steffen HEEGAARD

Senior advisor Jean-Jacques DE LAEY

Representative Stephanie BAILLIF, Local representative France 10

Venue

EVER 2018 will be held at the Acropolis Convention Center: 1, Esplanade Kennedy 06364 Nice cedex 4 Nice, France

 www.nice-acropolis.com

The scientific programme of the EVER congress starts on Thursday, October 4 at 08:30 and concludes on Saturday, October 6 at 18:00. 11

Congress Information

Registration

Everyone attending the scientific sessions - whether or not an EVER member - must register and pay the registration fee. Opening hours registration: - Wednesday Oct. 3 from 07:00-18:00 - EUPO Course - Thursday Oct. 4 from 07:30-18:00 - Friday Oct. 5 from 07:30-18:00 - Saturday Oct. 6 from 07:30-15:30

Please note that: • being or becoming an EVER member – or having an abstract accepted – does not imply that you are registered • if you register as a member-in-training, you need to prove your traineeship with a docu- ment signed by the Head of your Department • if you register as an Eye-care, Technician or Nurse, you need to prove your status

Registration fees on-site

EUR Member / Course invited speakers 546 Member-in-training 275 Non-member 960 Non-member-in-training 440 Eye-Care / Technician / Nurse 220 12

Congress Information

Internet access CME credits

Wi-Fi internet access is available in the Convention Continued Medical Education credits Center. Wifi login code: ever2018 We are pleased to inform you that EVER 2018, Nice, France, 04/10/2018-06/10/2018 has been granted 20 European CME credits Photographs (ECMEC®s) by the European Accreditation Council forContinuing Medical Education (EACCME®). It is strictly forbidden to take photographs or videos of the presentations in all lecture halls and Liability posters. Please respect this rule. The organisers cannot accept liability for personal accidents, loss of or damage to private property No-shows of participants and accompanying persons either during, or directly arising from the Meeting. Please note that any first author, whose paper or Participants must make their own arrangements poster has been accepted, will be prohibited from with respect to health and travel insurance. presenting papers at EVER for the next two years if a valid reason is not sent to the EVER office in writ- ing for not presenting. Publication of the abstracts Coffee / tea / refreshments The abstracts of the EVER 2018 congress will be Included in the registration fee are the coffee / published on-line in a special autumn issue of Acta tea and soft drinks offered throughout the whole Ophthalmologica, the EVER journal. Access for meeting. In addition coffee & croissants will be members-only through EVER homepage. served early morning. 13

Congress Information

Section Business Meetings EVER General Assembly

Friday, October 5 from 15:45 to 16:15 Friday, October 5 from 19:15 to 19:45 EVER Section Business Meetings of the scientific in room Hermes sections FOR MEMBERS ONLY Agenda see page 85 • ACB...... Rhodes 4 • COS...... Rhodes 2 Prize award ceremony and • EOVS ...... Rhodes 1 • G...... Rhodes 1 Closing remarks • IM...... Gallieni 1 & 2 Saturday, October 6 from 16:45 to 18:00 in room • LC ...... Hermes Hermes • MBGE...... Gallieni 1 & 2 Agenda see page 116 • NSHP ...... Rhodes 2 • PO ...... Rhodes 3 • PBP...... Rhodes 3 • RV...... Hermes

The sections • ACB • EOVS • MBGE will nominate at least 2 candidates for the succession of their representatives in the Board of EVER for elections in 2019. Agenda see page 77 14

Programme Information

Women 4 EVER YIA Young Investigators’ award session Women 4 EVER wishes to assist women in developing tools for career advancement and to foster The best Rapid Fire abstracts from young authors gender equality in ophthalmology and visual sci- of each section will be presented in these sessions. ence. We encourage mentorship, collaboration, and communication. In this informal and open session, EUPO course we invite all interested members of EVER to come European University Professors of Ophthalmology and meet colleagues, share experiences and ask for advice. It is also a venue where ideas about gen- Each year EUPO organises a 2 days course for der-based studies in ophthalmology may be devel- residents in training. This year, the course is on oped. See page 107. Retina, Intraocular Inflammation & Uveitis and is organized by Prof. Catherine Creuzot and Prof. Coffee with Profs Bahram Bodaghi. Wednesday, October 3 + Thursday, October 4 in the In an initiative to encourage dialogue amongst morning. The EUPO programme can be consulted speakers and EVER members, we have organised a in pages 117-120. session called “Coffee with Profs”. This will be a table of 6-8 “guests” at a table headed by one of the EVER speakers: - Sally-Anne Tsangarides - Mariya Moosajee - Chris Purslow - Marcela Votruba - Aki Kawasaki - Fabiana D’Esposito

The idea is to provide a casual yet personal venue where colleagues, in particular the younger faction, can share comments and ideas with an expert. See pages 41, 68. Please sign in at the registration desk. 15

Women 4 EVER

Saturday, October 6 from 12:30 to 13:45 in room Gallieni 1+2

Coffee with Profs

Thursday, October 4 from 16:00 to 17:00 in poster area Friday, October 5 from 14:45 to 15:45 in poster area

YOS session

Thursday October 4 from 17:00 to 18:15 in Rhodes 2 Followed by a cocktail.

YIA sessions

Saturday, October 6 from 14:15 to 15:30 and from 15:30 to 16:45 in Hermes

EUPO

Wednesday October 3 from 08:30 to 18:00 in Hermes and Thursday October 4 16

EVER section Travel support TS

We are pleased to announce that the following 14 members have received an EVER section Travel Support of 500 EUR each:

TS • ACB - S097 - Giorgia BULLI - Denmark Prevention of glutamate-induced retinal ganglion cell death by UCCB01-144 treatment

TS • COS - S015 - Jan KOSSL - Czech Republic Effects of mesenchymal stem cells on production of cytokines by injured cornea in in vitro and in vivo experimental models TS • COS - S012 - Lauriane ROUX - France Modeling of aniridia-related keratopathy by CRISPR/Cas9 genome editing of human limbal epithelial cells and rescue by recombinant PAX6 protein

TS • EOVS - 33306/F105 - Maria WAIZEL - Switzerland The influence of cataract light scatters on retinal vessel oxygen saturation • G - F047 - Benjamin DAVIS - United Kingdom TS Neuroprotective Activity of Curcumin Nanocarriers in Rodent Models of Retinal Injury • G - F045 - Ehtesham SHAMSHER - United Kingdom TS Resveratrol nanoparticles are neuroprotective in vitro suggesting a potential to cure glaucoma and Alzheimer’s disease • IM - 33502/T111 - Sina ELAHI - Switzerland TS Fine-Tuning of therapy in stromal choroiditis using indocyanine green angiography (ICGA) • LC - S019 - Thibaud GARCIN - France TS Correlations between subjective and objective preoperative assessment of cataract severity • MBGE - F119 - Khaled EL MATRI - Tunisia TS Clinical and Genetic Characteristics of Leber Congenital Amaurosis in the Tunisian Population: experience of the oculogenetic laboratory LR14SP01 • NSPH - F088 - Rachel EVANS - United Kingdom TS Activation of the phosphoinositide 3-kinase pathway promotes axon regeneration of the optic nerve in vivo • PBP - 3616/T100 - Francisco Javier VALIENTE-SORIANO - Spain TS Retinal ganglion cells loss and caspase 3 activation after ocular hypertension • PO - 3143 - Lauge Hjorth MIKKELSEN - Denmark TS High-throughput sequencing reveals no microbial pathogens in ocular adnexal extranodal marginal zone B-cell lymphoma • RV - 3515/T006 - Pankaj KUMAR - India TS A morphological study and expression patterns of iron regulatory proteins in aging Wistar rats retina after iron overload • RV - 33506/T027 - Diogo REIS CABRAL - Portugal TS Predictive biomarkers in OCT-Angiography of peripheral nonperfusion in retinal venous occlusions

The Travel Support certificates will be handed over during the Prize Award Ceremony on Saturday, 16:45 in Hermes. 17

EVER PP Poster Prizes

Poster Prizes will be awarded for the best posters across all sections.

The winners will be chosen by the poster moderators and will be announced in the Prize Award Ceremony on Saturday, 16:45 - 18:00 in Hermes. No prize will be given after the congress. The winners will be waived registration to the EVER congress 2019.

Young Investigators’ Award

The best Rapid Fire abstracts from young authors of each section will be presented in these sessions. 18

Floorplan - Acropolis Convention Center, 2nd floor

Poster area

Rhodes 2 Rhodes 3 Exhibition area

Rhodes 1 Rhodes 4

Speakers room Registration Gallieni 1&2 area

Mykonos restaurant Hermes 112 - Experimentica Ltd. 112 -Experimentica 100 -Dice 101 -DiagnosysUKLtd 113 -CarlZeiss 105 -ARVO 101 -DIA 104 - PHARMA 102 -NOV 103 -SANTHER 100 -DICE 105 -AR THEA PHARMA GNOSY PHARMA CEUTICALS ARTIS S UKLT VO A D 108 -Quantel-Medical Pharma 102 -Novartis 111 -Metrovision 109 -IrisPharma 110 -HorusPharma 102 105 103 104 100 101 Registration area

Exhibition area P oster area Exhibition area 107 113 112 111 110 109 108 106 108 -QU 112 -EXPERIMENTICA 110 -HORUSPHARMA 111 -METROVISION 109 -IRISPHARMA 106 - 113 -CARLZEISS 106 -Wisepress 104 -TheaPharma 107 -SOE Pharmaceuticals 103 -Santhera 107 -SOE WISEPRESS ANTEL-MEDICAL LT D 19 20

Partners

ARVO EUPO Association for Research in Vision and European University Professors of Ophthalmology - www.arvo.org Ophthalmology - www.eupo.eu

In many senses the counterpart of EVER in North EUPO is the organizer of the annual structured sub- America, the purposes of ARVO are to encourage specialty course for residents in training in Europe and assist research, training, publication, and dissem- since 1988. Most of the ophthalmology curriculum ination of knowledge in vision and ophthalmology. is covered over a 4 year period to allow residents Since 2005, EVER and ARVO are collaborating in to get an overview of theoretical knowledge during many fields, including an ARVO symposium held their residency rotation. EUPO courses are held in every year during EVER and an EVER symposium different places in Europe. The EUPO 2018 course is scheduled during ARVO. organised in conjunction with the EVER congress in Nice, France. See page 101

EBO FAN European Board of Ophthalmology European Fluorescein Angiography Club ebo-online.org www.fan-int.org

The European Board was founded in 1992 to guaran- The FAN Club started as a friendly reunion of pi- tee the highest standards of care in ophthalmology oneers of Medical Retina, in the early days of in the countries of the European Union by ensuring fluorescein angiography and lasercoagulation of that the training is raised to the best possible level. the retina. The FAN received a semi-official sta- It makes recommendations regarding the stand- tus, being invited to organize a session of Medical ards and syllabus for training ophthalmologists, Retina Case Presentations during large meetings assesses the content and quality of training by site in Ophthalmology. The Club runs itself without of- visits and the annual EBO Diploma Examination, fa- ficial status, there is no membership fee, and no cilitates the exchange of trainees and teachers, and registration fee for the meetings. Upcoming meet- promotes CME in ophthalmology. EBO works under ings are decided within the group, trying to change the Section of Ophthalmology of the European Un- the location from country to country, and offering ion of Medical Specialists (UEMS). Since 2007, EBO all members the opportunity to organize at least has organized review courses open to all delegates once a full day reunion in their hospital. Since during the EVER congress. 2012, FAN has organised joint meetings open to all delegates during the EVER congress.

See page 105 21

Partners

GDOA Optic Nerve Meeting

GuangDong Ophthalmologist Association www.optic-nerve-online.com GuangDong Ophthalmologist Association (GDOA) is the largest organization for eye Intended for basic scientists and clinicians to ad- care professionals in south China. GDOA has dress important topics in translational research, over 1000 members divided over 9 different including scientists in interdisciplinary areas such as subspecialties such as glaucoma and retina. neurology, neurodegenerations and autoimmunity. See page 63 Next Optic Nerve Meeting: Obergurgl, Austria, December 11-13, 2018 See page 58 OOG The Ophthalmic Oncology Group www.oog.eu SOPREF

OOG is an independent scientific workgroup de- Société Ophtalmologique Plastique voted to basic and clinical ophthalmic oncology. Reconstructrice Esthétique Française It has convened with EVER since 1998. The aims of www.sopref.net the OOG are to improve the practice of ophthalmic oncology in Europe, develop internet-based da- See page 106 tabases to share scientific information, organise multicenter studies and quality control studies, and meetings and other activities with the aim of improving the treatment of eye tumours and knowl- TFOS edge about them. OOG encourages all EVER delegates to take part in its sessions. The Tear Film and Ocular Surface Society See pages 89, 102, 106 www.tearfilm.org

The TFOS DEWS II involved the efforts of 150 clinical and basic science research experts from around the world and it was aimed to achieve a global consensus concerning multiple aspects of Dry Eye Disease. See page 63

FAN SOPREF 22

About the programme book

Sessions

BM KN Business Meeting Keynote lecture

C SIS Course Special Interest Symposium

CIS Industry Sponsored Symposium SOC Social

GA General Assembly POS Poster session

JM Joint Meeting PS Plenary session

RF Rapid Fire session

Symbols

= EVER section travel support recipient = Rapid fire presentation = Best rapid fire presentation = Conflict of interest disclosed

Scientific sections

ACB = Anatomy / Cell Biology COS = Cornea / Ocular Surface EOVS = Electrophysiology, Physiological Optics, Vision Sciences G = Glaucoma IM = Immunology / Microbiology LC = Lens and Cataract MBGE = Molecular Biology / Genetics / Epidemiology NSPH = Neuro-ophthalmology/Strabismology / Paediatric Ophthalmology / History of Ophthalmology PBP = Physiology / Biochemistry / Pharmacology PO = Pathology / Oncology RV = Retina / Vitreous Section programme secretaries 23

Scientific sessions

2018 Section programme secretaries

ACB Anatomy/Cell Biology Anu KAUPPINEN

COS Cornea/Ocular Surface Edward WYLEGALA

EOVS Electrophysiology, Physiological Optics, Vision Sciences Franziska RAUSCHER

G Glaucoma Eduardo NORMANDO

Francesca M CORDEIRO IM Immunology/Microbiology Joachim VAN CALSTER Programme Secretary Francesco PICHI

LC Lens and Cataract Ralph MICHAEL

MBGE Molecular Biology/Genetics/ Epidemiology Petra LISKOVA

NSPH Neuro-ophthalmology/Strabismus/ Paediatric Ophthalmology/History of Ophthalmology Patrick YU-WAI-MAN

PBP Physiology/Biochemistry/Pharmacology Neville OSBORNE

PO Pathology/Oncology Alexandre MOULIN

RV Retina/Vitreous Jean-Antoine POURNARAS

C EVER 2018 courses

 Beginner

 Intermediate

 Advanced

Thursday, October 4

09:15 - 10:30 Rhodes 2  EOVS - Basic principles of state-of-the-art ophthalmic p 30 instrumentation

09:15 - 10:30 Rhodes 3  MBGE - I have received a mutation report for my patient, p 30 but i don’t know what it means!

09:15 - 10:30 Rhodes 4  ACB - How to study mitochondria function, structure p 31 and clearance?

11:30 - 12:45 Rhodes 2  COS - Corneal nerves in health and disease p 34

11:30 - 12:45 Rhodes 4  ACB - Proteomics- a tool to find relevant biomarkers p 35 for ocular diseases, drug development and safety

17:00 - 18:15 Rhodes 2  G - Landmark papers in ophthalmology – how to do one! p 50

Friday, October 5

08:30 - 09:45 Rhodes 2  COS - Optical imaging techniques for the cornea and p 55 anterior eye segment – pearls and pitfalls

10:45 - 12:00 Rhodes 2  COS - Diagnosis and treatment of infectious keratitis in p 59 the clinical practice today

13:30 - 14:45 Rhodes 3  PO - Conjunctival tumors p 66

16:15 - 17:30 Rhodes 3  PO - Orbital inflammation p 79

Thursday October 4 28

Thursday, October 4 - Welcome session

8:30 - 8:45 | Hermes PS Welcome

Welcome by the EVER President 2018 - Alain BRON

Alain Bron

8:45 - 9:15 | Hermes PS EVER-ACTA lecture by Gisèle SOUBRANE

8:45 Introduction by Einar STEFANSSON

1111 8:50 OCT-A all what we need?

Gisèle SOUBRANE — Paris

Multimodal imaging (including Fluorescein and ICG Angiography as well as OCTB and Fundus AutoFluorescence) provides morphologic, dynamic and functional information of the retina and of the choroid. Unfortunately, dye-based techniques have drawbacks, such as Gisèle Soubrane

concealment of vascular detail by dye-leakage, absence of depth- resolution, and adverse reactions to dyes. OCT angiography (OCTA) a non-invasive, dye-free OCT-based imaging technique has shown great potential for visualizing the retinal and choroidal vasculature. It allows volumetric visualization of vasculature based on the motion-contrast

generated by flowing erythrocytes and is thus a direct marker for blood flow. The segmentation of the depth resolution permits delineation of individual vascular layers. However, frequent artefacts limit its interpretation. Under-or over-lying vasculature contamination poses a significant challenge. Dynamic flow information is missing . The field

of view is small and attempts to increase it result in decreased image quality. Surprisingly, OCTA encounters difficulties to authenticate typical choroidal abnormalities such as PVC. Absence of an OCTA signal does not necessarily imply a complete absence of blood flow, but rather the absence of blood flow above the lowest detectable

level. Studies claiming the superiority of OCT A compared to FA for the initial diagnosis always associate another technique either OCT B or ICG A. Nowadays, OCT A is used to assess the presence and maturity of CNV, to identify microaneurysms in the superficial and deep retinal capillary plexus, to identify and quantify macular ischemia .

Possibly this technique in conjunction with multimodal imaging will allow an earlier diagnosis and a better therapeutic approach.

9:15 Award presentation of the Certificate of Honour

Thursday, October 4 - First morning session

9:15 - 10:30 | Hermes JM EUPO session 4 - My children cannot see

For details, see page 120

9:15 - 10:30 | Rhodes 1 SIS G/ACB - Novel models to study glaucomatous neurodegeneration

Glaucomatous neurodegeneration causes visual disability if it is left untreated. Due to its age-related nature, the number of peo- ple with glaucoma will increase and future projections estimate a significant challenge in terms of costs and care of the critical number of visual impaired patients. The condition is related to increased intraocular pressure (IOP), but is classified by loss of the retinal ganglion cells (RGC). Although current IOP-lowering treatments decrease the rate of progression in most patients with glaucoma, the treatments offer no possibility of visual rescue and 15 percent of patients with diagnosed glaucoma will go blind. Previous attempts to rescue the RGCs have been unsuccessful. We believe that the lack of efficacy can be explained by the complexity of the condition as well as absence of ideal models to study the characteristic neurodegeneration. Although animal models of glaucoma have provided valuable information about the disease, there is still no ideal model for studying glaucomatous neurodegeneration due to its complexity. In the present SIS, novel methodologies and models to study the pathophysiology of glaucomatous neurodegeneration will be introduced. KOLKO M , CORDEIRO M F 1221 9:15 modelling optic neuropathies using human induced pluripotent stem cell- derived retinal ganglion cells Daniszewski M, Hewitt A, PEBAY A - Melbourne East

1222 9:40 models to study the impact of mitochondrial dysfunction on neurodegeneration MCMANUS M - Philadelphia 1223 10:05 A model to quantify retinal ganglion cell loss in patients CORDEIRO M F - London 30

Thursday, October 4 - First morning session

9:15 - 10:30 | Rhodes 2 C EOVS - Basic principles of state-of-the-art ophthalmic instrumentation

 Advanced This course is aimed at providing an overview of the basic principles of various state-of-the-art retinal-imaging systems such as scanning laser ophthalmoscopy, optical coherence tomography, as well as adaptive optics, and discusses how such imaging can even serve as a window into brain mechanisms. The goal is to illuminate for the clinician and scientist the underlying optical concepts and principles of various devices, even when not familiar with the particular technology employed within the instrument, and to demonstrate its potential with applications beyond those of retinal disease diagnosis and follow-up.

IRSCH K , BERNARDES R 1231 9:15 scanning Laser Ophthalmoscopy – Basic Optical Principles IRSCH K - Paris

1232 9:30 Optical Coherence Tomography – Basic Optical Principles IRSCH K - Paris

1233 9:45 Optical Coherence Tomography – Machine Learning BERNARDES R - Coimbra

1234 10:00 Adaptive Optics – Basic Optical Principles IRSCH K - Paris

1235 10:15 retinal Imaging – a Window into Brain Mechanisms CASTELO-BRANCO M - Coimbra

9:15 - 10:30 | Rhodes 3 C MBGE - I have received a mutation report for my patient, but I don’t know what it means!

 Beginner Genetics is getting increasingly important in many medical fields including ophthalmology. Patients with both Mendelian and complex disorders such as age-related macular degeneration seek genetic counselling and testing. This course will provide clinicians and scientists with the basic knowledge to understand mutation reports and pathogenicity evaluations. Practical examples from the ophthalmology field will be given. At the end of the course there will be a short workshop for all attendees. LISKOVA P , DUDAKOVA L 1241 9:15 Introduction to molecular genetics DUDAKOVA L - Prague

1242 9:33 standards and guidelines for the interpretation of sequence variants VERDIN H - Ghent

1243 9:51 molecular genetics in clinical practice I (Cornea) LISKOVA P - Prague

1244 10:09 molecular genetics in clinical practice II (Retina) LEROY B - Ghent 31

Thursday, October 4 - First morning session

9:15 - 10:30 | Rhodes 4 C ACB - How to study mitochondria function, structure and clearance?

 Intermediate

Increased oxidative stress seem to be one of the most important factor in normal aging and in the pathogenesis of various age-related retinal diseases. Mitochondria are especially important in the regulation of cellular redox balance, since the reactive oxygen species (ROS) are produced in their electron transport chain. The abundance of ROS can damage cellular components such as DNA and proteins. The aged retina is characterized by an increased level of ROS, accumulation of damaged DNA, proteins and mitochondria and increased low-grade inflammation. Lysosomal autophagy is key clearance system to remove damaged molecules from cells. Mitophagy is a mitochondria-specific selective autophagy that is an essential part of mitochondrial quality control to keep optimal redox balance in cells. In this course key methods to study mitochondria function, morphology and clearance in cell culture, animal models and human material are discussed. KAARNIRANTA K , BLASIAK J 1251 9:15 Key methods to study mitochondrial function FERRINGTON D A - Minneapolis

1252 9:33 methods to study mitochondrial DNA damage BLASIAK J - Lodz

1253 9:51 mitophagy as a research target SZÄSZUJFALUSI FELSZEGHY S - Kuopio

1254 10:09 mitochondria in the regulation of inflammation KAUPPINEN A - Kuopio

9:15 - 10:30 | Gallieni 1+2 SIS G/COS - Ocular surface in glaucoma – why bother?

Medical and surgical treatments for glaucoma can cause ocular surface disease (OSD) to an extent that more than half of patient with glaucoma have signs or symptoms of dry eye. Chronic use of preserved glaucoma drops has been associated with a high incidence of dry eye disease, which is related to the number and type of medications used and can alter treatment compliance and patients’ quality of life. Surgical treatments are also associated with a higher incidence of OSD and subsequent ocular lubricant use. Besides, OSD related to glaucoma medications can also reduce the success rate of filtrating surgeries. Furthermore, the tear film, one of the eye’s optical media, can be affected by IOP lowering medications. Its integrity is of paramount importance for generating reliable and reproducible retinal and optic nerve diagnostic images and for the assessment of disease progression. This SIS seeks to discuss the negative effects of preserved glaucoma medications and how to manage them, why the ocular surface is so important for the success of glaucoma surgery and how OSD can affect objective imaging parameters for glaucoma progression analysis. NORMANDO E M , RATNARAJAN G 1261 9:15 effect of topical medication on the ocular surface ROUSSEAU A - Le Kremlin Bicêtre

1262 9:40 importance of ocular surface for the success of glaucoma surgery RATNARAJAN G - East Grinstead

1263 10:05 effect of topical glaucoma treatments on OCT Image Quality NORMANDO E M - London 32

Thursday, October 4 - EVER lecture

11:00 - 11:30 | Hermes PS EVER lecture delivered by the Past President

11:00 Introduction by Alain BRON

1311 11:05 Ocular Inflammation

Andrew DICK — London - Bristol

The management of Ocular Inflammation until recently has lacked high level clinical trial evidence despite years of experience with DMARDs and Biologics. On the backdrop of this data, I will be discussing future approaches no longer quixotic, through our understanding of the immu- Andrew Dick nobiology of experimental models, advances in experimental medicine in man and our increasingly elegant imaging technologies to develop our future approaches that through endophenotypes of uveitis we will target patients appropriately, at the right time and with the right drugs.

11:30 Award presentation of the EVER Certificate of Honour

Thursday, October 4 - Second morning session

11:30 - 12:15 | Hermes JM EUPO session 5 - Surgical diseases and miscellaneous

For details, see page 120

12:15 - 12:45 | Hermes JM EUPO Round table 3 - My job is difficult!

For details, see page 120

12:45 - 12:50 | Hermes JM EUPO Closure

11:30 - 12:45 | Rhodes 1 SIS G/LC - P+p (phaco 'plus' procedures) - revolutionising glaucoma care

The advent of Minimally Invasive Glaucoma Surgery (MIGS) devices has shifted traditional glaucoma treatment paradigms, with phaco ‘plus' procedures (P+P) providing earlier opportunities in the treatment of mild to moderate glaucoma, improving control and patient experience. This highly relevant, contemporary symposium first considers the place of cataract surgery alone +/- goniosynechialysis (GSL), with reference to the landmark ‘EAGLE’ trial. The speakers will then summarise P+P indications and techniques for the devices most commonly used in Europe, including trabecular outflow (iStent), supra-choroidal trabecular bypass (CyPass) as well as phaco-ECP, an inflow procedure performed alone or in combination with MIGS. The speakers will discuss post-op care, results (evidence-based and real-world experience) and how to avoid common difficulties. Currently, trabeculectomy & tube surgery are still needed in many patients with moderate and advanced glaucoma; the place of MIGS in the schema of modern glaucoma management will be considered in panel discussion; we encourage attendance from audience members wishing to challenge the faculty to discuss the place of MIGS v traditional surgery in specific clinical cases / scenarios. BLOOM P , AHMED F 1421 11:30 Phaco alone +/- gonio-synechialysis Porteous A - London

1422 11:48 Phaco ECP BESINIS D - Nea Smyrni 1423 12:06 Phaco iStent AHMED F - London

1424 12:24 Phaco Cypass BLOOM P - London 34

Thursday, October 4 - Second morning session

11:30 - 12:45 | Rhodes 2 C COS - Corneal nerves in health and disease

 Intermediate Many diseases provoke unpleasant sensations and trophic alterations whose underlying neural mechanisms are not fully understood. The present course offers an overview on the functional mechanisms responsible for sensations evoked in the front of the eye, and on the morphological and functional changes produced by diseases, surgery and infection. The reciprocal influence between corneal nerves and immune cells will be also discussed. GALLAR J , KOVACS I 1431 11:30 Activity of corneal nerves in health and disease GALLAR J, Acosta M C - San Juan de Alicante

1432 11:48 Corneal nerves in keratoconus KOVACS I, Nagy Z - Budapest

1433 12:06 Corneal nerves after PRK and CXL treatment ZSOLT NAGY Z, Popper A - Budapest

1434 12:24 Immune cells and corneal nerves HAMRAH P - Boston

11:30 - 12:45 | Rhodes 3 PBP - Cone photoreception in huma retina: structure and functional evaluation of the SIS human fovea

The organization of the cone photoreceptors in the human fovea, their significance for visual acuity and their impairment in some well-known diseases such as Age related Macular Degeneration (AMD), Stargardt disease, or even dyschromatopsia make the field of cone physiology and restoration attractive for many researchers and ophthalmologist. The advancement of neurophysiological and image technologies has allowed a more precise and objective study of the cellular and morphological organization of human fovea in patients. Moreover, recent advances in neurophysiological techniques have opened the possibility to evaluate the function of the fovea both at the eye a cortex level. The Special Interest Symposium will present recent studies focussing on structure and function of the human fovea and recent approaches treat various types of human retinal diseases. The SIS will provide ample opportunity for interaction among scientists attending the conferences. DE LA VILLA P , VIDAL-SANZ M 1441 11:30 structure of the human fovea: from the microscopy to the OCT CUENCA N, Ortuño-Lizarán I, Pinilla I - Alicante

1442 11:48 Visual perception in the human fovea: functional evaluation of cone diseases by neurophysiological methods. DE LA VILLA P, Milla S, Vicente C - Alcala de Henares

1443 12:06 macular protection in AMD by Transposon mediated gene delivery FERNANDEZ-ROBREDO P - Pamplona

1444 12:24 evaluation of retinal function by mfVEP BLANCO R - Barcelona 35

Thursday, October 4 - Second morning session

11:30 - 12:45 | Rhodes 4 ACB - Proteomics - a tool to find relevant biomarkers for ocular diseases, drug C development and safety

 Intermediate

Proteomics, along with other omics, is a potentially valuable tool of personalized medicine and thus helping in selecting the most cost-effective diagnostic and therapeutic options for each patients. This type of personalized approach is becoming more common in the future, since new diagnostic and therapeutic methods are constantly being developed. On the other hand, processing and analyzing of the proteomic samples is becoming easier, more accurate and also cheaper. For these reasons, a lot of effort is currently going into finding potential biomarkers through discovery studies. In addition to sample processing and advanced equipment, proteomic research also requires the work of bioinformaticians as the research methods are yielding increasing amounts of statistical data. Hence, methods of analyzing big data are also increasingly important and therefore researchers in bioinformatics field are both developing new methods and utilizing old ones in order to tackle the growing data. This course will focus on methods of study design, sample processing, mass spectrometry and bioinformatics in diagnostic, therapeutic and safety studies. UUSITALO H , BEUERMAN R 1451 11:30 New technologies in proteomic research BEUERMAN R, Zhou L - Singapore

1452 11:48 Design of clinical efficacy and safety studies based on proteomic analysis UUSITALO H - Tampere

1453 12:06 From biomarker discovery to proteomic validation using mass spectrometry JYLHÄ A - Tampere

1454 12:24 Bioinformatics in tear fluid proteomics – connecting proteomic and clinical data NÄTTINEN J - Tampere

11:30 - 12:45 | Gallieni 1+2 IM - Don’t miss the diagnosis! How to survive against the worst enemies in your daily SIS practice

In the modern ophthalmology, the introduction of new technologies and the better knowledge on uveitis pathophysiology have helped in understanding the different clinical characteristics of most of the intraocular inflammatory diseases. Consequently, several old concepts were revised and new ones were introduced. The trend at this point is to create the conditions for a better strategy both for the diagnostic procedures and for the treatment choices by using appropriately all the available tools. For such reasons, the multimodal imaging procedures, systemic tests and even biopsies of ocular tissues are part of the daily practice of a uveitis specialist. In this special interest symposium the main uveitis subsets and masquerade syndromes will be discussed by addressing the critical points for the diagnostic assessment and bringing new concepts on the uveitis classification and the treatment methodology. NERI P , KHAIRALLAH M 1461 11:30 How ICGA can help in surviving in the jungle of choroidal inflammatory diseases HERBORT JR. C P - Lausanne

1462 11:48 How to detect a viral retinitis KHAIRALLAH M, Khochtali S, Abroug N, Ksiaa I - Monastir

1463 12:06 How to bare the great imitators KESTELYN P - Gent

1464 12:24 How to unmask a masquerade syndrome NERI P - Abu Dhabi 36

Thursday, October 4 - Noon session

12:45 - 14:00 | Rhodes 2 CIS Lunchtime CIS - Nothing to fear about Demodex

JAMES TE 12:45 How to detect Demodex in the clinical setting CRAIG J, New Zealand

12:57 The on-off relationship between Demodex and dry eye KAYA S, Austria

13:09 How Demodex affects my Blepharitis patients JAMES T E, United Kingdom

13:21 How to manage Demodex Blepharitis with Tea Tree Oil (TTO) KHAIRALLAH M, Tunisia

13:33 Is TTO the killing agent for Demodex? MERAYO-LLOVES J, Spain

13:45 Demodex in my clinical practice TERZIDOU C, Greece 37

Thursday, October 4 - Keynote lecture

14:15 - 14:45 | Hermes KN Keynote lecture by Rajendra APTE

14:15 Introduction by Andrew DICK

1611 14:20 An eye on aging and disease

Rajendra S. APTE — St. Louis

Organismal aging is associated with widespread tissue dysfunction. In the eye, a transition from aging to disease is associated with diverse pathophysiology that ranges from reduced tear production to diseases

such as glaucoma and age-related macular degeneration. Understand- Rajendra S. Apte ing the biologic basis of aging and the molecular mechanisms underlying the transition from aging to age-related eye disease is critical in order to find sensitive and specific biomarkers of disease and identifying targeted therapeutic strategies to prevent vision loss. Using genetic mouse models and human data, the role of molecular metabolism, lipid homeostasis and immunity in aging and eye disease will be presented.

14:45 Award presentation of the EVER Certificate of Honour 38

Thursday, October 4 - First afternoon session

14:45 - 16:00 | Hermes SIS RV - Bionic eye - where are we now?

This session is aimed to give an update about the development, current stage and future perspectives of Bionic eye technology. The speakers are the opinion leaders in their field. LYTVYNCHUK L 1711 14:45 Intraoperative OCT imaging of the Argus II retinal prosthesis and its clinical significance FALKNER-RADLER C, Lytvynchuck L - Vienna

1713 15:00 The functional results after Argus II implantation CINELLI L, Rizzo S - Florence

1714 15:15 New tacking forceps for fixation of epiretinal prosthesis LYTVYNCHUK L, Falkner-Radler C, Binder S, Lorenz B - Giessen 1715 15:30 restitution of visual functions in blind retinitis pigments patients with subretinal implant Alpha AMS STETT A - Reutlingen 1716 15:45 Innovation and advances in bioelectronic medicine progressing to address atrophic dry AMD with wireless sub-retinal photovoltaic implant MUQIT M - London

14:45 - 16:00 | Rhodes 1 SIS G/LC - Simulated ocular surgery - part II

Surgical training in Europe is very different according to each region. National regulations, different settings and allocated resources allow for a great heterogeneity in surgical learning opportunities. In order to acquire and practice the best surgical skills before starting to operate directly on patients’ eyes, simulated surgical training ensures excellent opportunities to build competencies on microsurgery. Simulation based learning enables to learn different surgical procedures, practice various interventions and deal with potential complications in a safe and sustainable educational environment. Besides learning and practicing technical skills, decision-making, teambuilding and communication skills can be trained. This symposium will give an overview on how surgical teaching is currently being conducted in Europe, how it can be effectively achieved and how simulated surgical training can maximize surgical skills transfer. We will search and interactively discuss solutions on how to best implement this training method in a structured way in European ophthalmological centers. SUNARIC MEGEVAND G , PRIOR FILIPE H 1721 14:45 The Use of Simulated Ocular Surgery (SOS) eyes in Glaucoma Surgical Training 2 – A U.K. Tertiary Referral Teaching Hospital Experience, One Year Later MERCIECA K - Manchester

1722 15:03 UK Trainee Trabeculectomy Outcomes incorporating Simulated Surgery BHARGAVA A - Manchester

1723 15:21 The Role of Simulators in Cataract Surgery RIBEIRO F - Lisbon

1724 15:39 six Essential Steps to Develop a Simulation Based Learning Program PRIOR FILIPE H - Lisbon 39

Thursday, October 4 - First afternoon session

14:45 - 16:00 | Rhodes 2 SIS COS/ACB - Aniridia-associated keratopathy (aak): from disease mechanisms to treatments

Aniridia is a multi-faceted condition characterized by underdevelopment of eye structures due to mutations in PAX6 and related genes. The condition is most often congenital and is commonly associated with misdevelopment of the fovea, iris, lens, and cornea often leading to glaucoma, cataract, and a progressive keratopathy called aniridia-associated keratopathy (AAK). AAK has a characteristic phenotype linked to the progressive deterioration of the limbal stem cell niche, that commonly results in inflammation, denervation, vascularization, fibrosis and keratinization. AAK presents numerous challenges for the ophthalmologist and decisions regarding treatment are often difficult. In this SIS, we focus on AAK and present insights into the condition at the molecular and morphologic levels, and describe experiences and outcomes with several surgical interventions for treatment of AAK when corneal transparency has been compromised. LAGALI N , WYLEGALA E 1731 14:45 Transcriptional analysis of corneal epithelium in AAK and related siRNA-based cell model LATTA L, Nordström K, Stachon T, Fries F, Szentmáry N, Seitz B, Käsmann-Kellner B - Homburg

1732 15:00 Unraveling the pathogenesis of AAK - insights from anterior segment imaging in children LAGALI N, Wowra B, Wylegala E, Fries F, Utheim T, Latta L, Seitz B, Käsmann-Kellner B - Linköping

1733 15:15 minimally-invasive surgical treatment of AAK WOWRA B, Dobrowolski D, Edward W - Katowice

1734 15:30 Triple procedure for treating advanced AAK with cataract DOBROWOLSKI D, Wowra B, Grolik M, Wylegala E - Katowice

1735 15:45 The use of keratoprosthesis in the treatment of AAK REMEIJER L, Dobrodjnova O, Littink K, Roels D - Rotterdam

14:45 - 16:00 | Rhodes 3 SIS PBP - Pathogenic role of the microglia in neuroretinal diseases

Microglia, the immunocompetent cells of the central nervous system (CNS), act as neuropathology sensors and are neuroprotective under physiological conditions. Microglia react to injury and degeneration with immune-phenotypic and morphological changes, proliferation, migration, and inflammatory cytokine production. An uncontrolled microglial response secondary to sustained CNS damage can put neuronal survival at risk due to excessive inflammation. A neuroinflammatory response is considered among the etiological factors of the major retinal neurodegenerative diseases like glaucoma, macular degeneration, diabetic retinopathy, and other optic nerve injuries, in which the microglial cells are key players. The aim of the present SIS is to analyze the contribution in retina to microglial-mediated neuroinflammation in the diseases mentioned above. DE HOZ R , VIDAL-SANZ M 1741 14:45 The Spider Effect: Morphological and Orienting Classification of Microglia in Response to Stimuli in Vivo JONAS J B - Mannheim

1742 15:03 The role of microglia in glaucoma SALOBRAR-GARCIA E, Ramirez A I, De Hoz R, Salazar J J, Ramirez J M - Madrid 1743 15:21 microglial response to optic nerve injuries AGUDO-BARRIUSO M, Galindo-Romero C, Boia R, Nadal-Nicolas F M, Ambrosio A F, Vidal-Sanz M, Santiago A R - Murcia

1744 15:39 The role of the microglia in age-related macular degeneration LANGMANN T - Cologne 40

Thursday, October 4 - First afternoon session

14:45 - 16:00 | Rhodes 4 SIS ACB - Crosstalk of mitochondria and lysosomes in the degeneration of rpe

Retinal pigment epithelial cells (RPE) are constantly exposed to reactive oxygen species (ROS), which may induce damage to proteins, nucleic acids, lipids and cellular organelles. Mitochondria are especially important in the regulation of cellular redox balance, since the ROS are produced in their electron transport chain. In normal circumstances, the amount of ROS is counterbal- anced by cellular antioxidant defence. An imbalance between the production and neutralization of ROS by antioxidant defence is associated with increased oxidative stress, which plays an important role in the pathogenesis of many age-related and degenerative diseases, including age-related macular degeneration. Chronic oxidative stress may lead to protein aggregation. Lysosomal autophagy processing of aggregated proteins is important for the cell to maintain its normal functioning and homeostasis. The protein aggregates become double membrane-wrapped organelles called autophagosomes, which become degraded by lysosomal enzymes when they fuse to lysosomes. Crosstalk of antioxidants, mitochondria and lysosomes is central in the regulation of proteostasis in retina. KAARNIRANTA K , UUSITALO H 1751 14:45 mitochondrial dysfunction in age-related macular degeneration FERRINGTON D A - Minneapolis

1752 15:10 Lysosomes as regulators of protein clearance SINHA D - Pittsburgh

1753 15:35 Antioxidants and mitochondria connection in the regulation of autophagy KAARNIRANTA K - Kuopio

14:45 - 16:00 | Gallieni 1+2 MBGE - Controversies in epidemiology: beneficial or harmful effects of nutritional SIS supplements in the prevention of AMD?

Age-related macular degeneration (AMD) is one of the severe eye disorders of the elderly, caused by genetic, life style and environmental risk factors. Since treatment options are rare, prevention by nutritional supplements are frequently discussed. How- ever, their beneficial or harmful effects might depend on the genetic background of the patients. These aspects will be discussed from different points of view. GRAW J , MCCARTY C 1761 14:45 Overview of the biological rationale for efficacy of nutritional supplements to prevent AMD MCCARTY C - Duluth 1762 15:10 Pharmacogenetic influences on nutritional supplementation in prevention of AMD SCHWARTZ S - Naples

1763 15:35 Is there a benefit of nutritional supplementation in the prevention of AMD? LAWRENSON J, Evans J - London

16:00 - 17:00 | Poster area Coffee SOC with Coffee with Profs - Part I Profs

In an initiative to encourage dialogue amongst speakers and EVER members, we have organised a session called “Coffee with Profs”. This will be a table of 6-8 “guests” at a table headed by one of the EVER speakers.

Sally-Anne Tsangarides General Manager, Northern Europe Cluster, Santhera Pharmaceuticals Mariya Moosajee Consultant Ophthalmologist, Moorfields Eye Hospital and Welcome Trust Clinical Research Career Develop- ment Fellow, Institute of Ophthalmology, UCL

The idea is to provide a casual yet personal venue where colleagues, in particular the younger faction, can share comments and ideas with an expert. 41

Thursday, October 4 - Poster session

16:00 - 17:00 | Poster area POS RV - Retina/Vitreous

Poster T001-T096

SOUBRANE G , DE LAEY JJ T001 Novel retinal artery pulse transit time measurement shows expected blood pressure dependency in rodents REZAEIAN M, Georgevsky D, Golzan M, Graham S, Avolio A, Butlin M - Sydney

T002 Retinal changes in continuous light: an electron microscopy and NADPH-diaphorase histochemistry evaluation MAURYA M, Nag T C, Kumar P - Delhi T003 Effect of raising in complete darkness on pathological and functional readouts in the mouse blight light exposure model Timonina A, Tenhunen A, Cerrada-Gimenez M, Ziniauskaite A, Kaja S, Kalesnykas G, Ragauskas S - Kuopio

T004 Modulation of oxidative stress in the rod outer segment by diterpene manool and sclareol extracted from Salvia tingitana PANFOLI I, Calzia D, Esposito A, Degan P, Bisio A, Pedrelli F, Schito A, Traverso C E - Genova T005 Strain differences in the rat streptozotocin-induced model of diabetic retinopathy JÄÄSKELÄINEN N, Tenhunen A, Thapa R, Ragauskas S, Dunlop T, Ziniauskaite A, Haapaniemi A M, Räsänen H, Kaja S, Kalesnykas G, Cerrada-Gimenez M - Kuopio T006 A morphological study and expression patterns of iron regulatory proteins in aging Wistar rats retina after iron overload KUMAR P, Nag T C, Velpandian T, Toy T S, Wadhwa S - New Delhi

T007 Functional and histological evaluation in iodoacetic acid induced photoreceptor degeneration feline model KIM C, Lee S, Lee S, Nam K - Busan T008 Protective Effects of Omega-3 Fatty Acids Supplementation Against Retinal Degeneration in Aged C57BL/6 Mice Prokopiou E, KOLOVOS P, Kalogerou M, Neokleous A, Potamiti L, Sokratous K, Kyriacou K, Georgiou T - Nicosia T009 Aflibercept inhibits physiological revascularization and pathological neovascularization in the mouse and rat oxygen-induced retinopathy models VÄHÄTUPA M, Hakkarainen J J, Kaja S, Uusitalo H, Järvinen T A, Uusitalo-Järvinen H, Kalesnykas G - Kuopio T010 Dose-dependency of intraperitoneally-injected aflibercept in the mouse choroidal neovascularization model RAGAUSKAS S, Cerrada-Gimenez M, Tenhunen A, Ziniauskaite A, Kaja S, Kalesnykas G - Kuopio T011 Selected pharmacology of PlGF neutralization over anti-VEGF on retinal gliosis and RGC survival assessed in a diabetic mouse model ETIENNE I, Van Bergen T, Feyen J - Leuven

T012 The association between macular thickness and axial length KWON J - Suwon

T013 In vivo retinal cells visible without adaptive optics using a novel full-field OCT MAZLIN V, Xiao P, Scholler J, Grieve K, Sahel J A, Fink M, Boccara C - Paris

T014 Repeatability of vessel density measurements using optical coherence tomography angiography in retinal diseases KIM J Y - Daejeon

T015 Macular retinal capillary density and blood flow differences between black and white subjects using optical coherence tomography angiography SKONDRA D, Chun L - Chicago

T016 Study of macular and optic disk blood flow by angio-OCT in Glucose-6-Phosphate Dehydrogenase (G6PD) deficient men and age-related G6PD-normal subjects D’AMICO RICCI G, Porcu T, Marzano J, Giancipoli E, Boscia F, Pinna A - Sassari

T017 Choriocapillaris changes during development of CNV – an OCT Angiography quantitative analysis RODRIGUES C, Cabral D, Coscas F, Pereira T, Cachado F, Geraldes C, Sellam A, Barrão S, Papoila A, Coscas G, Souied E - Lisbon 42

Thursday, October 4 - Poster session

16:00 - 17:00 | Poster area POS RV - Retina/Vitreous

Poster T001-T096

SOUBRANE G , DE LAEY JJ T018 Quantitative OCT-Angiography for neovascular age related macular degeneration: Six months follow-up study COSCAS F, Cabral D, Rodrigues C, Pereira T, Narotamo H, Geraldes C, Vila-Franca M, Barrão S, Papoila A, Coscas G, Souied E - Creteil

T019 Macular thickness and volume related to vascular macular capillary in OCTA in patients with Type 1 diabetes with no retinopathy BARTOLOMÉ I, Orduna-Hospital E, Acha J, Sanchez-Cano A I, Lopez Galvez M I, Perdices-Royo L, Idoate A, Montes P, Ascaso Puyuelo J, Pinilla-Lozano I - Zaragoza

T020 Correlation between diabetic macular edema and areas of capillary non perfusion detected by optical coherence tomography angiography ZHIOUA BRAHAM I, Kaouel H, Boukari M, Ammous I, Zhioua R - Tunis

T021 OCT Angiography findings in maternally inherited diabetes and deafness syndrome ZHIOUA BRAHAM I, Boukari M, Kaouel H, Ammous I, Mili Boussen I, Zhioua R - Tunis

T022 OCT-angiography: Deep irregular vascular network predictor of neovascular complication in angioid streaks EL MATRI K, Falfoul Y, Hassairi A, Maalej R, Maamouri R, Kort F, Chebil A, El Matri L - Tunis

T023 Optical coherence tomography findings after retinal artery occlusion BARTOLOMÉ I, Berniolles J, Idoate A, Sanchez Marin J I, Marco S, Montes P, Lopez Sangros I, Karlsruher G, Lazaro A I, Ascaso Puyuelo J, Pinilla Lozano I - Zaragoza

T024 The EYE-MI pilot study: a prospective acute coronary syndrome cohort evaluated with retinal optical coherence tomography angiography ARNOULD L, Guenancia C, Gabrielle P H, Bron A, Creuzot C, Cottin Y - Dijon

T025 Vascular features of surgical macular pathologies in OCT-A imaging CHRISTODOULOU E, Batsos G, Exarhopoulos D, Parikakis E, Stefaniotou M - Ioannina

T026 Swept-source OCT and OCT angiography findings in Alport maculopathy. ZHIOUA BRAHAM I, Smaoui S, Boukari M, Zhioua R - Tunis T027 Predictive biomarkers in OCT-Angiography of peripheral nonperfusion in retinal venous occlusions REIS CABRAL D, Coscas F, Glacet-Bernard A, Pereira T, Geraldes C, Papoila A, Vila Franca M, Coscas G, Souied E - Lisboa

T028 Effect of early age related macular degeneration on the disk halo size produced by a glare source PEREZ CARRASCO M J, Contreras I, Alía-González C, Gómez-Palacios V, García-Benítez N, Ciércoles-Rodríguez M, Hurtado-Ceña F J, Puell M C - Madrid

T029 Structural analysis and evolution of AMD Drusenoid deposits “P”, Protein-Cellular Type: study with OCT and Morphology-Structural software GONZALEZ C - Toulouse

T030 Structural analysis and evolution of AMD Drusenoid deposits “L”, Lipid type: study with OCT and Morphology-Structural software GONZALEZ C - Toulouse

T031 Analysis of choroidal structure changes in diabetic patients without diabetic retinopathy: a longitudinal study FIGUEIREDO R, Luís M E, Hipólito Fernandes D, Cunha J P, Alves M, Papoila A L, Abegão Pinto L, Tavares Ferreira J - Coimbra

T032 Dietary patterns and age-related macular degeneration in Korean population KIM Y C, Kang K T - Daegu 43

Thursday, October 4 - Poster session

16:00 - 17:00 | Poster area POS RV - Retina/Vitreous

Poster T001-T096

SOUBRANE G , DE LAEY JJ T033 Relationship between Macular Thickness and Mesopic Visual Acuity in Early to Intermediate Age-related macular Degeneration Subjects PUELL M, Hurtado-Ceña F, Ciércoles-Rodríguez M, García-Benítez N, Gómez-Palacios V, Alía-González C, Pérez-Carrasco M, Contreras I - Madrid

T034 A case report of Outer Retinal Tubulations in Age-Related Macular Degeneration - imaging and histologic correlates MOURA-COELHO N, Dutra-Medeiros M, Basílio A L, Hipólito Fernandes D, Vieira L, Flores R - Lisbon

T035 Progression of Age Macular Degeneration (AMD) after Cataract Surgery: A Case Series RAHAYU S, Iwan S - Bandung

T036 Three unusual cases of choroidal neovascular membrane (CNV) formation after pars plana vitrectomy for macular pathology TSOKOLAS G, Clarke B, Gupta B - Southampton

T037 Early changes in retinal thickness when using intravitreal Ranibizumab for age-related macular degeneration TOMKINSON C, Mahmood S, Chhabra R - Manchester

T038 Thermo-responsive injectable microgel is able to achieve controlled drug release in the vitreous environment LIU S, Kearns V, Mcdonald T - Leicester T039 Topical Treatment for Ocular Diseases of the Posterior Segment: Non-Invasive Delivery of Large Therapeutics such as Bevacizumab and Ranibizumab DE COGAN F, Slope L, Berwick M, Peacock A, Scott R, Xu H, Chen M - Birmingham

T040 The probability of over-treatment using the treat-and-extend regimen for wet-AMD SHIN K H, Jeong S H - Seoul

T041 Retinal oximetry in young patients with type 1 diabetes compared to healthy controls VEIBY N - Oslo

T042 Retinal neurodegeneration exists in type 1 diabetes prior diabetic retinopathy ORDUNA HOSPITAL E, Idoipe Corta M, Sanchez Cano A, Perdices Royo L, Acha J, Bartolome I, Cuenca N, Abecia E, Lopez Galvez M I, Pinilla Lozano I - Zaragoza

T043 Retinal neurodegeneration in patients with type 2 diabetes mellitus without diabetic retinopathy MOURA-COELHO N, Alves M, Dias Santos A, Costa L, Oliveira Santos B, Cunha J P, Papoila A L, Abegão Pinto L, Tavares Ferreira J - Lisbon

T044 Retinal measurements in type 2 diabetic patients without diabetic retinopathy using Spectralis Optical coherence tomography CIPRÉS ALASTUEY M, Gavin Sancho A, Rodrio Sanjuan M J, Satue Palacian M, Larrea Samper J G, Vilades Palomar E, Orduña Hospital E, Garcia-Martin E - Zaragoza

T045 Subclinical alterations in the visual function of type 2 diabetes mellitus patients without diabetic retinopathy ORDUNA HOSPITAL E, Viladés Palomar E, Larrea Samper J G, Gavin Sancho A, Satue Palacian M, Cipres Alastuey M, Rodrigo Sanjuan M J, Garcia Martin E - Zaragoza

T046 Retinal measurements in type 2 diabetic patients without diabetic retinopathy using Swetpt-Source Optical coherence tomography Triton device CIPRÉS ALASTUEY M, Gavin Sancho A, Satué Palacian M, Rodrigo Sanjuan M J, Orduña Hospital E, Vilades Palomar E, Larrea Samper J G, Garcia-Martin E - Zaragoza

T047 Fundus autofluorescence changes in diabetic retinopathy CHATZIRALLI I, Dimitriou E, Kabanarou S, Chatzirallis A, Xirou T, Theodossiadis G, Theodossiadis P - Athens 44

Thursday, October 4 - Poster session

16:00 - 17:00 | Poster area POS RV - Retina/Vitreous

Poster T001-T096

SOUBRANE G , DE LAEY JJ T048 Carotid-cavernous fistula in a patient with diabetic macular edema. A case report ASCASO F, Montes P, Karlsruher G, Mateo J, Marco S, Lopez I, Berniolles J, Bartolomé I - Zaragoza

T049 Dipeptidyl peptidase-4 inhibitors and risk of diabetic retinopathy progression in patients with type 2 diabetes: a population-based cohort study CHUNG Y R, Ha K H, Kim D J, Lee K - Suwon

T050 Coexistence of diabetic retinopathy and age-related macular degeneration: Epidemiology and management CHATZIRALLI I, Dimitriou E, Saitakis G, Chatzirallis A, Theodossiadis G, Theodossiadis P - Athens

T051 Bariatric surgery and its retinal repercussions – a pilot study LAIGINHAS R, Guimarães M, Santos-Sousa H, Preto J, Nora M, Chibante-Pedro J, Falcão-Reis F, Falcão M - Alijo

T052 Automatic Detection of Diabetic Retinopathy using Jointly Trained CNNs HIJAZI B, Quellec G, Lamard M, Cochener B - Brest

T053 Evaluation of an Artificial Inteligence clinical decision support suite for Diabetic Retinopathy and Age related macular degeneration screening TRANOS P, Karassavidou E, Tsirampidou E, Stavrakas P, Chrissafis C - Thessaloniki

T054 Development and validation of a risk-prediction nomogram for good functional response one year after treatment with anti-VEGF in naive-Diabetic macular edema GABRIELLE P H, Massin P, Arnould L, Bouche-Pillon J, Maupin E, Bron A, Kodjikian L, Creuzot C - Dijon

T055 Combining sub threshold laser therapy and anti-VEGF injections in diabetic macular edema EL MATRI L, Falfoul Y, Chebbi Z, Hassairi A, El Matri K, Chebil A - Tunis

T056 Analysis of factors related to early macular edema recurrence after intravitreal dexamethasone implant treatment in diabetic macular edema KIM K T, Chae J B, Kim D Y - Cheongju

T057 Eficacy and safety of corticosteroid implant (Fluocinolone Acetonide (FAc) 0.2 μg/day,Iluvien ®) for management of Diabetic Macular Edema (DME): a real-life study VIEIRA M, Pereira J, Santos M, Arruda H, Sousa J - Leiria

T058 Three year real-life outcomes from the use of the fluocinolone acetonide implant (Iluvien) in the treatment of refractory DMO KARATSAI E, Ali Y, Taylor S - Guildford

T059 Evidences of new risk factors for retinal vein thrombosis FRUSCHELLI M, Gelmi M C, De Bartolo G, Hadjistilianou T, Bocchia M, Gozzetti A, Calzoni P, Puccetti L - Siena

T060 Differentiated approach to the management of patients with retinal occlusions. MALGIN K, Zagrebneva M - Orenburg

T061 Comparison of the efficacy of intravitreal Bevacizumab and Dexamethasone implant in patients with macular edema by branch retinal vein occlusion according to macular perfusion type CHOI C W - Iksan-si

T062 Pseudophakic cystoid macular edema responding to the combination of topical and systemic treatment as first-line therapy с( ase-series study) PANFILOVA A, Arslanov G, Chistyakova N, Dal N, Krasavina M, Onishchenko E, Khudainazarova V - Saint-Petersburg

T063 Acute Endophthalmitis after Cataract Surgery: 164 Consecutive Cases Treated at a Referral Center in South Korea JEONG S, Chung J, Chang Y - Seoul 45

Thursday, October 4 - Poster session

16:00 - 17:00 | Poster area POS RV - Retina/Vitreous

Poster T001-T096

SOUBRANE G , DE LAEY JJ T064 Endophthalmitis rate following intravitreal injection of anti-VEGF and the impact of post-injection topical antibiotics HORNER F, Chavan R - Birmingham

T065 Acute endophthalmitis after intravitreal injections of corticosteroids or anti-vascular growth factor agents. A nationwide study in France from 2012 to 2015 BAUDIN F, Benzenine E, Mariet A S, Bron A, Daien V, Korobelnik J F, Quantin C, Creuzot C - Dijon

T067 Syphilitic placoid chorioretinitis: Clinical features and therapeutic response in two cases ASCASO F, Karlsruher G, Montes P, Marco S, Lopez I, Berniolles J, Bartolome I, Lara F, Minguez E - Zaragoza

T068 A case of total retinal detachment associated with AIDS-related cytomegalovirus retinal necrosis: the role of combined surgery VOLHA Y, Imshenetskaya T - Minsk T069 Post-hoc comparison of best-corrected visual acuity improvement in study and untreated fellow eyes with active non-infectious uveitis of the posterior segment in the SAKURA program BODAGHI B, Pavesio C, Abraham A - Paris

T070 Case series: Ozurdex® for macular edema in uveitis SOUSA F, Mano S, Marques R, Leal I, Prates-Canelas J - Lisbon

T071 Risk Factors for Central Serous Chorioretinopathy: Multivariate Approach in a Case-Control Study CHATZIRALLI I, Kabanarou S, Parikakis E, Chatzirallis A, Xirou T, Mitropoulos P - Athens

T073 The effect of eplerenone in chronic central serous chorioretinopathy refractory to PDT therapy PARIKAKIS E, Karagiannis D, Batsos G, Kontomihos L, Ktena E, Peponis V - Kifissia, Athens

T074 Histopathologic analysis as a tool for understanding the pathogenetic mechanisms in posterior pole pathologies CHRISTODOULOU E, Batsos G, Goussia A, Parikakis E, Stefaniotou M - Ioannina

T075 Optical Coherence Tomographic Changes of Subretinal Proliferation in Rhegmatogenous Retinal Detachment with Scleral Buckling KIM Y C, Kang K T - Daegu

T076 The role of disorganization of inner retinal layers as predictive factor in patients with epiretinal membrane XIROU T, Garnavou-Xirou C, Kabanarou S, Gkizis I, Bitza P, Koutropoulou N, Kontou E, Chatziralli I - Glyfada

T077 Longitudinal Evaluation of Retinal Structure in Patients with Idiopathic Epiretinal Membrane Using Optical Coherence Tomography LEE M Y - Uijeongbu-Si

T078 The effect of internal limiting membrane peeling in treatment of idiopathic epiretinal memebrane CHANG Y S, Song S H, Jeong S H - Daejeon

T079 Retinal detachment following elective macular surgery GRAJEWSKI L, Carstens J, Krause L - Dessau T080 The incidence of rhegmatogenous retinal detachment in France from 2010 to 2016: seasonal and geographical variations BEN GHEZALA I, Benzenine E, Mariet A S, Gabrielle P H, Bron A, Quantin C, Creuzot C - Dijon 46

Thursday, October 4 - Poster session

16:00 - 17:00 | Poster area POS RV - Retina/Vitreous

Poster T001-T096

SOUBRANE G , DE LAEY JJ T081 Localized versus 360-degree laser photocoagulation with pars plana vitrectomy in the management of primary rhegmatogenous retinal detachment RYOO N K, Kim S Y, Woo S J, Park K H - Seongnam-Si

T082 Surgical treatment of macular holes using platelet rich plasma MALGIN K, Lomukhina E - Orenburg

T083 Surgery for macular telangiectasia type 2 with lamellar hole or macular hole in Asians: Affirmative results and mechanisms LEE S C, Hwang D J, Moon B G, Kong M, Sohn J H - Bupyeong-gu

T084 Our experience two steps surgical treatment of optic disk pit maculopathy VOLHA Y, Imshenetskaya T, Markevich V, Vaskevich G - Minsk

T085 Pars plana posterior capsulectomy during combined pars plana vitrectomy and cataract surgery KIM Y C - Daegu

T086 Augmented field of view for ocular endoscopy using deap learning THIERY T, Lamard M, Guerre A, Quellec G, Cochener B - Brest

T087 Structural impact of arrested foveal development in preterms SJÖSTRAND J, Popovic Z - Mölndal

T088 Is that a torpedo near the fovea? Torpedo maculopathy a case report BERNIOLLES J, Batolome Sese I, Ramiro Millan P, Ascaso Puyuelo F J, Marco Monzon S, Montes P, Sierra Garcia M E - Zaragoza

T089 Retinal biomarkers for Alzheimer’s and Parkinson’s diseases BERNARDES R, Nunes A, Castelo-Branco M - Coimbra

T090 Changes in the retina in the evolution of Alzheimer’s disease SALOBRAR-GARCIA E, De Hoz R, Salazar J J, Ramirez A I, Lopez-Cuenca I, Yubero R, Gil P, Ramirez J M - Madrid

T091 Age Macular Degeneration - Alzheimer Disease: Ophthalmic exam - MCI in-between correlations. 5 years evolution GONZALEZ C - Toulouse

T092 Contribution of multimodal imaging in traumatic maculopathy ELBANY S, El Chehab H, Thibaud M, Maelle R, Agard E, Verrecchia S, Kodjikian L, Dot C - Lyon

T093 Characterization of Retinal Structure in CNGB3-associated Achromatopsia GEORGIOU M, Kalitzeos A, Litts K M, Singh N, Kane T, Hirji N, Mastey R, Kumaran N, Dubra A, Carroll J, Michaelides M - London T094 Mild Cone-rod dystrophy and sensorineural hearing loss with CEP250 mutation in a Japanese family GOCHO K, Kubota D, Takahashi H, Kameya S - Inzai

T095 Morpho-functional relationship and follow up of retinal dystrophy in subjects with Joubert syndrome using OCT and electrophysiology FALCIONE A, Ruberto G, Bertone C, Signorini S, Guagliano R, Bianchi P E - Pavia

T096 Diagnosis of pattern dystrophy in a case with multiple sclerosis (MS) on fingolimod (Gilenya) treatment and progressive dyschromatopsia GARNAVOU-XIROU C, Xirou T, Vasileias D, Boutouri E, Tsamis D, Ragkousis A, Gkizis I, Anastasakis A, Terzidou C, Kabanarou S - Ashford 47

Thursday, October 4 - Poster session

16:00 - 17:00 | Poster area POS PBP - Poster Session: Physiology/Biochemistry/Pharmacology in Poster area

Poster T097 - T109

SCHMETTERER L , STEFANSSON E T097 Effect of flicker stimulation on retinal and optic nerve head blood flow as measured by Laser Speckle Flowgraphy SCHMIDL D, Fondi K, Bata A, Luft N, Witkowska K, Werkmeister R, Schmetterer L, Garhofer G - Vienna

T098 Evaluation of sex differences in flicker light induced vasodilation and central retinal thickness in healthy young subjects. SZEGEDI S, Malin A G, Witkowska K J, Fondi K, Bata A M, Schmidl D, Garhofer G, Schmetterer L - Vienna

T099 Effects of focal light-emitting diode (LED)-induced phototoxicity in the albino rat retina MIRALLES DE IMPERIAL OLLERO J A, Di Phierdomenico J, Gallego-Ortega A, Villegas-Perez M P, Valiente-Soriano F J, Vidal-Sanz M - Murcia T100 Retinal ganglion cells loss and caspase 3 activation after ocular hypertension VALIENTE-SORIANO F J, Sánchez-Migallón Carreras M C, Agudo-Barriuso M, Vidal-Sanz M - Murcia

T101 Unilateral optic nerve axotomy at different distances from the optic disk cause the same course of retinal ganglion cells death GALINDO-ROMERO C, Lucas-Ruiz F, Albadalejo-García V, Ros-Alcobas L, Vidal-Sanz M, Agudo-Barriuso M - Murcia

T102 Different aetiologies cause distinct patterns of cone degeneration GARCÍA-AYUSO D, Di Pierdomenico J, Martínez-Vacas A, Hadj-Said W, Hernandez-Muñoz D, Marie M, Agudo-Barriuso M, Vidal-Sanz M, Picaud S, Villegas-Pérez M P - Murcia

T103 Microglial cell inhibition improves photorreceptor survival in two animal models of inherited retinal degeneration DI PIERDOMENICO J, García-Ayuso D, Agudo-Barriuso M, Vidal-Sanz M, Villegas-Pérez M P - Murcia

T104 Retinal response to hypoxia: new insight on the functional role of beta3 adrenoceptors DAL MONTE M, Cammalleri M, Filippi L, Bagnoli P - Pisa

T105 VEGF-induced VEGF release in the retina in response to oxidative stress DAL MONTE M, Amato R, Lulli M, Rossino M G, Cammalleri M, Casini G - Pisa

T106 Acute high-fat feeding exacerbates retinal degeneration in a mice model of retinitis pigmentosa LAX P, Kutsyr O, Noailles A, Maneu V, Cuenca N - San Vicente del Raspeig

T107 Metallothionein-mediated neuroprotection of retinal ganglion cells using FLOREC retinal explants culture MACHOWICZ J, Wojtyniak A, Witek P, Kocot E, Wawrzonkowski P, Ajeleti M, Pietrucha-Dutczak M, Lewin-Kowalik J, Smedowski A - Katowice

T108 Refinement for mouse EAE-model TENHUNEN A, Cerrada-Gimenez M, Thapa R, Jääskeläinen N, Nevalainen T, Kankkunen A, Partanen P, Mering S - Kuopio

T109 Laponite clay for long term delivery dexamethasone intravitreal inyections RODRIGO M J, Prieto E, Garcia-Martin E, Idoipe M, Vispe E, Fraile J M, Mayoral J A, Martinez T, Subias M, Lopez A, Polo V - Zaragoza 48

Thursday, October 4 - Poster session

16:00 - 17:00 | Poster area POS IM - Immunology/Microbiology

Poster T110-T123

WILLERMAIN F , DICK A T110 Suclinical signs persistance in Vogt-Koyanagi-Harada disease (VKHD) patients treated with early high-dose corticosteroids and immunosuppressive therapy YAMAMOTO TAKIUTI J H, Lavezzo M M, Sakata V M, Kanenobu C, Morita C, Oyamada M K, Hirata C E - Sao Paulo T111 Fine-Tuning of therapy in stromal choroiditis using indocyanine green angiography (ICGA) ELAHI S, Gillmann K, Gasc A, Jeannin B, Herbort Jr C P - Lausanne T112 Treatment of corticosteroid resistant Grave’s orbitopathy with tocilizumab GRIVET D, Perillat N, Gain P, Thuret G - Saint-Etienne T113 EYS606 for the Treatment of Non-Infectious Uveitis (NIU) BUGGAGE R - Paris

T114 Aciclovir-resistant HSV1 keratitis : a clinical and virological study ROUSSEAU A, Burrel S, Gueudry J, Deback C, Bordereau S, Mouriaux F, Labalette P, Bazard M C, Gabison E, Bourcier T, Schweitzer C, Labetoulle M - Le Kremlin Bicêtre

T115 Association between visual function and quality of life in patients with Vogt-Koyanagi-Harada disease YAMAMOTO TAKIUTI J H, Missaka R F, Souto F M, Marchiori B M, Caetano V M, Takiuti J T, Lavezzo M M, Oyamada M K, Hirata C E - Sao Paulo

T116 In vitro antimicrobial activity of a new ophthalmic solution containing povidone-iodine 0.6% (IODIM®) PINNA A, Donadu M G, Usai D, D’Amico-Ricci G, Boscia F, Zanetti S - Sassari T117 Interleukin-33 regulates mitochondrial function in the retinal pigment epithelium maintaining immune homeostasis SCOTT L, Vincent E, Dick A, Theodoropolou S - Bristol T118 Efficacy of a colloidal silver-based topical solution on microbial biofilms BLANCO A R, Marino A, D’Arrigo M, Nostro A - Napoli T119 Clinical follow-up of uveitis patients treated with TNF-alpha inhibitors and causes of treatment discontinuation LE A, Judice Relvas L, Makhoul D, Draganova D, Lefebvre P, Bazewicz M, Caspers L, Nubourgh I, Vanderhulst J, Goffin L, Ferster A, Postelmans L, Willermain F - Rognée

T120 Clinical characteristics and complications in intermediate uveitis: analysis of 15-years experience in a tertiary center for uveitis in Belgium VANCLOOSTER A, Tack M, Sys C, Leroy B P, De Schryver I - Gent

T121 Epidemiology in paediatric non-infectious uveitis treated with tumor necrosis factor-alpha inhibitors: a retrospective study Van Slycken M, VAN SLYCKEN A, Leroy B P, De Schryver I, Dehoorne J - Ghent

T122 Adalimumab in the management of Acute Zonal Occult Outer Retinopathy: a case report STOCKMAN M, Sys C, Balikova I, Leroy B, De Zaeytijd J, De Schryver I - Roeselare

T123 Visual electrophysiological assessment in birdshot chorioretinits treated with anti-TNF-α CLAEYS M, De Zaeytijd J, Sys C, Neu F, Leroy B P, De Schryver I - Ghent 49

Thursday, October 4 - Second afternoon session

17:00 - 18:15 | Hermes SIS RV - Oct-angiography biomarkers in choroidal and retinal disease

ZOGRAFOS L , COSCAS F

1811 17:00 OCT-A biomarkers for the macular surgical pathologies POURNARAS C - Genève

1812 17:15 structural versus Angiography OCT in AMD COSCAS F, Cabral D, Coscas G, Souied E - Creteil

1813 17:30 OCT-A in radiation induced maculopathy ZOGRAFOS L - Lausanne

1814 17:45 New insight on choroidal vasculature: multimodal morphofunctional approach LUPIDI M, Cagini C, Coscas F, Cardillo Piccolino F, Coscas G - Perugia

1815 18:00 3 D OCT angiography in choroid layer REIS CABRAL D, Coscas F, Pereira T, Narotamo H, Geraldes C, Vila-Franca M, Papoila A - Lisboa

SIS 17:00 - 18:15 | Rhodes 1 G - Laser treatments for glaucoma-old headlines or breaking news?

In recent years there has been a shift in the treatment of glaucoma to promote early & minimally invasive intervention. There is a drive to reduce dependency on topical medication given the known low rates of persistence with & adherence to topical treatment regimes. Studies suggest that minimising dependence on glaucoma drops for treatment effect can significantly improve quality of life. Laser treatments offer safe and effective pressure lowering and with increasing patient acceptance of laser as a primary treatment option this SIS will offer clinicians a review of the laser modalities available and late breaking news on new uses for traditional treatments. CRAWLEY L , AMEEN S 1821 17:00 eCP- reducing inflow from the inside CRAWLEY L - London

1822 17:18 micropulse diode laser trabeculoplasty- subthreshold is the new threshold AMEEN S - London

1823 17:36 ALPI- Post EAGLE to PI or not to PI BESINIS D - Nea Smyrni

1824 17:54 SLT- revolution or evolution Porteous A - London 50

Thursday, October 4 - Second afternoon session

17:00 - 18:15 | Rhodes 2 C G - Landmark papers in ophthalmology – how to do one!

 Beginner

This course will include four lectures covering personal reflections of established researchers on important steps that lead to the publication of a landmark paper. The lectures will include topics such as the importance of study design, important factors involving patient recruitment, how to get the money through grant applications, journal selection etc. Participants will have the opportunity to have an informal discussion with the lecturers at the end of the session. Participants can then continue to mingle and get to know each other over some drinks and food. JÓHANNESSON G 1831 17:00 study design - making the most of your resources when planning a trial BOWMAN R - London

1832 17:18 mitochondria to money, how to get that funding VOTRUBA M - Cardiff

1833 17:36 Keeping your trial on track - when to start recruiting, how to keep things moving and when to stop ROSA A, Oliveira M, Martins A - Coimbra

1834 17:54 end points for the 21st century and making your research understandable to the general public THOMPSON D - London

17:00 - 18:15 | Rhodes 3 SIS PO - Genetic predisposition syndromes in ophthalmology

Ophthalmology recognizes many syndromes, some of which have a known genetic basis. It is important to recognize the association between an eye disease and the systemic syndrome, as the presence of a germ line mutation may not only affect other organs of the patient, but may also be important for family members and offspring. Several important genetic predisposition syndromes will be discussed. KIVELÄ T , MOURIAUX F 1841 17:00 Von Hippel-Lindau tumor predisposition syndrome SCHALENBOURG A - Lausanne

1842 17:15 Xeroderma pigmentosum tumor predisposition syndrome TBD

1843 17:30 BAP1-TPDS: a wide-ranging tumor predisposition syndrome KIVELÄ T, Turunen J A, Repo P, Järvinen R S, Lehesjoki A E - Helsinki

1844 17:45 Familial adenomatous polyposis and associated differential diagnosis of RPE lesions KIILGAARD J F - Copenhagen

1845 18:00 second cancers in survivors of hereditary retinoblastoma VAN HOEFEN WIJSARD M, Fabius A W, Van Leeuwen F E, Moll A C - Amsterdam 51

Thursday, October 4 - Second afternoon session

17:00 - 18:15 | Rhodes 4 SIS ACB - Ocular surface as a target for drug development

In the maintenance of the fine homeostasis of ocular surfaces, cornea, conjunctiva and lacrimal glands are interacting via nervous system, growth factors and cytokines regulating several mechanisms like tear fluid secretion, cell differentiation, tissue regeneration, inflammation and wound healing. Ocular surface problems are clinically common, quality of life reducing and potentially vision threatening conditions. Currently it is estimated that there are nearly 350 million patients world wide suffering from dry eye only and the direct costs of it is $ 3,8 billions. Ocular surface is also a potential target of adverse events of topical medical therapies and several ocular intervention. This SIS is focusing on ocular surface as a potential target for drug development and safety issues including proteomic approach. Tear proteomics is a novel approach to study the mechanisms involved in disease processes and to find clinically relevant biomarkers for diagnostics and for the development of novel therapeutic interventions in clinical studies. UUSITALO H , BEUERMAN R 1851 17:00 The utility of proteomics for understanding the pathophysiology of dry eye STERN M E - Irvine

1852 17:15 Ocular surface disease and dessicating stress CALONGE M, Pinto-Fraga F J, Fernandez I, Gonzalez-Garcia M J, Enriquez De Salamanca A, Lopez-Miguel A - Valladolid

1853 17:30 Large data sets in Proteomics and new insights into eye disease BEUERMAN R - Singapore 1854 17:45 standardization of preclinical testing platforms for topical ophthalmic drugs KALESNYKAS G, Hakkarainen J J, Ziniauskaite A, Thapa R, Tenhunen A, Mering S, Kaja S - Kuopio

1855 18:00 Ocular surface and proteomic safety biomarkers in topical medication UUSITALO H - Tampere

17:00 - 18:15 | Gallieni 1+2 SIS MBGE - Grand rounds in animal & human genetics

This SIS will provide a forum to discuss clinical and molecular cases with peers and leaders from the field of ophthalmic genetics, with the specific aim to stimulate interaction between human and mouse ophthalmic geneticists. The format is simple, informal and is comparable to that of the Grand Rounds in departments of ophthalmology around the World. All EVER participants are invited to come and discuss cases during this session. All of us will learn! LEROY B , GRAW J 1861 17:00 Human Case LISKOVA P, Kousal B, Petra H, Kolarova H, Honzik T - Prague

1862 17:18 Animal Case ROUX M, Guimond A, Herault Y - Illkirch

1863 17:36 Animal Case AMARIE O, Fuchs H, Gailus-Durner V, Hrabě De Angelis M, Graw J - Neuherberg

1864 17:54 Human Case LEROY B - Ghent 52

Thursday, October 4 - Evening session

18:15 - 19:30 | Rhodes 2 SIS What does TFOS DEWS II bring to your clinical practice?

Rolando M 18:15 What’s new in TFOS DEWS II? ROLANDO M - Italy

18:33 Proteomics in tear fluid GRUS F - Germany

18:51 Breaking the chain: inflammation in dry eye SHORTT A - United Kingdom

19:09 A new weapon for chronic dry eye co-presenter Dr. Quintas EMESZ M - Austria Quintas A - Portugal 53

Friday October 5 54

Friday, October 5 - First morning session

8:30 - 9:45 | Hermes SIS RV - Ischemic ocular diseases: raise the red flag!

Theme: ocular ischemic diseases: from pole to pole The SIS will adress clinical consequences of ischemia in various ocular pathologies . The participants will receive useful clinical tips to manage such pathologies. AMBRESIN A , POURNARAS J 2111 8:30 Peripheral ischemia in diabetes: anti VEGF, PRP? AMBRESIN A - Lausanne

2112 8:42 Blood flow dysfunction in glaucoma Schmidl D - Vienna

2113 8:54 Techniques of phacoemulsification and vitreoretinal surgeries in ischemic eyes POURNARAS J A - Lausanne

2114 9:06 Choroidal and retinal occlusive vasculitis VAUDAUX J - Lausanne

2115 9:18 Acute ischemic retinal disease MANTEL I - Lausanne

2116 9:30 Ischemic optic neuropathies: does the origin of ischemia matter? TBC

8:30 - 9:45 | Rhodes 1 SIS G - Maximising information extraction from biological data

Big Data describes an approach to research where the aim is to extract all available information from a data source and therefore overcome some of the limits of conventional sampling based approaches. This multidisciplinary SIS presents recent developments in techniques to maximise information extraction from pre-clinical and clinical imaging datasets. The use of these practices to yield novel mechanistic insights into neurodegenerative processes in glaucoma will be discussed in addition to techniques that can be ultimately exploited for the development of novel diagnostic and therapeutic approaches in patients. DAVIS B , NORMANDO E M 2121 8:30 rGC cell size and susceptibility to loss in rodent glaucoma models DAVIS B, Guo L, Ravindran N, De Groef L, Cordeiro M F - London

2122 8:45 Improving information extraction from visual field data NORMANDO E M - London

2123 9:00 Neurodegeneration in the Brain – Before or after the retina? JOLLY J, Sheldon A, Alvarez I, Ip B, Maclaren R, Bridge H - Oxford 2124 9:15 Cortical anomalies in response to RGC damage: how do they affect the visual field and how should we measure them? REDMOND T - Cardiff

2125 9:30 Image analysis and data science for vessel network analysis in the retina DE BOEVER P - Mol 55

Friday, October 5 - First morning session

8:30 - 9:45 | Rhodes 2 C COS - Optical imaging techniques for the cornea and anterior eye segment – pearls and pitfalls

 Intermediate

Within the last 25 years more and more classical diagnostic techniques such as ultrasound were augmented or superseded by optical based diagnostic techniques. Amongst those we find Placido based corneal topography,S cheimpflug orO CT based tomography of the anterior segment of the eye, confocal microscopy of the cornea or specular microscopy of the corneal endothelium.

In this course we will give guidelines how to read and to interpret measurements of these instruments. The audience will get a comprehensive insight how to read the specific output parameters of these modern diagnostic tools and how to use them for instrument-assisted diagnosis. The interpretations will be illustrated and emphasized by typical clinical examples. SZENTMARY N , WYLEGALA E 2131 8:30 Placido-based corneal topography and Scheimpflug-based corneal tomography LANGENBUCHER A, Szentmáry N, Daas L, Wylegala E, Eppig T - Homburg

2132 8:45 High resolution anterior segment OCT CASIA 2 for corneal and anterior segment diagnosis WYLEGALA E - Katowice

2133 9:00 Confocal microscopy for diagnosis of infectious processes in the cornea DAAS L, Szentmáry N, Flockerzi E, Langenbucher A, Seitz B - Homburg

2134 9:15 measurement of corneal biomechanics using the high-speed Scheimpflug system CORVIS EPPIG T, Szentmáry N, Spira-Eppig C, Langenbucher A, Seitz B - Homburg/Saar

2135 9:30 Analysis and interpretation of specular microscopy measurements of the corneal endothelium SZENTMARY N, Tóth G, Butskhrikidze T, Hager T, Langenbucher A, Seitz B - Budapest

8:30 - 9:45 | Rhodes 3 SIS IM - Therapeutic update: biologic agents in uveitis

The treatment of non infectious uveitis continues to remain a challenge for many ophthalmologists. Unfortunately, in spite of a multitude of highly unfavourable systemic effects, corticosteroids are still regarded as the mainstay of treatment for many patients with chronic and refractory non infectious uveitis. However, with the success of other conventional and biologic immu- nomodulatory agents in treating systemic inflammatory and autoimmune conditions, interest in targeted treatment strategies for uveitis is increasing. Multiple clinical trials on steroid-sparing immunosuppressive agents and biologic agents have already been completed, and many more are ongoing. This symposium highlights the results and implications of these clinical trials investigating novel treatment options for non infectious uveitis.

VAN CALSTER J , BODAGHI B 2141 8:30 Introduction / clinical trial results of TNF alfa blocking agents VAN CALSTER J - Leuven 2142 8:48 role of other biologics in adult uveitis patients WILLERMAIN F - Bruxelles

2143 9:06 Biologics in childhood uveitis DICK A - Bristol

2144 9:24 New molecules under development BODAGHI B - Paris 56

Friday, October 5 - First morning session

8:30 - 9:45 | Rhodes 4 SIS LC/RV - New approaches in myopia diagnosis, prevention and treatment

Myopia is a global problem, being particularly prevalent in the urban areas of East Asia. It is progressing at faster than predicted rates for reasons that are still unknown. Besides the direct economic and social burdens, associated ocular complications from pathologic myopia may lead to significant visual impairment and blindness due to various pathologies in the macula, peripheral retina and the optic nerve. The epidemiology of myopia is characterized by increasingly early onset, combined with high myopia progression rates. In fact, with prevalence of myopia above 80% and high myopia over 20%, it is crucial to control this degenerative disease. New generation optical coherence tomography (OCT) technologies, including enhanced depth imaging (EDI-OCT), swept source OCT (SS-OCT) and OCT angiography, have led to a greater insight in pathophysiology of high-grade myopia. The aim of this symposium is to provide an update on diagnostic tools, interventions to slow the onset of myopia and retard its progression, as well as a review on current treatment options and their efficacy. GRZYBOWSKI A , ASCASO F 2151 8:30 myopia epidemiology MORGAN I - Ainslie

2152 8:45 oCT angiography in myopia ASCASO F - Zaragoza 2153 9:00 myopic CNV – current diagnosis and management SCHWARTZ S - Naples

2154 9:15 myopia control with Atropine in Europe KLAVER C, Tan E, Tideman W, Polling J R - CA Rotterdam

2155 9:30 other strategies of Myopia control GRZYBOWSKI A - Olsztyn

8:30 - 9:45 | Gallieni 1+2 SIS MBGE/NSPH - Understanding retinal ganglion cell loss — from genes to disease mechanisms

Primary inherited optic neuropathies are a group of blinding genetic disorders in which optic atrophy secondary to loss of retinal ganglion cells is a key clinical feature. The commonest causes worldwide are mutations in mitochondrial DNA (causing Leber’s hereditary optic neuropathy: LHON) and OPA1 mutations (causing Autosomal Dominant Optic Atrophy: ADOA). Based on published data from different geographical populations, 60-80% of patients with ADOA have mutations in the OPA1 gene. Although inherited optic neuropathies are considered as ‘orphan’ diseases, grouped together, the prevalence is about 1 in 10,000 – representing an important cause of blindness in both the paediatric and young adult population. Recent trials of drugs and gene therapy in patients with LHON, have shown the first glimmer of hope for the treatment of this group of patients. At this exciting time, this SIS will focus on disease mechanisms and clinical phenotyping and potential avenues towards novel and effective therapies. VOTRUBA M , YU-WAI-MAN P 2361 8:30 The pathogenic mechanisms of mitochondrial optic neuropathies studied in iPSCs-derived neurons CARELLI V - Bologna

2362 8:48 retinal vascular changes in mitochondrial optic neuropathy BARBONI P - Bologna

2363 9:06 What have metabolism studies taught us about ADOA pathophysiology and possible future therapies? LENAERS G, Reynier P, Chao De La Barca M, Bocca C, Kouassi Nzoughet J, Charif M - Angers

2364 9:24 Novel strategies to treat autosomal dominant optic atrophy VOTRUBA M - Cardiff 57

Friday, October 5 - Keynote lecture

9:45 - 10:15 | Hermes KN Keynote lecture by Leonard LEVIN

9:45 Introduction by Francesca M CORDEIRO

2211 9:50 The Axon is dead: long live the Axon!

Leonard LEVIN — Montreal

In 2002 Martin Raff and colleagues wrote a seminal paper identifying an axonal self-destruction program as separate for the more familiar programs for somal loss. Given that so many central nervous system

diseases begin (and usually end) with axonal injury and degeneration, Leonard Levin several laboratories focused on dissecting the mechanisms by which these processes occur. More recently, we have developed an ability to identify the very earliest signals associated with axonal degeneration. Coupled with the development of pharmacological therapies that might protect axons (“axoprotection”) and the availability of animal models where axon degeneration is severely inhibited, we are in a golden age of axon biology and therapy.

10:15 Award presentation of the EVER Certificate of Honour 58

Friday, October 5 - Second morning session

10:45 - 12:00 | Hermes SIS RV - Laser photocoagulation of capillary macro-aneuvrysms in retinal vascular diseases

During diabetic macular edema (DME) and retinal vein occlusion (RVO), it has recently been shown that focal vascular anomalies (capillary macro-aneurysms) may play a central role. Indeed, their prevalence is estimated to be around 30% of cases (Dupas, unpublished data). The systematic detection of macro-aneurysms followed by their OCT-controlled photocoagulation is of interest because it may diminish the need for intravitreal injections. We subsequently developed a procedure called Indocyanine green-Guided Targeted Laser photocoagulation (IGTL) which combines the detection of macro-aneurysms by ICG angiography, their photocoagulation by laser. We have shown that targeted photocoagulation of those macro-aneuvrysms may improve vision while decreasing retinal edema, with low need for intra vitreal injection (Paques et al, BJO 2016). The proposed SIS intends to re-assess the role of photocoagulation in chronic macular edema management, while discussing indications and treatment modalities. DUPAS B , PAQUES M 2311 10:45 Capillary macroaneurysms in retinal vascular diseases : an overview PAQUES M - Paris

2312 11:03 laser photocoagulation of macroaneurysms; clinical cases in DME DUPAS B - Paris 2313 1:21 macroaneurysms and their photocoagulation in other diseases DELYFER M N - Bordeaux

2314 11:39 Technological developments for improving indocyanine-guided laser photocoagulation MEIMON S - Paris

SIS 10:45 - 12:00 | Rhodes 1 G - EVER Obergurgl optic-nerve-conference symposium 2017

The EVER optic nerve conference takes place every year in Obergurgl in the austrian alps. This conference explores the current state of our understanding of research related to optic nerve and neurodegeneration and regeneration. Topics identify the crucial challenges and promising future research directions for boosting visual function in optic nerve disease. To stimulate ideas and discussion, leading experts from a variety of fields emphasize a cross-sectional, interdisciplinary approach. The conference bring together clinicians and basic scientists from different fields and highlight translational research providing a platform for networking and stimulating discussions. In this special interest symposium SIS some of the topics of the Obergurl optic nerve conference 2017 will be presented. GRUS F 2321 10:45 redox-dependent signaling in axonal degeneration LEVIN L - Montreal

2322 11:00 seeing is believing : live imaging of microvascular pathology in glaucoma DI POLO A - Montreal

2323 11:15 Ageing, neuronal metabolism and mitochondria in glaucoma WILLIAMS P - Bar Harbor

2324 11:30 mitochondrial genetic variation and its implications for glaucoma KHAWAJA A - London

2325 11:45 meCP2 association with glaucoma and protein interactions in the retina FUNKE S - Mainz 59

Friday, October 5 - Second morning session

10:45 - 12:00 | Rhodes 2 C COS - Diagnosis and treatment of infectious keratitis in the clinical practice today

 Intermediate

We summarize up-to-date diagnostic and treatment options of infectious keratitis using literature data and clinical examples. In the clinical practice, most commonly bacterial, herpetic, mycotic and acanthamoeba keratitis occur. Beside slitlamp examination, for diagnostic purpose, corneal sensitivity is analysed. We routinely perform in vivo confocal microscopy, polymerase-chain-reaction (PCR) and histological examination of the corneal sample. As conservative treatment we use primarily topical moxiflox- acin or cephazolin with fortified tobramycin or gentamycin in bacterial, topical antiviral gel (in some cases in combination with systemic antiviral treatment) in part in combination with topical corticosteroids in herpetic, voriconazole or amphotericin-B in mycotic, and topical-triple-therapy (diamidine, biguanid and antibiotics) in acanthamoeba keratitis. In case of early diagnosis and initiation of topical therapy, most cases of infectious keratitis recover successfully. However, beside conservative treatment, amniotic membrane transplantation, crosslinking and penetrating keratoplasty therapy may be necessary in well-selected cases and well-defined details. SZENTMARY N , SEITZ B 2331 10:45 Bacterial keratitis – standard treatment? MÓDIS L - Debrecen

2332 11:00 “Herpetic keratitis” – a chameleon SEITZ B - Homburg

2333 11:15 Aciclovir resistant herpetic keratitis - diagnosis and treatment REMEIJER L, Verjans G - Rotterdam

2334 11:30 Acanthamoeba keratitis – when to use conservative and surgical treatment? SZENTMARY N, Laurik-Feuerstein K L, Daas L, Shi L, Langenbucher A, Seitz B - Budapest

2335 11:45 mycotic keratitis – the threat of today? DAAS L, Szentmáry N, Flockerzi E, Langenbucher A, Seitz B - Homburg

10:45 - 12:00 | Rhodes 3 SIS IM/PO - Uveitis: translational insights in invasive diagnostics

Patients with intraocular inflammation can present with very difficult diagnostic challenges. Over the last years, our understanding of the underlying mechanisms of uveitis has grown and the possibilities of immunologic and microbiologic testing have increased. As a result, it has become clear that uveitis entails a multitude of diseases. Although some eyes are inflamed due to local ocular immune phenomena, many of them are ocular manifestations of systemic diseases. The spectrum of disease pathogenesis is highly diverse, including trauma, infectious diseases, autoimmunity and neoplasia. Hence, an accurate diagnosis is the cornerstone of adequate treatment. Even after a profound workup, a precise diagnosis cannot be found in up to 30% of the patients. Fortunately, new yet invasive diagnostic techniques are being developed, such as the determination of inflammatory mediators and the cellular reaction on ocular fluid samples. VAN CALSTER J , VAN GINDERDEUREN R 2341 10:45 Introduction / surgical techniques / Outcome in 2018 VAN CALSTER J - Leuven

2342 11:03 Future in translational research: proteomics? DICK A - Bristol

2343 11:21 Uveitis and histopathology in 2018 VAN GINDERDEUREN R - Leuven

2344 11:39 Translational research in lymphoma NERI P - Abu Dhabi 60

Friday, October 5 - Second morning session

10:45 - 12:00 | Rhodes 4 SIS LC - Optical and refractive changes with aging

This Special Interest Symposium will give an overview about the refractive development from childhood to adulthood, highlighting the unresolved questions which will define future research. We will cover the topics of eye modelling and will focus on age related changes in the cornea and crystalline lens. MICHAEL R , ROZEMA J 2351 10:45 The physics of light scattering changes with aging VAN DEN BERG T J - Amsterdam

2352 11:00 Clinical and research applications of modelling ocular biometry ROZEMA J - Edegem

2353 11:15 optical quality of the cornea and its age-related changes NAVARRO R - Zaragoza

2354 11:30 refractive development of the lens and it's relation to cataract type MICHAEL R, Pareja Aricó L A, Barraquer R I - Barcelona

2355 11:45 multiple stages of refractive development MORGAN I - Ainslie

10:45 - 12:00 | Gallieni 1+2 LC/MBGE - Cholesterol, oxysterols and eye disease SIS

Cholesterol and its derived oxysterols are associated with a range of different eye diseases. Cholesterol deposits are found in eye tissues as a result of mutations in cholesterol-processing enzymes (eg Smith-Lemli-Opitz syndrome (SLOS)) and in these cases they are associated with lens cataract. Statin use is also linked to cataract incidence. Recently though it is the identification of cholesterol metabolism as a risk factor for Age Related Macular Degeneration that has sparked most interest in this oxysterol and its metabolism. Indeed, finding a number of oxysterols in drusen including, 7keto-cholesterol, which also correlates with age related cataract evidences the close association between cholesterol, its derivatives and oxidized products and the maintencance of eye health. The retina exhibits both concentration and oxysterol specific cytotoxic responses and yet oxysterols have also emerged as potential therapeutic leads for cataract. The importance of cholesterol to lens (Subczynski/Raguz) and retinal (Fliesler) homosta- sis as well as its link with AMD (Curcio) and cataract (Uwineza/Quinlan) will be presented. Gender and Early Career Investigator balance is a factor in speaker selection. QUINLAN R 2161 10:45 Cholesterol oxidation and cataract UWINEZA A, Cummins I, Kalligeraki A, Jarrin M, Ainsbury E, Quinlan R - Durham

2162 11:03 slos, oxysterols and retinal homeostasis FLIESLER S - Buffalo

2163 11:21 Cholesterol dependent homeostasis in the lens - a biophysical perspective SUBCZYNSKI W - Milwaukee

2164 11:39 Cholesterol and the extracellular deposits of age-related macular degeneration (AMD) CURCIO C - Birmingham 61

Friday, October 5 - European Ophthalmology Heritage lecture

12:00 - 12:30 | Hermes PS European Ophthalmology Heritage lecture by Jean-Jacques DE LAEY

12:00 Introduction by Alain BRON

2411 12:05 A brief history of cataract surgery

Jean-Jacques DE LAEY — Gent

Although the Eber’s papyrus dating from 1525 BC possibly mentions cataract, it is by no way certain that the ancient Egyptians performed cataract surgery. Sushutra is considered the father of Indian surgery. He is probably the first to mention cataract surgery. His technique of Jean-Jacques lens couching may have reached Rome via Alexandria. In his book “De DE LAEY Medicina” Celsius gives a precise description of lens couching and this technique will remain the standard operation for cataract surgery till the 18th Century. It was often performed by itinerant surgeons, one of the most famous being Chevalier John Taylor who operated unsuccessfully on Bach. Jacques Daviel, who will become surgeon-oculist to king Louis XV describes in the Mémoires de l’Académie de Chirurgie in 1753 his first extracapsular cataract extraction for which he performed an inferior corneal incision. Although this first eye was lost by endophthalmitis Daviel continued to experiment with this technique and claimed that by 1756 he had performed 434 cataract extractions of which 354 were “perfectly successful”. Whereas couching still had its firm supporters like Scarpa, re- sulting in what was sometimes called “The Hundred Years War”, Daviel’s technique became gradually universally accepted. A guillotine type corneal knife was designed by Guerin (1769) and later by Dumours and Du- mont (1760). The most successful cataract knife was however that of von Graefe. Further improvements were the introduction of corneal sutures by Williams in 1866, phenol asepsis by Lister in 1869 and especially local anaesthesia with cocaine by Koller in 1888. The next important steps will be the introduction of intraocular lenses by Ridley in 1949 and of phacoemulsification by Charles Kelman in 1962.

12:30 Award presentation of the EVER Certificate of Honour 62

Friday, October 5 - Noon session

12:30 - 13:30 | Hermes CIS Lunchtime CIS

GuangDong Ophthalmologist Association (GDOA) is the largest organization for eye care professionals in south China. GDOA has over 1000 members divided over 9 different subspecialties such as glaucoma and retina. 63

Friday, October 5 - Noon session

12:30 - 13:30 | Rhodes 3 CIS Innovations & Novel Products in Ophthalmology (INPO)

FUCHSLUGER T 2511 12:30 Fluorescence Lifetime Imaging Ophthalmoscopy KATAYAMA Y - Germany

2512 12:45 Novel ophthalmic applications of neurokinin 1 receptor antagonists FERRARI G - Italy

2513 13:00 Laponite clay as a carrier for controlled drug delivery system for intravitreal injections RODRIGO MJ - Spain

2514 13:15 Articor - a biosynthetic material for ocular surface reconstruction FUCHSLUGER T - Germany 64

Friday, October 5 - Noon session

12:30 - 13:30 | Rhodes 1 SIS COS/MBGE - TFOS DEWS II: Dry Eye redefined

This SIS will summarize the main findings and novelties presented in the TFOS DEWS II report, including the updated definition and classification, evidences on epidemiology and pathophysiology, the proposed diagnostic algorithm and therapeutic approach. VILLANI E , SULLIVAN D A 2521 12:30 TFOS DEWS II Definition and Classification Report VILLANI E - Milan

2522 12:40 TFOS DEWS II Epidemiology and Pathophysiology Reports SULLIVAN D A - Boston, MA

2523 12:50 TFOS DEWS II Pain & Sensation Report BELMONTE C - Alicante 2524 13:00 TFOS DEWS II Iatrogenic Dry Eye Report MESSMER E M - Munich

2525 13:10 TFOS DEWS II Diagnostic Methodology Report PULT H - Weinheim

2526 13:20 TFOS DEWS II Management and Therapy Report BARABINO S - Sanremo 65

Friday, October 5 - First afternoon session

13:30 - 14:45 | Hermes SIS RV - Macular interface surgery

AIM: To present all the new facts regarding macular interface pathology METHODS: We will provide lectures and questions and answers in the field of macular interface pathophysiology, macular hole, ERM, Vitreomacular Traction Sundrome, New Techniques, New Instrumentation. RESULT: We believe that at the end of rhe session we will provide all the necessary knowledge for a safer and better management of the macular interface pathology. CONCLUSION: Macular interface pathology is a good proportion of a Vitreoretinal Surgeon's every day activity. The more you know the better management you can provide. PAPPAS G , POURNARAS J 2611 13:30 macular hole management VIESTENZ A - Halle (Saale)

2612 13:45 erm management TRANOS P - Thessaloniki

2613 14:00 New Instrumentation POURNARAS J A - Lausanne

2614 14:15 macular interface surgery complication and management STAPPLER T - Lausanne

2615 14:30 20 Questions and answers regarding macular interface pathology and surgery PAPPAS G - Heraklion

13:30 - 14:45 | Rhodes 1 SIS G/IM - The latest update on uveitic glaucoma

Uveitic glaucoma is a common complication which afflicts up to 20% of these patients. Uveitic glaucoma is a challenging task for the ophthalmologist. The treatment is longitudinal and the type of inflammation affects the choice of topical glaucoma medication, IOP control, cataract development, surgical decision making, and medical management after glaucoma surgery. This SIS tries to review the latest update on management and offers some recommendations on treatment options. POURJAVAN S , NERI P 2621 13:30 The incidence of Glaucoma in uveitic patients NERI P - Abu Dhabi

2622 13:48 The pathophysiology and medical management of uvitic glaucoma POURJAVAN S - Brussels

2623 14:06 surgical options and management in uvitic patients VAN CALSTER J - Leuven

2624 14:24 Glaucoma, surgical treatment in uveitic and JIA patients KESTELYN P - Gent 66

Friday, October 5 - First afternoon session

13:30 - 14:45 | Rhodes 2 SIS COS - New approaches for unmet needs in anterior segment diseases

This symposium discusses novel basic scientific and translational approaches regarding unmet needs in anterior segment diseases. FUCHSLUGER T , FERRARI G 2631 13:30 Nerves in the cornea: proper functioning and healing potential FERRARI G - Milan

2632 13:45 Novel biomaterials for ocular surface surgery THIEME D, Fuchsluger T, Schubert D W - Erlangen

2633 14:00 Inhibition of apoptosis for the treatment of corneal endothelial diseases FUCHSLUGER T - Erlangen

2634 14:15 link between genetic and functional analyses in pseudoexfoliation glaucoma BERNER D - Erlangen

2635 14:30 TFG-ß1 and LOXL1 affect the Pseudoexfoliation syndrome pathology LIRAVI P - Erlangen

13:30 - 14:45 | Rhodes 3 C PO - Conjunctival tumors

 Advanced

We describe benign and malignant conjunctival tumors with their clinical and histological aspects We summarise the practical management of benign conjunctival lesions, the surgical approach of conjunctival tumors and the management of epithelial and melanocytic malignancies. We give all the indications of radiotherapy and local chemotherapy and guidelines for follow up of patients Rare tumors of the conjunctiva will also be described DESJARDINS L , MOULIN A 2641 13:30 Conjunctival tumors: clinics and pathology MOULIN A - Lausanne

2642 13:42 What to do in case of papilloma or nae SCHALENBOURG A - Lausanne

2643 13:54 Principles of surgical approach of conjunctival tumors CASSOUX N - Paris

2644 14:06 management of epithelial malignancies ( radiotherapy and local chemotherapy) DESJARDINS L - Paris

2645 14:18 management of malignant conjunctival melanoma ( radiotherapy and local chemotherapy) ZOGRAFOS L - Lausanne

2646 14:30 rare conjunctival tumors:( choristomas, neurinomas , sebaceous carcinomas…..) MATET A - Paris 2647 14:42 High-throughput sequencing reveals no microbial pathogens in ocular adnexal extranodal marginal zone B-cell lymphoma MIKKELSEN L H, Mollerup S, Hansen A, Heegaard S - Copenhagen 67

Friday, October 5 - First afternoon session

13:30 - 14:45 | Rhodes 4 SIS PBP/ACB - Modern tools to examine the retina

The Special Interest Symposium will present recent studies focussing on modern techniques to identify and study specific populations of retinal neurons, alterations in blood supply and fate of cell transplants following several experimental situations mimicking common retinal diseases. The SIS will provide ample opportunity for interaction among scientists attending the conferences. VIDAL-SANZ M , SALINAS NAVARRO M A 2651 13:30 New approaches to study retinal pericytes ALARCÓN-MARTÍNEZ L - Montreal

2652 13:48 Cell Tracking: The key to understanding the phenomena after photoreceptor transplantation ORTÍN-MARTÍNEZ A, Tsai E L S, Comanita L, Tachibana N, Gurdita A, El-Sehemy A, Nickerson P E, Wallace V A - Toronto

2653 14:06 Population of Pituitary Adenylate Cyclase-Activating Polypeptide and Melanopsin-Expressing retinal Ganglion Cells in the Albino Adult Rat Retina SALINAS NAVARRO M A, Nadal Nicolas F M, Agudo-Barriuso M, Vidal-Sanz M - El Palmar 2654 14:24 Choosing the best marker to identify retinal ganglion cells GALINDO-ROMERO C, Nadal-Nicolas F M, Lucas-Ruiz F, Marsh-Armstrong N, Vidal-Sanz M, Agudo-Barriuso M - Murcia

13:30 - 14:45 | Gallieni 1+2 SIS MBGE - New insights in ocular developmental dysgenesis

The symposium aims i) to reveal novel phenotypes or phenotypes-genotypes correlations; ii) to bring samples of mutations in coding regions and impairing the gene function and iii) to question an intriguing regulatory mechanism in congenital microcoria. -Describing the X-linked BCOR gene role in two different syndromes with eye defects the OFCD syndrome, which occurs exclu- sively in females and a severe recessive microphthalmia syndrome, in males. -Reporting a wide spectrum of eye anomalies with different modes of inheritance of FOXE3 mutations demonstrating correlations between the mutation type, the mode of inheritance and the phenotype severity. -Evidencing mutations pattern in non-coding regions of PAX6 in 3/4 of 27 patients suffering aniridia without coding sequence mutations. -Studying 13q32.1 deletions encompassing TGDS & GPR180 in Congenital microcoria (MCOR). The role of both genes and elements regulating the expression of neighboring genes in MCOR was addressed in transgenic mouse lines with variable deletions of the region. Molecular analysis clearly shows iris-specific modification of distant genes expression, suggesting a regulatory landscape modification and the fate of embryonic cells involved in iris formation. CALVAS P , ROZET J 2661 13:30 Pathogenic variants in the X-linked BCOR gene cause two different syndromes RAGGE N - Oxford

2662 13:48 FOXE3 mutations correlations between mutation types, inheritance pattern, and phenotype severity PLAISANCIE J, Ragge N, Dollfus H, Kaplan J, Lehalle D, Francannet C, Morin G, Colineaux H, Calvas P, Chassaing N - Toulouse

2663 14:06 PAX6 non-coding regions variants leading to aniridia spectrum Plaisancié J, Tarilonte M, Ramos P, Dollfus H, Blanco-Kelly F, Kaplan J, Fares-Taie L, Francannet C, Goldenberg A, Rozet J M, Ayuso C, Chassaing N, Calvas P, CORTON PEREZ M - Madrid

2664 14:24 Is the modification of the 13q32.1 regulatory landscape the cause of congenital microcoria? FARES-TAIE L, Nedelec B, David P, Gerber S, Crippa S, Passet B, Vilotte J L, Chassaing N, Kaplan J, Kostic C, Calvas P, Rozet J M - Paris 68

Friday, October 5 - Coffee with Profs and Poster session

14:45 - 15:45 | Poster area Coffee with SOC Coffee with Profs - Part II Profs

Chris Purslow Head of Medical Affairs, Thea Pharmaceuticals, UK & Ireland Marcela Votruba MA BM BCh PhD FRCOphth Head of School & Consultant Ophthalmologist, School of Optometry & Vision Sciences, Cardiff University Aki Kawasaki Hôpital Ophtalmique Jules Gonin, Dept. of Neuro-Ophthalmology, Lausanne, Switzerland Fabiana D’Esposito MD, PhD Ophthalmologist, Ophthalmic Genetics, Honorary Senior Lecturer, Imperial College, London, UK, Consultant, Western Eye Hospital, Imperial NHS Trust, London, UK Visiting Professor, University of Naples “Federico II”, Italy, Magi Euregio, Bolzano, Italy

The idea is to provide a casual yet personal venue where colleagues, in particular the younger faction, can share comments and ideas with an expert.

14:45 - 15:45 | Poster area POS G - Glaucoma

Poster F001-F050

YAP T , DAVIS B

F001 Diagnostic accuracy of a new thresholding glaucoma screening programme using temporally modulated flicker JINDAL A, Fidalgo B, Ctori I, Tyler C, Lawrenson J - London

F002 Transconjunctival bleb sutures for post-trabeculectomy hypotony RULE E, Beer F, Manns R, Ambrose I, Walker L, Lockwood A, Kirwan J - Portsmouth

F003 The Role of the αvβ3 Integrin in Lamina Cribrosa Cells and the Possible Role in Glaucoma Pathogenesis HOPKINS A, Murphy R, Irnaten M, Wallace D, Brennan D, Clarke A, O’Brien C - Dublin

F004 Intravitreal rituximab for the treatment of ocular lymphoma and glaucoma LOCKWOOD A, Farnworth D, Rainsbury P, Balendra S - Portsmouth

F005 Peripapillary microvasculature and Lamina cribrosa: is there a role in the diagnosis of primary open-angle glaucoma? RODRIGUES C, Sousa Silva R, Cabral D, Rodrigues P, Marques M, Camacho P, Valadares J, Segurado J, Fernandes J, Barrão S - Lisbon F006 Results from an international observatory survey on the management of glaucoma treatments and its impact on the ocular surface disease (OSD), an ECOS-G (European Club of Ocular Surface in Glaucoma) initiative. KOLKO M, Iliev M E, Benitez Del Castillo J M, Thygesen J, Baudouin C - Glostrup

F007 Incidence and prevalence of glaucoma in native and immigrant groups living in Denmark HORWITZ A, Klemp M, Torp-Pedersen C, Kolko M - Copenhagen

F008 Comparing the mid-term efficacy and safety of the Stegmann Canal Expander Canaloplasty with the prolene suture Canaloplasty in cases of open angle glaucoma ADLJU R, Brazitikos I, Stangos A, Mameletzi A, Sunaric Mégevand G - Geneva

F009 Anatomical position of the raphe in the human retina JANSONIUS N, Schiefer U - Groningen

F010 Effects of acute ocular hypertension on the adult rat retina: in vivo an ex vivo retinal analysis. GALLEGO ORTEGA A, Segura-Castro P, Gómez-Serna C, De La Villa P, Di Pierdomenico J, Bernal-Garro J, Villegas-Pérez M P, Valiente-Soriano F J, Vidal-Sanz M - Murcia 69

Friday, October 5 - Poster session

14:45 - 15:45 | Poster area POS G - Glaucoma

Poster F001-F050

YAP T , DAVIS B

F011 Peripapillary vascular analysis from optical coherence tomography angiography to differentiate glaucoma and normal eyes MARQUES M, Cabral D, Rodrigues P, Alves S, Valadares J, Barrão S - Lisboa

F012 Potential metabolic markers in glaucoma and their regulation in response to hypoxia TIEDEMANN D, VOHRA* R, Marie Dalgaard L, Vibæk Jensen J, Hildegaard Bergersen L, Vidiendal Olsen N, Hassel B, Abbas Chaudhry F, Kolko M - Copenhagen F013 The effect of the Valsalva maneuver on the retinal veins STODTMEISTER R, Stroehla H, Spoerl E, Pillunat L E, Terai N - Rodalben

F014 Noninvasive intracranial pressure assessment using otoacoustic emissions: an application in glaucoma LOISELLE A, De Kleine E, Van Dijk P, Jansonius N M - Groningen

F016 XEN gel stent to treat intraocular hypertension induced by Dexamethasone-implant intravitreal injections: about 5 cases REZKALLAH A, Mathis T, Denis P, Kodjikian L - Lyon

F017 Quantitative evaluation of peripapillary microvasculature in Pseudoexfoliation Syndrome RODRIGUES C, Sousa Silva R, Cabral D, Rodrigues P, Marques M, Camacho P, Joana V, Segurado J, Fernandes J, Barrão S - Lisbon

F018 Retinal blood supply and oxygen extraction as a function of blood pressure status and vascular dysregulation assessed by optical coherence tomography-angiography and dual-wavelength retinal oximetry PAPPELIS K, Jansonius N - Groningen

F019 Long-term follow-up of transscleral cyclodiode for rubeotic glaucoma WALKER L, Weston K, Rule E, Lockwood A - Portsmouth

F020 Comparison of 1-year outcomes of XEN implantation alone vs combined phacoemulsification-XEN surgery at a Tertiary Center of Ophthalmology in Portugal MOURA-COELHO N, Hipólito Fernandes D, Crisóstomo S, Basílio A L, Tavares Ferreira J, Dutra-Medeiros M, Sa Cardoso M, Gomes T - Lisbon

F021 Prevalence of unknown ocular hypertension, pre-perimetric glaucoma and glaucoma in patients seen in primary refraction center in France CHAMARD C, Villain M, Causse A, Bentaleb Y, Pelen F, Baudouin C, Daien V - Castelnau Le Lez

F022 Above Tenons Conjunctival dissection – A modification for Trabeculectomy Surgery SRIKANTHA N, Macgregor C, Kirwan J, Lockwood A - Winchester

F023 Modeling the circadian pattern of intra-ocular pressure DEFORCE F, Renault D, Cattaert T, Aptel F - Sint Agatha Berchem

F024 Long term postoperative refractive outcomes of combined cataract and glaucoma surgery CHUNG J K - Seoul

F025 Nutritional oral supplement containing L-arginine, L-citruline, α-lipoic acid, vitamin B2, vitamin B12, folic acid and Gingko biloba in primary open angle glaucoma patients - a prospective, randomized, controlled study. WASYLUK J, Krajewska M, Oseka M, Sobol M, Prost M - Warszawa

F026 Clinical implications of reactive epiretinal patches in open-angle glaucoma KIM E K, Park H Y L, Park C K - Seoul

F027 Clinical course of prematurity with enlarged cup to disc ratio - 24 months retrospective consecutive case series JIN S W - Busan 70

Friday, October 5 - Poster session

14:45 - 15:45 | Poster area POS G - Glaucoma

Poster F001-F050

YAP T , DAVIS B F028 EEvaluation of a 24 Hour Circadian Rhythm Model for Intraocular Pressure after Implant with a Supraciliary Micro-Stent VERA L F, Vontress M, Sarangapani R - Milan F029 EComparing the predicted efficacy of one versus two supraciliary micro-stents for lowering intraocular pressure in glaucoma patients using an ocular computational fluid dynamic model VERA L F, Missel P, Sarangapani R - Milan

F030 Association between autonomic dysfunction and retinal nerve fiber layer thinning in healthy subjects JUNG Y H, Shin J A - Seoul

F031 Long term follow-up of patients with plateau iris syndrome after treatment with argon laser peripheral iridoplasty TSOKOLAS G, Tzamos G, Datta A - Southampton

F032 The promoter polymorphism -308G>A in the gene of Tumor necrosis factor alpha and the risk for open-angle glaucoma in Bulgarians VLAYKOVA D, Dzhelebov D, Tacheva T, Dimov D, Kurzawski M, Drozdzik M, Vlaykova T - Stara Zagora

F033 An unusual case of neo-vascular glaucoma in the post-partum period secondary to severe peripheral retinal ischaemia STAHL M, Sheck L, Anastasia T, Yang E, Pal B - Slough

F034 Comparison between the 24-2 new grid program of the Compass fundus automated perimeter and the 24-2 program of the Humphrey field analyser FENOLLAND J R, Alves Chaves M, Sendon D, Charpentier S, Manchart T, Renard J P, Giraud J M - Saint Mande

F035 Changes in circumpapillary retinal nerve fibre layer thickness after phaco surgery only in patients with primary angle closure glaucoma OH W H, Kim B G, Kim J S - Seoul

F036 Altered Antioxidant-Oxidant Status in the Peripheral Blood of Patients with Low-Tension Glaucoma and Ocular Hypertension LANGBØL M, Baskaran T, Dalgaard L, Vibæk Jensen J, Tiedemann D, Toft-Kehler A K, Kolko M - Copenhagen

F037 Bilateral activation of retinal microglia: quantitative analysis of the area the retina occupied by IBA-1 + cells in the nerve fiber layer-ganglion cell layer at different time points after laser-induced ocular hypertension in mice SALAZAR J J, De Hoz R, Fernandez-Albarral J A, Ramirez A I, Salobrar-Garcia E, Rojas B, Triviño A, Aviles-Triguero M, Vidal-Sanz M, Ramirez J M - Madrid

F038 Bilateral activation of retinal microglia: quantitative analysis of the microglia cell number at different time points after laser-induced ocular hypertension in mice DE HOZ R, Fernandez-Albarral J A, Ramirez A I, Salazar J J, Salobrar-Garcia E, Rojas B, Triviño A, Valiente-Soriano F J, Villega-Perez M P, Ramirez J M - Madrid

F039 Visual field changes after epiretinal membrane surgery in glaucomatous eyes LEE K S, Kim Y - Gyeonggi-do

F040 Comparison of vessel diameters during hypoxia in patients with low tension glaucoma, ocular hypertension and age-matched control BASKARAN T, TIEDEMANN* D, Langbøl M, Vohra R, Jensen P S, Bek T, Jensen P K, Olsen N V, Kolko M - Copenhagen F041 Reactive astrocytosis alters gene expression of ECM components in primary optic nerve head astrocytes KAJA S, Stubbs E, Rao V, Kalesynkas G, Ghosh A - Kuopio 71

Friday, October 5 - Poster session

14:45 - 15:45 | Poster area POS G - Glaucoma

Poster F001-F050

YAP T , DAVIS B F042 ISY (satISfaction surveY): First real-life data of use of a preservative-free multidose glaucoma device (EasyGrip® delivery system) in 5 European countries DENIS P, Erb C, Puska P, Skov J, Chen E, Klyve P, Duch S - Lyon

F043 Three better than two? A twin study to examine the accuracy of IOP measurement MANZAR H, Simcoe M, Hammond C - London

F044 Amniotic membrane transplantation and conjunctival autograft for repair of leaking glaucoma filtering bleb BARTOLOMÉ I, Berniolles J, Marco S, Lopez Sangros I, Montes P, Karlsruher G, Idoate A, Sanchez Marin J I, Perez Garcia D, Martinez Morales J, Ascaso Puyuelo J, Ibañez J - Zaragoza F045 Resveratrol nanoparticles are neuroprotective in vitro suggesting a potential to cure glaucoma and Alzheimer’s disease SHAMSHER E, Davis B, Dev P, Grgic L, Somavarapu S, Guo L, Cordeiro F - London

F046 Glaucoma drainage devices: making surgery simpler MANNS R, Rule E, Ambrose I, Hunter G, Lockwood A - Portsmouth F047 Neuroprotective Activity of Curcumin Nanocarriers in Rodent Models of Retinal Injury DAVIS B, Guo L, Pahlitzsch M, Balendra S, Shah P, Ravindran N, Malaguarnera G, Sisa C, Shamsher E, Hamze H, Noor A, Sornsute A, Somavarapu S, Cordeiro M F - London

F048 Combined phacocanaloplasty for open-angle glaucoma and cataract Perez Garcia D, IBANEZ J, Martinez Morales J, Ascaso J, Garces A - Zaragoza

F049 Implant of micro-stent cypass in glaucoma Perez Garcia D, MARTINEZ MORALES J, Ibanez J, Ascaso J, Isabel B, Berniolles J, Marco S, Lopez I - Zaragoza

F050 Just how broken are we? Neck and back pathology among ophthalmologists HUNTER G, Macgregor C, Ambrose I, Manns R, Lockwood A - Portsmouth 72

Friday, October 5 - Poster session

14:45 - 15:45 | Poster area POS NSPH - Neuro-ophthalmology/Strabismology/Paediatric/History

Poster F051-F098

BARBONI P , CARELLI V F051 Management of congenital dacryocystocele, complicated by early post-natal dacyrocystitis TSAKIRIS K, Quinn A G - Exeter

F052 Brushfield spots and Wölfflin nodules unveiled in dark irides using near-infrared light POSTOLACHE L, Parsa C - Brussels

F053 Ophthalmic Manifestations of Tuberous Sclerosis: A Tertiary Hospital Experience MANO S, Marques R, Sousa F, Fonseca A, Pinto F, Campos F - Lisbon

F054 Orbital exenteration with superficial temporalis muscle flap: an innovating approach BENNEDJAI A, Bremond-Gignac D, Kolb F, Bennis Y, Picard A, Kadlub N - Paris

F055 Association between myopia and optic nerve head drusen in children Lee S K, Lim D H, LYU I J - Seoul

F056 Vascular Complications of Optic Nerve Head Drusen TEIXEIRA F, Esteves Marques R, Mano S, Couceiro R, Pinto F - Lisboa

F057 Screening and follow-up of acute ROP: reproducibility and diagnostic accuracy of fluorescein angiography GUAGLIANO R, Barillà D, Bertone C, Maffia A, Verticchio Vercellin A C, Periti F, Plaitano C, Tinelli C, Arpa C, Bianchi P E - Pavia

F058 Suspecting a goldenhar syndrome: a case report MARCO MONZON S, Lopez I, Karlsruher G, Montes P, Bartolome I, Ramiro P, Castillo J, Ascaso J - Zaragoza

F059 Retinal layer thinning in Parkinson’s disease: a meta-analysis of optical coherence tomography studies CHRYSOU A, Jansonius N, Van Laar T - Groningen

F060 Macular and papillary morphometric evaluation with SD-OCT in children affected by mild-severe refractive errors ARPA C, Bianchi P E, Barillà D, Bertone C, Milano G, Plaitano C, Periti F, Verticchio A, Tinelli C, Guagliano R , Manzoni F - Cabiate

F061 Optical coherence tomography outcomes in patients with Friedreich ataxia: a longitudinal study ROJAS LOZANO M P, Ferreras A, De Hoz R, Ramírez A I, Salobrar-Garcia E, Muñoz Blanco J L, Urcelay J L, Salazar J J, Ramirez J M - Madrid

F062 Anterior Segment swept-source Optical Coherence Tomography evaluation of patients submitted to lateral recti hang-back recession surgery REIS CABRAL D, Pereira T, Rodrigues P, Vila-Franca M, Camacho P, Oliveira Rodrigues C, Seldon R, Braz F, Varandas G - Lisboa

F063 Spectral-Domain Optical Coherence Tomography findings in 64 patients with aniridia : a retrospective study DARUICH-MATET A, Bremond-Gignac D - Paris

F064 Inner retinal layers of the retina predict visual cortical thickness and structural connectivity in early Alzheimer’s Disease CASTELO-BRANCO M, Jorge L, Alves C, Canário N, Santiago B, Santana I, Quental H, Reis A, Ambrosio F, Bernardes R - Coimbra

F065 Is the OCT useful in monitoring idiopathic intracranial hypertension? SOUSA F, Lopes P, Marques R, Pinto F - Lisbon

F066 Ability of Swept-source OCT to detect retinal changes in patients with bipolar disorder GAVIN SANCHO A, Cipres Alastuey M, Satue Palacian M, Rodrigo Sanjuan M J, Orduna Hospital E, Vilades Palomar E, Larrea Samper J G, Garcia-Martin E - Zaragoza 73

Friday, October 5 - Poster session

14:45 - 15:45 | Poster area POS NSPH - Neuro-ophthalmology/Strabismology/Paediatric/History

Poster F051-F098

BARBONI P , CARELLI V F067 Optical Coherence Tomography as a Diagnostic Tool for Detecting Mild Cognitive Impairment in Parkinson’s Disease SUNG M S - Gwangju

F068 Optical coherence tomography angiography of the foveal avascolar zone and vessel density in children: comparison between preterm and full term patients PERITI F, Plaitano C, Toma C, Guagliano R, Bertone C, Barillà D, Vandelli G, Bianchi A, Arpa C, Vulpetti A, Tinelli C, Bianchi P E - Piacenza

F069 The ability of Spectral domain Optical coherence tomography to detect retinal changes in patients with essential tremor: is neurodegeneration an underlying cause? SATUE M, Vilades E, Orduna E, Gavin A, Cipres M, Rodrigo M J, Larrea G, Garcia-Martin E - Zaragoza

F070 Evaluation of visual function and retinal changes caused by Multiple sclerosis after a 10-year follow-up SATUE M, Orduna E, Vilades E, Gavin A, Cipres M, Rodrigo M J, Larrea G, Garcia-Martin E - Zaragoza

F071 Evaluation of retinal thickness asymmetry in patients with multiple sclerosis against healthy controls VILADES E, Orduna Hospital E, Larrea Samper J G, Rodrigo Sanjuan M J, Cipres Alastuey M, Gavin Sancho A, Satue Palacian M, Garcia Martin E - Zaragoza

F072 Retinal thinning in patients with multiple sclerosis: evaluation of the pattern of retinal loss during disease progression VILADES E, Orduna Hospital E, Larrea Samper J G, Rodrigo Sanjuan M J, Ciprés Alastuey M, Gavin Sancho A, Satué Palacian M, Garcia Martin E - Zaragoza

F073 Changes in the Vision, Visual Field and Retina by OCT in Early ALS Patients: a longitudinal study ROJAS LOZANO M P, Ferreras A, Ramirez A I, De Hoz R, Salobrar-García E, Salazar J J, Muñoz-Blanco J L, Urcelay J L, Ramirez J M - Madrid

F074 Vision involvement in optic neuritis and non-optic neuritis eyes in patients with multiple sclerosis or neuromyelitis optica spectrum disorder ROJAS LOZANO M P, Cadena M, Cuello J P, García-Domínguez J M, Martinez Ginés M - Madrid

F075 Ganglion cell layer complex measurement in the evaluation of an optic chiasm compression CHARPENTIER S, Fenolland J R, Sendon D, Thomas Lavaud A, Manchart T, Renard J P, Garcia C, Dolz M, Bordier L, Giraud J M - Saint Mande

F076 Retina, a mirror of the brain: an association between macular and cerebral structural integrity over age JORGE L, Canário N, Quental H, Bernardes R, Castelo-Branco M - Coimbra

F077 OCT- Angiography: perspectives of differential diagnostics of pathology optic nerve IOYLEVA E, Kabanova E - Moscow

F078 Woman –ophthalmologists in the past POLAK A - Lublin

F079 The development of anatomy of the eye and its optics POLAK A, Grzybowski A - Lublin

F080 Creators of Polish ophthalmology in 19thc and their achievements POLAK A, Grzybowski A - Lublin

F081 Pseudo-Foster Kennedy syndrome due to uncontrolled Diabetes Mellitus RAHAYU S, Kartika A, Setioadji B, Handayani R - Bandung

F082 Visual function and retinal changes in patients with bipolar disorder GAVIN SANCHO A, Cipres Alastuey M, Satue Palacian M, Rodrigo Sanjuan M J, Orduña Hospital E, Vilades Palomar E, Larrea Samper J G, Garcia-Martin E - Zaragoza 74

Friday, October 5 - Poster session

14:45 - 15:45 | Poster area POS NSPH - Neuro-ophthalmology/Strabismology/Paediatric/History

Poster F051-F098

BARBONI P , CARELLI V F083 Early prognostic factor for irreversible damage by optical coherence tomography in patients with ethambutol-induced optic neuropathy KIM E W, Park C K, Bae H W, Lee S Y, Kim S A, Lee K H, Kim C Y - Seoul

F084 Optic nerve biopsy in unexplained progressive optic neuropathy VAN LINT M, De Vin T, De Keizer R, Vandewalle E, Cassiman C, Appeltans A - Jette

F085 Maintained treatment with idebenone increases the probability and magnitude of visual acuity recovery in patients with Leber’s hereditary optic neuropathy (LHON) LLORIA X, Silva M, Catarino C, Rudolph G, Lob F, Von Livonius B, Klopstock T - Liestal

F086 Natural history findings from a large cohort of patients with Leber’s hereditary optic neuropathy (LHON): New insights into the natural disease-course SILVA M, Lloria X, Catarino C, Klopstock T - Pratteln F087 Long-term maintenance of visual acuity in patients with Leber’s hereditary optic neuropathy treated with idebenone LLORIA X, Silva M, Rudolph G, Lob F, Von Livonius B, Catarino C, Klopstock T - Liestal F088 Activation of the phosphoinositide 3-kinase pathway promotes axon regeneration of the optic nerve in vivo EVANS R, Pearson C, Cave J, Deshpande S S, Conceição R, Fawcett J, Eva R, Martin K, Barber A C - Cambridge

F089 Statins ameliorate the ultrastructural alterations in the optic nerve in a rabbit model of hypercholesterolemia RAMIREZ A I, Fernandez-Navarro J, De Hoz R, Rojas B, Salazar J J, Triviño A, Ramirez J M - Madrid

F090 Silent sinus syndrome: a rare clinical entity PEREZ GARCIA D, Ibañez Alperte J, Martinez Morales J, Ascaso Puyuelo J - Zaragoza

F091 Neurodegeneration in non-proliferative diabetic retinopathy: new biomarkers and their relation to vasculopathy and visual function NGUYEN A, Naso S, Kardon R, Abdulghafor M, Kawasaki A - Lausanne

F092 Evaluation of multifocal visual evoked potentials in patients with multiple sclerosis using Retiport device LARREA SAMPER J G, Viladés Palomar E, Orduna Hospital E, Rodrigo Sanjuan M J, Gavin Sancho A, Ciprés Alastuey M, Satue Palacian M, García Martín E - Zaragoza

F093 Evaluation of the multifocal electrorretinogram in patients with multiple sclerosis using Retiport deviced LARREA SAMPER J G, Viladés Palomar E, Orduna Hospital E, Rodrigo Sanjuan M J, Gavin Sancho A, Ciprés Alastuey M, Satue Palacian M, García Martín E - Zaragoza

F094 Sarcomere remodeling following strabismus surgery HOCHHARD K, Vicente A, Pedrosa Domellöf F - Umeå

F096 Accomadative convergence pupillary eye system and psychological status of healthy school aged children BUSHUYEVA N, Pasechnikova N, Shakir D, Ushan O - Odessa

F097 Acute facial asimmetry as the presentig sign of an underdiagnosed entity MARCO MONZON S, Isabel L, Montes P, Karlsruher G, Berniolles J, Ramiro P, Perez D, Dominguez A, Ascaso J - Zaragoza

F098 A software based measurement of horizontal muscles insertion MARQUES M, Cabral D, Rodrigues P, Santos C, Traz F, Seldon R, Varandas G - Lisboa 75

Friday, October 5 - Poster session

14:45 - 15:45 | Poster area POSSIS EOVS - Electrophysiology, physiological Optics, Vision Sciences

Poster F099-F115

ROZEMA J, LAWRENSON J

F099 New analysis of the Farnsworth D-15 test EVANS B, Barbur J, Rodriguez-Carmona M - London

F100 The Rayleigh equation: reasons for a standard in application KRASTEL H, Kirchhübel R, Bischoff P, Jonas J B - Neckargemünd

F101 Uncorrected refractive error and associated risk factors among socially vulnerable older adult population living in Armenia GILOYAN A, Harutyunyan T, Petrosyan V - Yerevan

F102 Corneal astigmatism distribution at Indonesia National Eye Center Cicendo Eye Hospital SUGANDA R, Renata Musa I, Wahyu M S, Virgana R - Jakarta utara

F103 Conservative Treatment of Newly Diagnosed Keratoconus MRAZOVAC D, Jandrokovic S, Zimak Z, Petricek I - Zagreb

F104 A new reaction time test (Ocusweep® Reaction Time Test) for assessing visual performance and compliance TIGCHELAAR I, Mäntysalo T, Leinonen M - Turku F105 The influence of cataract light scatters on retinal vessel oxygen saturation WAIZEL M, Türksever C, Todorova M G - Basel

F106 Correlating macular inner retinal layer thickness with photopic and mesopic contrast sensitivity in healthy young and older subjects PUELL M, Palomo-álvarez C, Pérez-Carrasco M - Madrid

F107 Different retinal layers thickness measurements change with age in healthy eyes RODRIGO M J, Vilades E, Orduna E, Gavin A - Zaragoza

F108 Measurement of macular ganglion cell–innerplexiform layer with spectral-domain optical coherence tomography in patients with optic nerve head drusen and papilledema IOYLEVA E, Kabanova E, Krivosheeva M - Moscow

F109 Spectral optical coherence tomography with multiple sclerosis. Regression analysis IOYLEVA E - Moscow

F110 Electrophysiology and retinal thickness alterations in patients with multiple sclerosis with and without previous optic neuritis ORDUNA HOSPITAL E, Vilades Palomar E, Rodrigo Sanjuan M J, Gavin Sancho A, Cipres Alastuey M, Larrea Samper J G, Satue Palacian M, Garcia Martin E - Zaragoza

F111 Pattern electroretinogram steady-steate in dyslexis and normal readers CELLINI M, Campos E C - Bologna

F112 Investigating the movement of the centre of the multifocal hexagonal stimulus array using an electroretinogram function SUZUKI N, Yamane K - Numazu

F113 The effect of sustained eye rotation upon central and peripheral axial length in young, adult myopic subjects ALKHALDI S, Seidel D, Gray L - Glasgow

F114 Indications for electrostimulation method in the treatment of children with concomitant non-accomodative strabismus BOYCHUK I, Mazur V - Odessa

F115 Maximum human objectively measured pilocarpine stimulated accommodative amplitude GRZYBOWSKI A, Schachar R A, Gaca-Wysocka M, Schachar I H, Pierscionek B K - Olsztyn 76

Friday, October 5 - Poster session

14:45 - 15:45 | Poster area POS MBGE - Molecular Biology/Genetics/Epidemiology

Poster F116-F131

LISKOVA P , DAVIDSON A F116 Clinical and Genetic Characteristics of enhanced S-cone syndrome in a Tunisian cohort: experience of the oculogenetic laboratory LR14SP01 FALFOUL Y, Turki A, Habibi I, Hassairi A, El Matri K, Chebil A, Schorderet D, El Matri L - Tunis

F117 Novel CDHR1 mutation causing cone rod dystrophy FALFOUL Y, Habibi I, Turki A, Hassairi A, El Matri K, Chebil A, Schorderet D, El Matri L - Tunis

F118 Phenotype in homozygous and heterozygous carriers of BEST1 mutations in autosomal recessive Bestrophinopathy EL MATRI K, Falfoul Y, Habibi I, Turki A, Chebil A, Schorderet D, El Matri L - Tunis F119 Clinical and Genetic Characteristics of Leber Congenital Amaurosis in the Tunisian Population: experience of the oculogenetic laboratory LR14SP01 EL MATRI K, Falfoul Y, Habibi I, Turki A, Hassairi A, Chebil A, Schorderet D, El Matri L - Tunis

F120 Novel C8ORF37 mutation causing cone rod dystrophy EL MATRI L, Falfoul Y, Habibi I, Turki A, El Matri K, Chebil A, Schorderet D - Tunis

F121 NMNAT1 mutation causing retinitis pigmentosa EL MATRI L, Habibi I, Falfoul Y, Turki A, Hassairi A, El Matri K, Chebil A, Schorderet D - Tunis

F122 A possible novel TGFBI mutation Ser591Phe in a Finnish family with lattice corneal dystrophy JAAKKOLA A M, Järventausta P, Repo P, Kivelä T, Turunen J - Helsinki

F123 Ocular manifestations in S77T transthyretin-related familial amyloid polyneuropathy BUNOD R, Cauquil C, Bourenane H, Adam C, Barreau E, Labetoulle M, Adams D, Rousseau A - Le Kremlin-Bicêtre

F124 On the day cataract operation cancellations: A prospective audit BALENDRA S, Srikantha N, Evans A - London

F125 The 100,000 Genomes Project and the Western Eye Hospital Experience D’ESPOSITO F, Miodragovic S, Normando E, Bonetti P, Cordeiro M F - London

F126 miRNAs as putative biomarkers for recurrent hemorrhage after PPV MAMMADZADA P, Gudmundsson J, Kvanta A, Andre H - Stockholm

F127 Heritability of corneal curvature and Pentacam topometric indices: a population based study YEKTA A A, Hashemi H, Khabazkhoob M, Heydarian S, Ostadimoghaddam H, Derakhshan A, Heravian J, Azimi Khorasani A, Momeni-Moghaddam H, Yekta R - Mahhad

F128 Mapping of proteomic profile and effect of the spongy layer in the human amniotic membrane NAZARI HASHEMI P, Bisson A, Chaventre F, Guillou C, Cosette P, Boyer O, Muraine M - Rouen

F129 Cornea donation for research versus for transplantation: a one year prospective study of acceptance rates in a French University Hospital GARCIN T, Pugniet J L, Peyragrosse T, Barallon M, Rogues F, Acquart S, Thuret G, Gain P - Saint Etienne

F130 Vision-Related and Health-Related Quality of Life in Patients with Giant Cell Arteritis NÍ MHÉALÓID Á, Conway R, Molloy E, Murphy C C - Dublin

F131 Does the presentation of orbital cellulitis exhibit seasonality? AMBROSE I, Rule E, Manns R, Hunter G, Lockwood A - Portsmouth 77

Friday, October 5 - Section Business Meetings

15:45 - 16:15 Section Business BM Section Business Meetings Meetings

Agenda

1. Report of the chair of section

2. Report of the programme secretary

3. Next year’s meeting:

• Nomination of the 2019 section programme secretary (different from the section chair)

• Proposals of 2019 Special Interest Symposia (SIS)

• Proposals of 2019 Courses

• Proposals for 2020 Keynote speakers

4. Comment on the EVER activities

5. Other business

In addition to the agenda:

- all sections will nominate nominate candidates for the election of the new treasurer 2019 - 2023

- the sections ACB, EOVS and MBGE will nominate at least 2 candidates for section chair 2019 - 2023

ACB Gallieni 1+2

COS Rhodes 2

EOVS Rhodes 1

G Rhodes 1

IM Rhodes 4

LC Hermes

MBGE Rhodes 4

NSPH Rhodes 2

PBP Rhodes 3

PO Rhodes 3

RV Hermes 78

Friday, October 5 - Second afternoon session

16:15 - 17:30 | Hermes SIS RV - Advanced oct and oct-angiography in challenging cases

OCT angiography (OCT-A) as a new non-invasive imaging technology that enables the monitoring of the macular retinal and choroidal circulation. OCT-A allows a detailed detection either of the macular retinal capillaries plexus as well as the subretinal choroidal neovascularisation. The correlation of OCT-A with OCT longitudinal or “en face” sections resulted to a better understanding of the pathologic features of the macular degenerative or vascular pathologies. OCT-A became a useful imaging modality in the evaluation and management of macular hemodynamic changes observed during the evolution of the retinal ischemic micronagiopathies and the treatment and follow up of the maculopathies related to a subretinal neovascularisation. Applications of OCT and OCT-A were focused on the evaluation of particular cases of the retinal or the optic nerve head pathologies. The aim of the symposium is to organize an interactive discussion on the new imaging aspects for the detection and management of the most common maculopathies, as well as an interactive discussion of typical clinical cases. POURNARAS C , ZOGRAFOS L 2711 16:15 Hand handled OCT in paedriatic ocular oncology STATHOPOULOS C, Gaillard M C, Munier F - Lausanne

2712 16:30 evaluation of small particles in motion in diabetic macular edema MANE V, Couturier A, Dupas B, Bonnin S, Gaudric A, Tadayoni R - Paris 2713 16:45 oCT-A evaluation in glaucoma PUECH M, Aimadaly M - Paris

2714 17:00 evaluation of the retinal pigment epithelium defects with OCT-A ZOGRAFOS L - Lausanne

2715 17:15 multimodal imaging of diabetic retinopathy, the role of OCT angiography POURNARAS C - Genève

16:15 - 17:30 | Rhodes 1 SIS G - Neuroprotection in glaucoma – challenges and opportunities

Glaucoma is a degenerative optic neuropathy characterised by retinal ganglion cell (RGC) loss for which intraocular pressure modulation remains the only clinically modifiable risk factor. Neuroprotective therapies seek to slow or prevent RGC death via an IOP independent mechanism. Despite some early promise, recent clinical trials assessing the efficacy of neuroprotective therapies have had mixed results. This session seeks to discuss recent pre-clinical developments in this field to spark discussions regarding methods to overcome challenges in the design and translation of future neuroprotective therapies to the clinic. DAVIS B , DE GROEF L 2721 16:15 Neuroprotective efficacy of a multi-loaded micro particulate drug delivery system in an ocular hypertension model of glaucoma ARRANZ-ROMERA A - Madrid

2722 16:30 evidence for MMP-3 as neuroprotection target at the crossroad of inflammation and neurodegeneration DE GROEF L, Lefevere E, Salinas-Navarro M, Andries L, Geeraerts E, Van Hove I, Movahedi K, Moons L - Leuven

2723 16:45 Assessment of memantine loaded PEGylated biodegradable nanoparticles in a rodent glaucoma model SÁNCHEZ-LÓPEZ E, Davis B M, Guo L, Espina M, Silva A M, Souto E B, Ravindran N, Ettcheto M, Camins A, Garcia M L, Cordeiro M F - Barcelona

2724 17:00 evaluation of topical curcumin nanoparticles in of rodent glaucoma models DAVIS B, Pahlitzsch M, Balendra S, Shah P, Ravindran N, Malaguarnera G, Sisa C, Guo L, Noor A, Sornsute A, Somavarapu S, Cordeiro M F - London

2725 17:15 Neuroprotection in glaucoma – outstanding challenges NORMANDO E M - London 79

Friday, October 5 - Second afternoon session

16:15 - 17:30 | Rhodes 2 SIS COS - Translational concepts in ophthalmology

This symposium will discuss current translational concepts in cornea, glaucoma, and retinal pathologies. Innovative surgical and non-surgical therapies will be presented. JUENEMANN A , SEITZ B 2731 16:15 Cold plasma - a novel approach to treat therapy-resistant corneal infections FUCHSLUGER T - Erlangen

2732 16:30 laser systems in corneal surgery SEITZ B, Langenbucher A - Homburg

2733 16:45 Trace elements in glaucoma HOHBERGER B - Erlangen 2734 17:00 Development of antifibrotics for glaucoma surgery - synergy of molecular biology and bioinformatics JUENEMANN A, Stahnke T, Gajda-Derilo B, Struckmann S, Möller S, Barrantes I, Hamed M, Stachs O, Füllen G - Rostock 2735 17:15 electronical subretinal implants - recent developments STETT A - Reutlingen

16:15 - 17:30 | Rhodes 3 C PO - Orbital inflammation

 Intermediate

The spectrum of orbital inflammatory disease (OID) ranges broadly from specific disease diagnoses, for example, Wegener’s granulomatosis or sarcoïdosis, to nonspecific inflammation that may involve one or multiple structures of the orbit as anterior -or bit, muscle (myositis), lacrimal gland, diffuse or posterior orbit. Mimics of idiopathic OID must be considered in a comprehensive differential diagnosis and include malignancies (metastasis and lymphomas). Idiopathic OID may be secondary to an underlying systemic inflammatory disease, which must be diagnosed in order to develop a comprehensive therapeutic plan, or may repre- sent localized pathologic processes without systemic involvement. Thus, pathologist’s role is important. Therapeutic options for inflammatory diseases are focused on corticosteroids. MOURIAUX F , KIVELÄ T 2741 16:15 Clinical features and differential diagnosis of orbital inflammation MOURIAUX F - Rennes

2742 16:33 Pathology of orbital inflammation KIVELÄ T, Tynninen O - Helsinki

2743 16:51 Biopsy of orbital inflammation ECKSTEIN A, Mattheis S, Pförtner R, Esser J - Essen

2744 17:09 Imaging of orbital inflammation LAGIER J - Nice 80

Friday, October 5 - Second afternoon session

16:15 - 17:30 | Rhodes 4 ACB/COS - Scleral contact lenses: hands on - fitting, maintenance & clinical advantages - SIS it’s no magic !

Scleral Contact Lenses are a high-tech and versatile medical tool for the treatment in many different scenarios of ocular surface dysfunction and disease. This reaches from irregular corneas of any kind, e.g. high astigmatism, keratoconus and keratoglobus, over recurrent wounding of the epithelium and stem cell deficiency to the improvement of scars and corneal opacities, to cases of severe dry eye disease, and Sclerals have even proven to be useful in ocular infections. Still, the practical application of this enormously useful tool is limited because conventional wisdom seems to know that they are just too difficult to fit and to use for the ordinary clinician. Therefore, the aim of the present SIS is to explain – in a kind of “Hand On” Approach – in detail and in concrete specific patient settings, how a Scleral Contact Lens is practically fitted and obtained, how it is managed by the patient himself and supported by the clinician and which clinical advancements have occurred in specific concrete patients. KNOP E 2751 16:15 Which pitfalls does ocular anatomy have in store for the application of Scleral Contact Lenses? KNOP E - Berlin

2752 16:30 How do I fit a Scleral contact lens in a specific patient? NAU C - Minnesota

2753 16:45 The DOs and DON´T s of Scleral Lens fitting NAU A - Boston

2754 17:00 Which concrete advantages have Sclerals provided for my patient? CARRASQUILLO K G - Needham 2755 17:15 Is it possible to run a self-supporting Scleral Contact Lenses practise? MEKKI M B - Algiers

16:15 - 17:30 | Gallieni 1+2 SIS MBGE - Gene regulation in eye development and disease

This SIS will cover studies of transcriptional regulation in multiple ocular tissues, including the lens, retina, and retinal pigment epithelium and will link these studies to cataract, glaucoma, and retinal degenerations. State-of-art methods, including single cell RNA-seq, ChIP-seq, genome editing by CRISPR-Cas9, and differentiation of ES and iPS cells will be discussed. Studies of eye development are driven by dissecting the critical roles of specific DNA-binding transcription factors and regulation of their activities by extracellular signaling in specific compartments of the eye. Organization of gene regulatory networks that govern vertebrate eye development will be also presented. Critical gaps and novel research opportunities in our understanding of gene function during normal and abnormal eye development will be summarized and discussed in the context of understanding of ocular cell and tissue homeostasis. Collectively, these proposed presentations will add novel insights into understanding of eye development, regenerative potential of multiple ocular tissues, and rational design of therapies to prevent and/or delay onset of age-related eye diseases. CVEKL A , KOZMIK Z 2761 16:15 Gene regulation and lens development: Insights from single-cell RNA-seq analysis CVEKL A, Mcgreal R, Yilin Z, Phil W, Larry D, Deyou Z - Bronx

2762 16:33 The role of Meis family transcription factors in retina development KOZMIK Z, Fujimura N, Antosova B - Prague

2763 16:51 The molecular role of the Six6 transcription factor in glaucoma SKOWRONSKA-KRAWCZYK D, Nguyen Huu V A, Jabari M, Rocha L - La Jolla

2764 17:09 Transcriptional networks regulating timing and differentiation of the retinal pigmented epithelium ASHERY-PADAN R - Ramat Aviv, Tel Aviv 81

Friday, October 5 - Keynote lecture

17:30 - 18:00 | Hermes KN Keynote lecture by Christine CURCIO

17:30 Introduction by Catherine CREUZOT

2811 17:35 Microarchitecture and timeline of geographic atrophy: the x,y,z,t of AMD

christine CURCIO — Birmingham, USA

Population-based eye pathology and clinicopathologic correlation have validated at the subcellular level features of age-related macular degeneration (AMD) newly appreciated in optical coherence tomography Christine CURCIO (OCT). Clinical OCT has advanced through signal averaging, eye-tracking, integration with multimodal imaging, frequent imaging during the course of anti-VEGF therapy, and new high-resolution histology. Clarified AMD pathologies include subretinal drusenoid deposit (extracellular deposits distinct from sub-RPE drusen), outer retinal tubulation (a neurodegeneration and gliosis), a catalogue of RPE morphology at all AMD stages, landmarks of atrophy like refractile drusen and persistent basal laminar deposit, Friedman lipid globules, and clinicopathologic correlation of major neovascularization subtypes. Combined with experimental re-creation of sub-RPE deposits in vitro, it is possible to see the growth of drusen in vivo and the migration and death of RPE off the top, as a precursor to drusen-related atrophy. Thus, the targeting of drusen is mo- tivated, to forestall atrophy as well as neovascularization. AMD is more approachable than ever, as imaging fills in missing pieces and targetable precursors to end-stages are found.

18:00 Award presentation of the EVER Certificate of Honour 82

Friday, October 5 - Evening session

18:00 - 19:15 | Hermes SIS RV - Adaptive optics: clinical applications and beyond

Cellular-scale imaging of the eye is a growing area for clinicians. Adaptive optics-enhanced fundus imaging has been developed for two decades and its technical maturity enables us to trace outlines of the major clinical applications. New techniques are being developed in parallel such as Doppler holography and full fieldO CT which also enables novel insights into the fine structural and functional aspects of the retina and other ocular tissues such as the cornea. In this SIS a multidisciplinary panel of speakers (physicists-computer scientists-ophthalmologists) will present the latest advances in the medical use of new imaging techniques. Emphasis on clinical pertinence and mulltimodal imaging will allow clinicians but also physicists interested in the field to appreciate the related opportunities PAQUES M , GRIEVE K 2911 18:00 Clinical use of flood-illumination adaptive optics fundus camera ophthalmoscopy PAQUES M - Paris

2912 18:10 structural and functional imaging of ocular tissues with full-fieldO CT GRIEVE K, Scholler J, Xiao P, Mazlin V, Thouvenin O, Fink M, Sahel J A, Paques M, Boccara C - Paris

2913 18:20 Adaptive optics scanning laser ophthalmoscopy: clinical applications MERINO D - Barcelona

2914 18:30 Adaptive optics in the eye as window to brain function DUBIS A, Houston S, Nunez Do Rio J, Greenwood J - London

2915 18:40 High speed adaptive optics angiography Meimon S, GOFAS E - Paris

2916 18:50 Adaptive Optics for inherited retinal disease clinical trials MOOSAJEE M, Dubis A - London

2917 19:00 Infrared autofluorescence in adaptive optics ophthalmoscopy for imaging retinal pigment epithelial cells in health and disease ROSSI E A, Ferguson D R, Paques M, Sahel J A, Grieve K - Pittsburgh

18:00 - 19:15 | Rhodes 1 SIS NSPH - From Francisco de Goya´s eyesight difficulties to famous one-eyed warriors

Historic ocular disorders, like tracoma, first described on papyrus about 1927 BC in Ancient. Egypt. Old ophthalmological therapies, such as cryosurgery and aesthetic blepharoplasty. Famous doctors like the Polish ophthalmologist Tadeusz Krwawicz and well recognized patients, such as the Spanish painter Francisco de Goya or certain monocular warriors: Hannibal, Philip of Mac- edon, Date Masamune, Duke of Urbino and Admiral Nelson. We will take a look at six topics, all of which show the importance of eyes along the history. GRZYBOWSKI A , ASCASO F 2921 18:00 Influence of eyesight difficulties in the late work of the Spanish painter Francisco de Goya (1746-1828) ASCASO F - Zaragoza

2922 18:15 Tadeusz Krwawicz , MD, PhD – inventor of cryo-surgery GRZYBOWSKI A, Kanclerz P - Olsztyn

2923 18:30 The System of Fighting Trachoma in Poland (1928-1939) POLAK A, Rejdak R - Lublin 2924 18:45 Famous monocular warriors SCHWARTZ S - Naples

2925 19:00 Aesthetic blepharoplasty through the ages PAPADAKIS M - Wuppertal 83

Friday, October 5 - Evening session

18:00 - 19:15 | Rhodes 2 COS - Keratoconus – from molecularbiological background through corneal stabilization SIS to keratoplasty

Keratoconus is a multifactorial disease with an incidence of 1/2000. This symposium discusses pathophysiology and molecularbiological background of keratoconus as much as earliest device-based diagnostics and stage-related therapy. We focus on surgical treatment options, which stabilize the cornea in order to delay or even avoid the necessity of lamellar or penetrating keratoplasty. SZENTMARY N , SEITZ B 2931 18:00 New aspects on the pathophysiology and molecularbiological background of keratoconus STACHON T, Latta L, Seitz B, Langenbucher A, Szentmáry N - Homburg

2932 18:15 Changes of the subbasal nerve plexus in keratoconus FLOCKERZI E, Daas L, Seitz B - Homburg

2933 18:30 device-based earliest instrument guided diagnosis of keratoconus EPPIG T, Spira-Eppig C, Szentmáry N, Langenbucher A, Seitz B - Homburg/Saar

2934 18:45 Intracorneal ring segments (INTACS) – long-term results of the first 100 keratoconus patients DAAS L, Langenbucher A, Seitz B - Homburg

2935 19:00 excimerlaser-guided deep anterior lamellar keratoplasty (DALK) or penetrating keratoplasty (PKP) in advanced keratoconus SEITZ B - Homburg

18:00 - 19:15 | Rhodes 3 SIS PO - Intravitreal pharmacotherapy in ocular oncology

Intravitreal pharmacotherapy is widely used in ocular oncology, mainly for the treatment of vitreous invasion of intraocular tumors and the prevention and treatment of neovascular glaucoma related to ocular radiotherapy. This therapeutic approach is applied both in pediatric and adult ocular oncology. Thanks to intraocular pharmacotherapy, it was possible to improve the eye retention probability as well as the functional results following conservative management of uveal melanomas and to resolve the problem of conservative management of retinoblastomas with vitreous seeding. ZOGRAFOS L , DESJARDINS L 2941 18:00 Intravitreal chemotherapy for vitreal seeding for retinoblastoma HADJISTILIANOU T - Sienna

2942 18:10 Intravitreal anti-VEGF in pediatric ocular oncology STATHOPOULOS C, Munier F, Gaillard M C, Beck-Popovic M - Lausanne

2943 18:20 Intravitreal pharmacotherapy for the prevention of neovascular glaucoma SCHALENBOURG A - Lausanne

2944 18:30 Intravitreal anti-VEGF for the treatment of irradiation induced optic neuropathy and maculopathy ZOGRAFOS L - Lausanne

2945 18:40 Intravitreal chemotherapy in ocular lymphomas CASSOUX N - Paris

2946 18:50 Intravitreal anti-VEGF for the treatment of intraocular vascular tumors KIVELÄ T - Helsinki

2947 19:00 Intravitreal steroids for ocular tumors: indications and limits\r MATET A - Paris 84

Friday, October 5 - Evening session

18:00 - 19:15 | Rhodes 4 SIS ACB/COS - Keratoconus in all its states under a contact lens

Keratoconus is a typically progressive and often severe form of corneal ectasia that can occur inherited but also secondary to different types of ocular surface disease often in conjunction with ocular allergy and types of chronic inflammation that weaken the structure of the collagenous tissue matrix. Due to the irregular shape of the cornea and the often high dioptric impact, the visual rehabilitation in keratoconus can typically not be made by glasses. Therefore contact lenses of the rigid type and often scleral contact lenses are the mainstay of conservative therapy in keratoconus patients. Due to the typically progressive nature of keratoconus if is often not only the visual rehabilitation that is of interest but also the potential inhibition of progression of this corneal ectasia in order to prevent or to delay the necessity of a potential penetrating keratoplasty. The aim of the present SIS is to elucidate and to discuss, which types of contact lenses are suitable for which patients in order to provide them a suitable therapeutic approach in keratoconus and to delay progression of the disease. KNOP E , MEKKI M B 2951 18:00 Keratoconus – more than a simple morphological change of corneal shape KNOP E - Berlin

2952 18:15 Which patient and which eye is suitable for which type of lens ? CARASQUILLO K - Needham

2953 18:30 Which lens fit the best for which patient ? NAU C - Minnesota

2954 18:45 What do we know of indications and outcome of corneal crosslinking – alternative or in addition to Scleral Lenses ? NAU A - Boston 2955 19:00 After SURGERY CXL or ICRS implantation or after graft (DALK or PK) ? MEKKI M B, Yahiaoui S, Titah O, Taibi A - Algiers

18:00 - 19:15 | Gallieni 1+2 SIS NSPH - Understanding ocular anterior dysgenesis phenotype genotype

Ocular Anterior Dysgenesis refer to a wide group of anterior segment diseases that are genetically determined. Clinically there is a large spectrum of findings from posterior embryotoxon to more severe forms such as aniridia, kerato-irido-lenticular dysgenesis as Peters anomaly, primary congenital glaucoma or Axenfeld-Rieger syndrome. The new molecular information is challenging the traditional thinking that was usually guided by the histopathological findings. Our understanding of anterior segment phenotype has improved with new techniques of anterior segment imaging and early genotype-phenotype correlations. Recent advances in genetics help us for a better understanding of the underlying of ocular development mechanisms. An overview of the innovating diagnosis, imaging and treatment is summarized. BREMOND-GIGNAC D , ATILLA H 2961 18:00 What’s new in ocular anterior dysgenesis imaging? BREMOND-GIGNAC D - Paris

2962 18:15 ocular phenotype of ocular anterior dysgenesis ROBERT M, Bremond-Gignac D - Paris

2963 18:30 Classification of ocular anterior dysgenesis: new insights ATILLA H - Ankara

2964 18:45 Congenital cataract: new insights SAUER A - Strasbourg

2965 19:00 Corneal transplant and pediatric ocular anterior dysgenesis DAIEN V - Montpellier 85

Friday, October 5 - General Assembly

19:15 - 19:45 | Hermes EVER GA General EVER General Assembly Assembly

MEMBERS ONLY

Agenda

1. President’s address by Alain Bron

2. Minutes of the General Assembly 2017

3. Report of the Secretary General, Thomas Fuchsluger

4. Report of the Programme Secretary, Francesca Cordeiro

5. Report of the Treasurer, Steffen Heegaard:

• approval of the accounts 2017

• discharge to the directors

• approval budget for 2018

6. Results of the elections 2018

7. Presentation of the board 2019

8. Future congresses

9. Miscellanea

10. Handover of chain of office

Saturday October 6 88

Saturday, October 6 - First morning session

8:30 - 9:45 | Hermes SIS RV - Controversies in new technology for the diagnosis and management of retinal and choroidal disease

Technological advances in Ophthalmology have been extraordinary in recent years with the introduction of new equipment and new techniques. Such an introduction, however, is not always accompanied with enthusiasm but also scepticism, especially when well established diagnostic or therapeutic approaches that have been shown to be essential in patient care are challenged or presumably replaced. In this special interest symposium, the pros and cons of new technology and the challenges in its im- plementation in relation to standard practice will be examined in the form of three separate debates involving OCT angiography, intraoperative OCT and 3D vitrectomy respectively. The first debate will address the important question as to whether OCT angiography can replace fluorescein angiography in clinical practice. Vasilios Papastefanou will argue in favour of this and Irini Chatziralli will argue against. The second debate will address 3D vitrectomy and whether it can replace conventional vitrectomy. Jean-Antoine Pournaras will argue in favour and Tina Xirou will argue against. The third debate will address whether intraoperative OCT is or not of clinical use. Odysseas Georgiadis will argue in favour and Evgenia Kontou will argue against. PAPASTEFANOU V , XIROU T 3111 8:30 OCT angiography can replace fluorescein angiography in clinical practice - For PAPASTEFANOU V - London

3112 8:42 OCT angiography can replace fluorescein angiography in clinical practice - Against CHATZIRALLI I - Athens

3113 8:54 3D vitrectomy can replace conventional vitrectomy - For POURNARAS J A - Lausanne

3114 9:06 3D vitrectomy can replace conventional vitrectomy - Against XIROU T - Glyfada

3115 9:18 Intraoperative OCT: Is it of clinical use? - For GEORGIADIS O, Da Cruz L - London

3116 9:30 Intraoperative OCT: Is it of clinical use? KONTOU E - Athens

8:30 - 9:45 | Rhodes 1 SIS G - Ocular imaging in glaucoma

Since the introduction of the first ophthalmoscope it has become rapidly clear that imaging of the eye is critical for diagnosis and for monitoring of eye disease. This holds also true for glaucoma. Although the diagnosis of glaucoma is still clinical, the fast technical development of new and sophisticated instruments for the non-invasive and in-vivo assessment of ocular structures allows now the evaluation of the most critical components, such as the optic nerve head and the ganglion cell layer in unprec- edented high resolution. Further, new tools such as OCT angiography, wide field OCT imaging or functional imaging may have the potential to open new horizons for the early identification of risk patients. However, despite the progress that has been made, several questions are still not sufficiently answered. One important issue is that the association between structural changes and loss of function in the progressing patients is still not well understood. In this SIS, new developments in ocular imaging and their application in the field glaucoma will be discussed. Further, the potential role of functional imaging will be covered and limitations in our current understanding the structure function relationship will be elaborated. GARHOFER G , SCHMETTERER L 3121 8:30 Value of OCT Angiography in glaucoma LABBE A - Paris

3122 8:48 Wide Field OCT angiography in glaucoma SCHMETTERER L - Singapore

3123 9:06 Functional imaging of the retina: New way to assess ocular disease GARHOFER G - Vienna 89

Saturday, October 6 - First morning session

8:30 - 9:45 | Rhodes 2 SIS COS - Visual rehabilitation in keratoconus beyond keratoplasty

Nowadays, modern, minimally invasive, interventional approaches are employed for visual rehabilitation in patients with keratoconus, thereby significantly reducing the need for keratoplasty. Corneal collagen crosslinking (CXL), implantation of intracorneal ring segments, combined treatment modalities including corneal surface ablation together with CXL, as well as the use of toric phakic intraocular lenses, have revolutionized our concept of visual rehabilitation in patients with keratoconus. These interventional procedures are able to achieve satisfactory visual outcomes with remarkable safety, improving the quality of life in patients with keratoconus. This Special Interest Symposium aims to provide a comprehensive overview of the above-mentioned treatment approaches, highlighting recent advances, controversial issues and the current state, as well as emphasizing on pearls and pitfalls for young physicians and anterior segment surgeons. The speakers are international leaders in the field with vast experience in the topics that will be discussed, and they will offer an in-depth insight into the challenging, but also fascinating treatment algorithm for visual rehabilitation in keratoconus. GATZIOUFAS Z , SZENTMARY N 3131 8:30 CXL and visual rehabilitation in keratoconus: myths and reality HAMADA S - Caterham

3132 8:48 Intracorneal ring segment implantation in keratoconus: an evidence-based approach GATZIOUFAS Z - Basel

3133 9:06 Corneal surface ablation and CXL for visual improvement in keratoconus: when, what and how. KANELLOPOULOS J - Athens

3134 9:24 Toric phakic IOL implantation in keratoconus: indications and outcomes. COCHENER B - Brest

8:30 - 9:45 | Rhodes 3 OOG Ocular Oncology Group I - Ocular adnexa, imaging and intraocular tumors JM

HEEGAARD S , KIVELÄ T 3141 8:30 Use of ocular ultrasound for diagnosis of orbital lesions SOUSA F, Mano S, Teixeira F, Pinto F - Lisbon

3142 8:35 evisceration with autogenous scleral graft and bioceramic implantation within the modified scleral shell: 133 cases over 17 years NADAL J, Daien V, Villain M - Nimes

3144 8:55 Assessing eye color Inside and out MADIGAN M C, Cao D, Ton H T T - Sydney

3145 9:05 The role of chemotherapy in malignant ocular medulloepithelioma SHERIFF I, Karaa E K, Chowdhury T, Scheimberg I, Duncan C, Reddy M A, Sagoo M S - London

3146 9:15 Choroidal osteoma in old age (an unexpectedly difficult diagnosis) Krastel H, KALTAKJI F, Schlichtenbrede F - Neckargemünd

3147 9:20 Neonatal Retinoblastoma HADJISTILIANOU T, Barchitta M, Esposti G, Defrancesco S, Fruschelli M - Sienna

3148 9:30 An “unexplainable” progressive regression of vitreous seeding in advanced retinoblastoma. HADJISTILIANOU T, Barchitta M, Defrancesco S, Esposti G, Menicacci C - Sienna 90

Saturday, October 6 - First morning session

8:30 - 9:45 | Rhodes 4 SIS ACB/RV - Functional hypoxia in the eye: a role for hypoxia-inducible factors

Hypoxia contribute to specific functions in ocular tissues, in both physiological and pathological conditions. The molecular roles of hypoxia-inducible factors (HIF) signaling in the eye will be illustrated, particularly in vascularization, and avascularity, of the different tissues. Studies on HIF-mediated responses and functions in models of ocular pathologies have been increasing during the previous years, and will be elaborated. Furthermore, the impact of hypoxia and HIFs will be addressed in a bench-to-clinic translational perspective. ANDRE H , KAUPPINEN A 3151 8:30 Who’s driving? Investigating the role of the HIF-1/PKM2 axis in the Warburg effect in mammalian retina PEET D, Kittipassorn T, Wood J, Mammone T, Haydinger C, Casson R - Adelaide 3152 8:45 Non-invasive imaging of retinal oxygen metabolism STEFANSSON E, Hardarson S, Olafsdottir O - Reykjavik

3153 9:00 methylation-dependent control of HIF-1/VEGF axis in a mouse model of oxygen-induced retinopathy. Potential role of the glial water channel Aquaporin-4 PISANI F, Cammalleri M, Dal Monte M, Locri F, Mola M G, Nicchia G P, Frigeri A, Bagnoli P, Svelto M - Bari

3154 9:15 rod-specific inactivation of Vhl leads to HIF-dependent retinal degeneration GRIMM C, Barben M, Schori C, Samardzija M - Schlieren

3155 9:30 Hypoxia and eye: from bench to bedside ARJAMAA O - Turku

8:30 - 9:45 | Gallieni 1+2 SIS MBGE - The role of non-coding variants in ocular disease

Decreasing costs of whole-exome sequencing and copy number variation analysis has enabled the identification of vast number of disease-causing mutations and novel genes implicated in ocular disease over the past few years. Despite these state of the art technologies many patients still lack their molecular diagnosis. Attention in the field of human genetics field has now turned to understanding the pathological relevance of non-coding variants within the human genome. This special interest symposium will discuss the recent discoveries in the field of non-coding variation and mechanisms on how these variants can lead to ocular pathology. LISKOVA P 3161 8:30 Antisense therapy for Fuchs endothelial corneal dystrophy ameliorates TCF4 repeat-expansion mediated toxicity DAVIDSON A - London

3162 8:48 Posterior polymorphous corneal dystrophy – a disease caused by dysregulation of transcription factors involved in epithelial-to-mesenchymal transition LISKOVA P - Prague

3163 9:06 The non-coding morbid genome of inherited retinal diseases DE BAERE E - Ghent

3164 9:24 Whole genome analysis of inherited retinal disease patients reveals non-coding mutations intractable to other detection strategies ARNO G, Carss K J, Niblock M, Waseem N, Cheetham M E, Michaelides M, Moore A T, Raymond F L, Webster A R - London 91

Saturday, October 6 - Ophthalmic Research lecture

9:45 - 10:15 | Hermes PS Ophthalmic Research lecture

9:45 Introduction by Alain BRON

3211 9:50 DARC Development and Translation

Francesca M CORDEIRO — London

The DARC Technology (Detection of Apoptosing Retinal Cells) is a revolu- tionary technique that enables direct visualization of nerve cells through labelling of the apoptotic process with fluorescently-labelled Annexin V

(ANX776). DARC has successfully completed Phase 2 clinical trials, with Francesca M

development supported through the Wellcome Trust, and is an example CORDEIRO of basic science to clinical translation. DARC has potential to monitor and assess multiple neurodegenerative conditions, with Phase 2 including patients with age-related macular degeneration (AMD), optic neuritis (ON) and Down’s Syndrome (a model of Alzheimer’s (AD)) in addition to glaucoma. Moreover, its use as an exploratory endpoint in clinical trials of new therapies is an exciting prospect.

10:15 Award presentation of the Certificate of Honour 92

Saturday, October 6 - Poster session

10:15 - 11:15 | Poster area POSSIS COS - Cornea/Ocular Surface

Poster S001-S080

FUCHSLUGER T , SZENTMARY N S002 An innovative bioreactor allows corneal storage for up to 3 months GARCIN T, Gauthier A S, Crouzet E, Herbepin P, Perrache C, He Z, Thuret G, Gain P - Saint Etienne

S003 Using the angular backscattered light to assess transparency of human corneal grafts after treatment by various anti-edematous eye drops GIL M, Dubald M, Guerin C, Georges G, Siozade Lamoine L, Deumie C, Ho Wang Yin G, Hoffart L - Saint Laurent du Var

S004 Characterization of corneas following different time and storage methods for use as a source of stem-like limbal epithelial cells RODRIGUEZ M, Romano-Ruiz P, Etxebarria J, Andollo N - Barakaldo S005 Processed human umbilical cord lining as transplant for sclera defect: an in vivo study BARNOUIN L, Michel A, Douet J Y, Robin M C, Regnier A - Mions S006 Development of secured amniotic membranes as ophthalmologic allografts BARNOUIN L, Michel A - Mions S007 Effects of a hydrocortisone plus sodium hyaluronate solution on wound healing and inflammatory biomarkers in corneal epithelial cells BUCOLO C, Lazzara F, Fidilio A, Platania C B M, Zasa G, Drago F - Catania S008 A synthetic metalloporphyrin SOD mimetic protects corneal epithelial cells from oxidative stress-induced damage in vitro and in vivo THAPA R, Žiniauskaitė A, Ghosh A K, Tenhunen A, Ragauskas S, Kalesnykas G, Hakkarainen J J, Kaja S - Kuopio

S009 Effect of Biphalin on Corneal Epithelial Wound Healing YILDIZ E, Özer B, Gedar M, Mollica A, Sahin A - Istanbul

S010 The effect of estrogen and dihydrotestosterone on hyperosmolarity-induced expression and production of IL-1β, TNF-α and IL-8 through MAPK pathway in human corneal epithelial cells ÖZER B, Yildiz E, Sahin A - Istanbul S011 Novel model for corneal permeability in vitro testing through the combined use of collagen-based hydrogels with stratified corneal epithelial cells ZINIAUSKAITE A, Cepla V, Valiokas R, Kalesnykas G, Hakkarainen J J - Kuopio S012 Modeling of aniridia-related keratopathy by CRISPR/Cas9 genome editing of human limbal epithelial cells and rescue by recombinant PAX6 protein ROUX L, Concordet J P, Zhou J H, Ferrigno O, Aberdam D - Paris

S013 Aniridia-Related Keratopathy in naïve corneas and after keratolimbal allograft VICENTE A, Byström B, Pedrosa Domellöf F - Umeå

S014 Anti-inflammatory properties of corneal stroma-derived stem cells: Potential as a topical therapy for the ocular surface SIDNEY L, Orozco Morales M L, Marsit N, Mcintosh O, Hopkinson A - Nottingham S015 Effects of mesenchymal stem cells on production of cytokines by injured cornea in in vitro and in vivo experimental models KOSSL J, Hermankova B, Javorkova E, Bohacova P, Zajicova A, Holan V - Prague

S016 Comparison of calcium signalling between native and cultured human corneal endothelium after mechanical stimulation LAPAJNE L, Schollmayer P, Hawlina M, Andjelic S - Ljubljana 93

Saturday, October 6 - Poster session

10:15 - 11:15 | Poster area POS COS - Cornea/Ocular Surface

 Intermediate Poster S001-S080

FUCHSLUGER T , SZENTMARY N S017 Verification of splicing alteration caused by a novel SLC4A11 intronic mutation using an autologous induced pluripotent stem cell-derived corneal endothelial-like cell model BREJCHOVA K, Dudakova L, Skalicka P, Vachova V, Dobrovolny R, Liskova P - Prague S018 Corneal endothelial follow-up after intracameral injection of lidocaine, tropicamide and phenylephrine for mydriasis during cataract surgery GAIN P, Crouzet E, Khatib W, Thuret G - Saint-Etienne

S019 Phenotype-genotype correlation of p.R124S mutation in granular type 1 corneal dystrophy of Tunisian origin FALFOUL Y, Bouyacoub Y, Munier F L, Sayeb M, Ouederni M, Chargui M, El Matri L, Abdelhak S, Cheour M - Tunis

S020 Keratoendotheliitis Fugax Hereditaria is Caused by a Mutation in the NLRP3 Gene TURUNEN J, Wedenoja J, Repo P, Järvinen R S, Jäntti J, Mörtenhumer S, Riikonen A, Lehesjoki A E, Majander A, Kivelä T - Helsinki

S021 Gonococcus: A Rare Cause of Infective Conjunctivitis JONES R, Vakros G - Manchester

S022 The study of conjunctival bacterial flora isolated in patients undergoing intravitreal injection and cataract surgery KANG J, Nam K Y, Lee S U, Lee S J - Busan

S023 Bilateral acute corneal melting secondary to nonsteroidal anti-inflamatory drugs LÓPEZ SANGRÓS I, Marco S, Montés P, Karlsruher G, Ascaso F J, Del Buey M A - Zaragoza

S024 Clinical Outcomes for the Treatment of Corneal Blindness using an Epidescemetic Keratoprothesis VEGA-ESTRADA A, Al-Shymali O, Alio J - Alicante

S025 Non-contact millimeter-field imaging of in vivo corneal cells by full-field OCT MAZLIN V, Xiao P, Grieve K, Sahel J A, Fink M, Boccara C - Paris

S026 Use of ultra high-frequency ultrasound VevoMD (70 MHz) in ophthalmology TRONE M C, Perrot J L, Grivet D, Cambazard F, Cinotti E, Gain P, Thuret G - Saint-Etienne

S027 Management of Salzmann’s nodular degeneration by scleral contact lenses TRONE M C, Perillat N, Thuret G, Gain P - Saint-Etienne

S028 Evaluation of the impact of tear layer thickness in scleral lenses on the optical quality of the eye by means of Optical Quality Analysis System (OQAS) TRONE M C, Garcin T, Thuret G, Gain P - Saint-Etienne

S029 Diclofenac release from LbL coated silicon based contact lenses PRIOR FILIPE H, Silva D, Sousa H, Gil H, Moutinho G, Alvarez-Lorenzo C, Saramago B, Serro A P - Lisbon

S030 Novel Polymeric Inserts Comprising Nanomicelles for Topical Ocular Delivery of Cyclosporine-A TERRENI E, Monti D, Chetoni P, Burgalassi S, Tampucci S, Chipala E, Alany R G, Al-kinani A A - Pisa S031 Cyclosporine pharmacokinetics in healthy volunteers after ocular administration of OTX-101, a novel nanomicellar cyclosporine formulation ROLANDO M, Weiss S L, Arntz R, Justice A, Kramer W G, O’connor P - Genoa

S032 Prevalence and clinical patterns of ocular complications associated with anti PD-1/PDL-1 anticancer immunotherapy BITTON K, Barreau E, Rémond A L, Bodaghi B, Michot J M, Champiat S, Mateus C, Marabelle A, Couret C, Best A L, Labetoulle M, Rousseau A - Villejuif 94

Saturday, October 6 - Poster session

10:15 - 11:15 | Poster area POSSIS COS - Cornea/Ocular Surface

Poster S001-S080

FUCHSLUGER T , SZENTMARY N

S033 Ocular pharmacokinetics profile of different hydrocortisone ophthalmic formulations BUCOLO C, Salomone S, Piazza C, Blanco A R, Drago F - Catania

S034 The impact of long term glaucoma medications on structure and function of meibomian glands SCEMLA B, Labetoulle M, Andrieu S, Lambotin C, Barreau E, Rousseau B, Rousseau A - Paris

S035 Efficacy and tolerability of Blephademodex® in patients with demodex blepharitis KHAIRALLAH M, Riadh M, Serge D - Monastir

S036 Gender Differences in Symptoms and Signs of Dry Eye Disease in a Norwegian Cohort of Patients TELLEFSEN S, Badian R A, Stojanovic A, Paaske Utheim T, Aas Utheim Ø, Tashbayev B, Raeder S, Chen X - Oslo S037 Clinical signs in dry eye: a multicentric cross-sectional study CANTALAMESSA E, Villani E, Nucci P, Rolando M - Milan

S038 Comparison of Ocular Surface Index Score and Clinical Dry Eye Disease Parameters in the Young (aged 0-19) and the Elderly (aged 80-99) UTHEIM O, Raeder S, Badian R, Chen X, Tashbayev B, Utheim T P - Oslo

S039 Failure to validate the fluorescein breakup patterns classification in an italian sample of dry eye patients CANTALAMESSA E, Villani E, Luccarelli S V, Lucentini S, Rolando M, Nucci P - Milan S040 Developement of a safe and biocompatible powder to be reconstituted as keystone for dry eye syndrome treatment Barnouin L, MICHEL A - Mions

S041 Effect of a new topical soft steroid hydrocortisone phosphate 0.335% on treatment of dry eye disease SHORTT A - London

S042 All-in one automated measurement of ocular surface parameters: interferometry, tear meniscus, non-invasive break-up time and meibography COURRIER E, Trone M C, Renault D, Lambert V, Lazreg S, Thuret G, Gain P - Saint Priest en Jarez S043 Effect of a new opthalmic hydrocortisone and sodium hyaluronate formulation on two experimental dry eye models BUCOLO C, Lazzara F, Fidilio A, Platania C B M, Blanco A R, Drago F - Catania

S044 Blinking during exercise affects tear osmolarity Wylegala A, WYLEGALA E - Katowice

S045 The effect of eliminating tear evaporation on tear osmolarity ALZAMIL H, Madden L, Pearce E I - Glasgow

S046 Impact of preserved and preservative-free latanoprost on the survival of conjunctival goblet cells AHMAD MOUHAMMAD Z, Taul Brændstrup C, Begun X, Nagymihály R, Heegaard S, Petrovski G, Kolko M - Copenhagen

S047 Ocular surface involvement on GVHD patients LAZREG S, Renault D - Blida

S048 Ocular surface temperature, blinking rate and corneal sensitivity in young contact lens wearers Pastor-Zaplana J Á, Morales-Villellas M, Monteserín-Rodríguez M, GALLAR J, Acosta M C - San Juan de Alicante

S049 Corneal surface temperature decrease during the interblink interval is greater in Sjögren’s syndrome Merino M L, Belmonte J, Acosta M C, Rosas J, Belmonte C, GALLAR J - San Juan de Alicante 95

Saturday, October 6 - Poster session

10:15 - 11:15 | Poster area POS COS - Cornea/Ocular Surface

Poster S001-S080

FUCHSLUGER T , SZENTMARY N S050 Corneal Sub basal nerve plexus 10 years after LASIK CANADAS SUAREZ P, Aranda R, Rodero A, García-González M - Valladolid

S051 Immunolabeling of nerves by anti-neurofilament and anti-βIII-Tubulin in the different compartments of the human ocular surface HE Z, Lambert V, Forest F, Bergandi F, Garcin T, Perrache C, Gain P, Thuret G - Saint-Etienne

S052 First case of immunohistochemical study of a corneal button after treatment by recombinant Neuronal Growth Factor (cenegermin). THURET G, Lambert V, Trone M C, Forest F, Gain P, He Z - Saint-Etienne

S053 Orbital biomechanical changes in Graves’ disease and Thyroid eye disease: application of Corvis ST VIEIRA M, Neves A, Carvalheira F, Batista A, Santos M, Sousa J - Leiria

S054 Longitudinal evaluation of corneal biomechanical parameters in a 7-11 years old Iranian population YEKTA A A, Hashemi H, Momeni-Moghaddam H, Khabazkhoob M, Zarei-Ghanavati S, Ostadimoghaddam H, Heravian J, Yekta R - Mahhad

S055 Corneal scattering and biomechanical behavior in eyes with Fuchs’ endothelial dystrophy KETABI SHADVAR S, Gros-Otero J, Katsanos A, Rodrigo Rey S, Castaño Martin B, Garcia-Gonzalez M, Teus M A - Alcobendas

S056 Corneal posterior surface characterization in normal and keratoconus patients according to the degree of visual limitation VEGA-ESTRADA A, Jorge A - Alicante

S057 Late onset corneal haze after corneal collagen crosslinking for progressive keratoconous PARIKAKIS E, Peponis V, Kontomihos L, Kontadakis G, Batsos G, Tsilioni A, Ktena E, Karagiannis D - Kifissia, Athens

S058 Dynamics of local antioxidant status in patients with keratoconus after various protocols of ultraviolet crosslinking of the cornea. EMIN U, Bikbov M, Bikbova G, Khalimov A, Usubov E - Ufa

S059 Riboflavin levels in the aqueous humour of the rabbit’s eye with standard UV corneal cross-linking in different Epi-Off areas EMIN U, Bikbov M, Bikbova G, Khalimov A, Shevchuk N, Usubov E - Ufa

S060 The effects of corneal collagen cross-linking and the discrepancy between epithelium on and epithelium off treatment – Results from the Portsmouth population cohort MACGREGOR C, Hunter G, Maycock N, Lockwood A, Jayaswal R - Portsmouth

S061 Testing ANN: a neural network to guide keratoconus treatment with ICRS VEGA-ESTRADA A, Jorge A - Alicante

S062 Effect of intracorneal ring segment implantation on tear film properties in patients with keratoconus SAGRI D, Thabit A, Elalfy M, Hamada S, Goldblum D, Scholl H, Gatzioufas Z - Zurich

S063 In vivo biocompatibility of a new intrastromal inlay for spherical ametropia and presbyopia correction, in a rabbit model CROUZET E, Castignoles F, Dommanget C, Perrache C, Forest F, Trone M C, Thuret G, Gain P - Saint Priest en Jarez

S064 Epidemiologic study of dry eye disease (DED) in pre-surgery refractive patients YANCHENKO S - Krasnodar

S066 Results of treatment of transient dry eye syndrome with increasing of intraocular pressure in the patient after LASIK Bikbov M, KHIKMATULLIN R, Usubov E, Zaynetdinov A - Ufa 96

Saturday, October 6 - Poster session

10:15 - 11:15 | Poster area POS COS - Cornea/Ocular Surface

Poster S001-S080

FUCHSLUGER T , SZENTMARY N S067 Effect of laser-assisted subepithelial keratectomy with mitomycin C on corneal optical density measured with confocal microscopy CANADAS SUAREZ P, Drake P, Laucirika G, Teus M - Valladolid

S068 Morphological and refractive consequences of traumatic loss of LASIK corneal flap ASCASO F, Montes Rodríguez P, Karlsruher Riegel G, López I, Marco S, Berniolles J, Bartolomé M I, Del Buey M A - Zaragoza

S069 Dropmeter interest in clinical trials RENAULT D, Garhöfer G, Courrier E, Lambert V, Garcin T, Rebika H, Thuret G, Gain P - Clermont-Ferrand S070 The OBSERV platform (Ophthalmic Bioreactor Specialized in Experimental Research & Valorisation): overview of possible applications THURET G, Crouzet E, Garcin T, Herbepin P, He Z, Courrier E, Perrache C, Al Bourgol S, Lambert V, Maurin C, Saunier V, Gauthier A S, Gain P - Saint-Etienne

S071 The OBSERV platform (Ophthalmic Bioreactor Specialized in Experimental Research & Valorisation): Assessment of corneal biomechanics SAUNIER V, Crouzet E, Legout P, Herbepin P, Thuret G, Touboul D, Gain P - Bordeaux

S072 The OBSERV platform (Ophthalmic Bioreactor Specialized in Experimental Research & Valorization): study of a new intrastromal inlay for presbyopia CROUZET E, Trone M C, Garcin T, Castignoles F, Dommanget C, Al Bourgol S, Perrache C, Forest F, Thuret G, Gain P - Saint-Etienne

S073 The OBSERV platform (Ophthalmic Bioreactor Specialized in Experimental Research & Valorization): simulation of a DMEK HE Z, Crouzet E, Perrache C, Garcin T, Trone M C, Forest F, Gain P, Thuret G - Saint-Etienne

S074 The OBSERV platform (Ophthalmic Bioreactor Specialized in Experimental Research & Valorisation): study of a retro-corneal implant for corneal edema CROUZET E, Garcin T, Trone M C, Perrache C, Forest F, Daphan O, Marcovich A, Ferara N, Thuret G, Gain P - Saint-Etienne

S075 The OBSERV platform (Ophthalmic Bioreactor Specialized in Experimental Research & Valorisation): Kinetics of human cornea swelling and deswelling in the bioreactor as a function of IOP and endothelial status PERRACHE C, Crouzet E, Guindolet D, Herbepin P, Garcin T, He Z, Courrier E, Gain P, Thuret G - Saint-Etienne

S076 The OBSERV platform (Ophthalmic Bioreactor Specialized in Experimental Research & Valorisation): study of new lyophilized amniotic membranes GAIN P, Crouzet E, Al Bourgol S, Barnouin L, Perrache C, He Z, Forest F, Thuret G - Saint-Etienne

S077 The OBSERV platform (Ophthalmic Bioreactor Specialized in Experimental Research & Valorisation): regeneration of corneal and limbal epithelium of stored human corneas GUINDOLET D, Crouzet E, Perrache C, Gabison E, He Z, Thuret G, Gain P - Paris

S078 The OBSERV platform (Ophthalmic Bioreactor Specialized in Experimental Research & Valorization): simulation of the endothelial cells injection therapy for corneal edema HE Z, Crouzet E, Perrache C, Garcin T, Forest F, Gain P, Thuret G - Saint-Etienne

S079 The OBSERV platform (Ophthalmic Bioreactor Specialized in Experimental Research & Valorisation): an ex vivo model of human Staphylococcus aureus keratitis LAMBERT V, Courrier E, Maurin C, Charaoui S, Verhoeven P, Al Bourgol S, Crouzet E, Perrache C, Herbepin P, He Z, Gain P, Thuret G - Saint-Etienne

S080 The OBSERV platform (Ophthalmic Bioreactor Specialized in Experimental Research & Valorisation): an innovative ex vivo model of human herpetic keratitis COURRIER E, Lambert V, Maurin C, Bourlet T, Verhoeven P, Charaoui S, Al Bourgol S, Crouzet E, Perrache C, Herbepin P, He Z, Gain P, Thuret G - Saint Priest en Jarez 97

Saturday, October 6 - Poster session

10:15 - 11:15 | Poster area POS ACB - Anatomy/Cell Biology

Poster S081-S102

KAUPPINEN A S081 Improved wound resolution for Entropion Surgery using a microscope-assisted 8’0’ vicryl suture technique. BALENDRA S, Rainsbury P, Makuloluwe S, Lockwood A, Maclean H - Portsmouth

S082 Increased TRAIL and TRAIL receptor expression in rat corneal stroma exposed to chemical burn damage DRAGONI F, Amirkavei M, Kaarniranta K, Viiri J, Amadio M - Kuopio S083 Effect of Pseudomonas and Acanthamoeba infection upon inflammation produced by human cornea epithelial cells BISEVAC J, Korhonen E, Noer A, Moe C. M, Kaarniranta K, Kauppinen A, Petrovski G - Oslo

S084 Effect of trypsin-EDTA on expression of DNA damage repair enzyme APE1 in human conjunctival epithelial cells NICOLAISSEN B O, Nguyen G, Beraki K, Moe M C, Petrovski G, Nicolaissen B, Lorenzo Y - Drammen S085 The role of caspase-8 in inflammasome activation in RPE cells RANTA-AHO S, Piippo N, Korhonen E, Hytti M, Kauppinen A, Kaarniranta K - Kuopio

S086 Morphologic and electroretinographic phenotype of NRF-2 and PGC-1α deficient mice: a novel model for dry age-related macular degeneration SZÄSZUJFALUSI FELSZEGHY S, Johanna V, Koskela A, Chen M, Ferrington D, Kauppinen A, Kaarniranta K - Kuopio

S087 New nature-inspired hybrids activating the Nrf2-HO1 pathway in retinal pigment epithelial cells and their potential use in pathologies featured by oxidative stress AMADIO M, Catanzaro M, D’Angelo I, Kaarniranta K, Kauppinen A, Rosini M, Govoni S, Lanni C - Pavia S088 Oxidative stress and mitochondrial damage overloads mitophagy in dry age-related macular degeneration like PGC-1α/Nrf-2 knockout mice model SRIDEVI GURUBARAN R, Viiri J, Koskela A, Hyttinen J, Kauppinen A, Urtti A, Szäszujfalusi Felszeghy S, Kaarniranta K - Kuopio S089 Rab 7 characterization and its regulatory role on autophagy in retinal pigment epithelium cells MYSORE Y, Piippo N, Hyttinen J M T, Kaarniranta K, Kauppinen A - Kuopio

S090 Ex vivo expansion of human primary RPEs for potential use in clinical transplantation studies NAGYMIHALY R, Lytvynchuk L, Moe M, Bergersen L H, Petrovski G - Oslo

S091 Contribution of the monocyte-derived macrophages to retinal microglia response after a peripheral nerve injury POZO LORENZO F J, Bográn-Rodríguez H R, David S, Vidal-Sanz M, Aviles-Trigueros M - El Palmar, Murcia

S092 TIM2: a new player in iron homeostasis in the retina VALENÇA A, Ramos D, Catita J, Bonet A, Nacher V, Navarro M, Carretero A, Mendes-Jorge L, Ruberte J - Lisboa

S093 Sitagliptin, a dipeptidyl peptidase-IV inhibitor, attenuates retinal neurodegeneration in rd10 mice KUTSYR O, Fernández-Sánchez L, Maneu V, Lax P, Ambrósio A F, Cuenca N - Alicante S094 Neurogenesis detection in the adult human retina ORTUÑO-LIZARÁN I, Peterson D A, Cuenca N - San Vicente del Raspeig

S095 Lactate: More than merely a metabolic waste product VOHRA R, Aldana B I, Skytt D M, Waagepetersen H, Bergersen L H, Kolko M - Copenhagen

S096 Optic nerve remodeling event due to a retinal ganglion cell degeneration in patients with Parkinson disease SÁNCHEZ SÁEZ X, Ortuño-lizarán I, Beach T G, Serrano G E, Adler C H, Cuenca N - Sant vicent del Raspeig, Alicante 98

Saturday, October 6 - Poster session

10:15 - 11:15 | Poster area POS ACB - Anatomy/Cell Biology

Poster S081-S102

KAUPPINEN A

S097 Prevention of glutamate-induced retinal ganglion cell death by UCCB01-144 treatment BULLI G, VOHRA* R, Skytt D M, Strømgaard K, Kolko M - Copenhagen S098 Cenupatide is an effective antiangiogenic in a novel mouse model of rubeosis iridis associated with neovascular glaucoma ANDRE H, Locri F, Aronsson M, Maurizio C, Dal Monte M, Bagnoli P, De Rosa M, Pavone V, Kvanta A - Stockholm

S099 Aflibercept Treatment Leads to Vascular Abnormalization of the Choroidal Neovascularization WYLEGALA A - Katowice

S100 MicroRNA regulation underlines an interplay between autophagy and neovascularization in wet AMD KAARNIRANTA K, Watala C, Filip A, Winiarczyk M, Zmorzyński S, Mackiewitcz J, Blasiak J - Kuopio

S101 Epiretinal membranes in a db/db model of diabetic retinopathy BONET A, Valença A, Catita J, Nacher V, Navarro M, Carretero A, Mendes-Jorge L, Ramos D, Ruberte J - Bellaterra, Barcelona

S102 SIRT1 overexpression induces VEGF expression and pericyte recruitment in the retina RAMOS D, Catita J, Valença A, Bonet A, Carretero A, Navarro M, Nacher V, Mendes-jorge L, Ruberte J - Lisbon 99

Saturday, October 6 - Poster session

10:15 - 11:15 | Poster area POS LC - Lens and Cataract

Poster S103-S114

QUINLAN R , ROZEMA J S103 Image registration demonstrates central lens thickness minimally changes during accommodation GRZYBOWSKI A, Schachar R A, Gaca-Wysocka M, Schachar I H, Kamangar F, Pierscionek B K P - Olsztyn

S104 Comparison of collagen and alpha smooth muscle actin distribution in in-vitro and in-vivo developed posterior capsule opacification D’ANTIN J C, Ribeiro Koch C, Tresserra F, I. Barraquer R, Michael R - Barcelona

S105 Calcium signaling in ex vivo cultured human anterior lens epithelial cells after mechanical stimulation ANDJELIC S, Gosak M, Gojic D, Hawlina M - Ljubljana

S106 Intraocular lens surface roughness studied by atomic force microcopy in different environments in vitro KETABI SHADVAR S, Gros-Otero J, Villa-collar C, Garcia-gonzalez M, Teus M A - Alcobendas

S107 Influence of steam and pressure and gamma radiation sterilization on drug loaded intraocular lenses for endophthalmitis prevention PRIOR FILIPE H, Topete A, Saramago B, Serro A P - Lisbon S108 Prediction of postoperative spherical equivalent after cataract surgery using a machine learning approach DEBELLEMANIERE G, Dubois M, Gatinel D - Paris S109 Correlations between subjective and objective preoperative assessment of cataract severity, and intraoperative ultrasound energy GARCIN T, Grivet D, Thuret G, Gain P - Saint Etienne

S110 Phacoemulsification and zonular weakness: contribution of the wired capsular tension ring. LAMBERT V, Courrier E, Renault D, Thuret G, Gain P, Malek Y, Oudjani N - Saint-Etienne

S111 Vivinex© toric lenses refractive results after cataract surgery, preliminary study including 50 eyes VERRECCHIA S, Hussam E C, Elbany S, Agard E, Dot C - Lyon

S112 Implantation of toric intraocular lens and femtolaser arcuate keratotomy as ways for corneal astigmatism correction at single-stage phacoemulsification MALGIN K - Orenburg

S113 Clinical outcomes after cataract surgery with a Precizon Multifocal intraocular lens LEE G, Jun I H, Koh K M, Kim T I - Seoul

S114 Molecular genetic analysis in three cases with syndromic cataracts DUDAKOVA L, Skalicka P, Magner M, Plevova P, Honzik T, Liskova P - Prague 100

Saturday, October 6 - Poster session

10:15 - 11:15 | Poster area POSSIS PO - Pathology/Oncology

Poster S115-S119

VAN GINDERDEUREN R , JAGER MJ S115 Orbital cellulitis secondary to malignat neoplasia LÓPEZ SANGRÓS I, Marco S, Bartolomé M I, Marta C B, Castillo J, Berniolles J, Dominguez A M, Montes P, Karlsruher G, Ascaso J - Zaragoza

S116 Invasive retinoblastoma – case report MRAZOVAC D, Juri Mandic J, Zimak Z, Vukojevic N - Zagreb

S117 Tunisian retinoblastoma clinical and genetic profile ROUATBI A, Chebbi A, Ben Selem M, Bouguila H - Tunis

S118 Tunisian uveal melanoma’s epidemiological study ROUATBI A, Chebbi A, Ben Selem M, Bouguila H - Tunis

S119 Tunisian experience with antimitotic agents in ocular surface squamous neoplasia ROUATBI A, Chebbi A, Ben Selem M, Bouguila H - Tunis 101

Saturday, October 6 - Second morning session

11:15 - 12:30 | Hermes SIS RV - Management of proliferative diabetic retinopathy

AIM: To present all the new facts regarding Proliferative Diabetic retinopathy METHODS: We will provide lectures and questions and answers in the field of Proliferative Diabetic retinopathy pathophysiology, medical treatment , Surgical treatment, New Techniques, New Instrumentation. RESULT: We believe that at the end of rhe session we will provide all the necessary knowledge for a safer and better management of the Proliferative Diabetic retinopathy . CONCLUSION: Proliferative Diabetic retinopathy is a good proportion of a Vitreoretinal Surgeon's every day activity. The more you know the better management you can provide PAPPAS G , POURNARAS J 3311 11:15 Laser or Anti-VEGF for prolipherative diabetic retinopathy PARIKAKIS E - Kifissia, Athens

3312 11:30 Investigation techniques for proliferative diabetic retinopathy PETROU P - Athens

3313 11:45 27g for proliferative diabetic retinopathy PAPPAS G - Heraklion

3314 12:00 3D surgery for proliferative diabetic retinopathy POURNARAS J A - Lausanne

3315 12:15 Guidlines for the management of Proliferative Diabetic retinopathy TBC

SIS 11:15 - 12:30 | Rhodes 1 G: ARVO@EVER - Advances in glaucoma

This session will summarise the lates advances in the different aspects of glaucoma management including medicine, laser and surgery. Highlights of the newest treatments as well as the latest tthoughts on existing/best practice will be covered. Additionally, all speakers will cover future therapies/technologies in the field. CORDEIRO M F , BRON A 3321 11:15 Medicine CORDEIRO M F - London 3322 11:40 Lasers MEIER-GIBBONS F - Rapperswil

3323 12:05 Can we individuaize glaucoma surgery? SUNARIC MEGEVAND G - Geneva 102

Saturday, October 6 - Second morning session

11:15 - 12:30 | Rhodes 2 RF EOVS - Rapid Fire session

LAWRENSON J , CASTELO-BRANCO M 33301 11:15 The Rayleigh equation: reasons for a standard in application KRASTEL H, Kirchhübel R, Bischoff P, Jonas J B - Neckargemünd 33302 11:21 Uncorrected refractive error and associated risk factors among socially vulnerable older adult population living in Armenia GILOYAN A, Harutyunyan T, Petrosyan V - Yerevan 33303 11:27 Corneal astigmatism distribution at Indonesia National Eye Center Cicendo Eye Hospital SUGANDA R, Renata Musa I, Wahyu M S, Virgana R - Jakarta utara 33304 11:33 Conservative Treatment of Newly Diagnosed Keratoconus MRAZOVAC D, Jandrokovic S, Zimak Z, Petricek I - Zagreb 33305 11:39 A new reaction time test (Ocusweep® Reaction Time Test) for assessing visual performance and compliance TIGCHELAAR I, Mäntysalo T, Leinonen M - Turku 33306 11:45 The influence of cataract light scatters on retinal vessel oxygen saturation WAIZEL M, Türksever C, Todorova M G - Basel 33307 11:51 Correlating macular inner retinal layer thickness with photopic and mesopic contrast sensitivity in healthy young and older subjects. PUELL M, Palomo-álvarez C, Pérez-Carrasco M - Madrid 33308 11:57 Different retinal layers thickness measurements change with age in healthy eyes RODRIGO M J, Vilades E, Orduna E, Gavin A - Zaragoza 33309 12:03 electrophysiology and retinal thickness alterations in patients with multiple sclerosis with and without previous optic neuritis ORDUNA HOSPITAL E, Vilades Palomar E, Rodrigo Sanjuan M J, Gavin Sancho A, Cipres Alastuey M, Larrea Samper J G, Satue Palacian M, Garcia Martin E - Zaragoza 33310 12:09 Pattern electroretinogram steady-steate in dyslexis and normal readers CELLINI M, Campos E C - Bologna 33311 12:15 Investigating the movement of the centre of the multifocal hexagonal stimulus array using an electroretinogram function SUZUKI N, Yamane K - Numazu

11:15 - 12:30 | Rhodes 3 JM OOG Business Meeting

Heegaard S Agenda

1. Financial update

2. OOG membership

3. Future meetings

4. Collaborative studies

5. Any other business 103

Saturday, October 6 - Second morning session

11:15 - 12:30 | Rhodes 4 RF IM/LC - Rapid Fire session

PICHI F , NERI P , MICHAEL R , BARRAQUER R I 33501 11:15 suclinical signs persistance in Vogt-Koyanagi-Harada disease (VKHD) patients treated with early high-dose corticosteroids and immunosuppressive therapy YAMAMOTO TAKIUTI J H, Lavezzo M M, Sakata V M, Kanenobu C, Morita C, Oyamada M K, Hirata C E - Sao Paulo 33502 11:21 Fine-Tuning of therapy in stromal choroiditis using indocyanine green angiography (ICGA) ELAHI S, Gillmann K, Gasc A, Jeannin B, Herbort Jr C P - Lausanne 33503 11:27 eYS606 for the Treatment of Non-Infectious Uveitis (NIU) BUGGAGE R - Paris 33504 11:33 Aciclovir-resistant HSV1 keratitis : a clinical and virological study ROUSSEAU A, Burrel S, Gueudry J, Deback C, Bordereau S, Mouriaux F, Labalette P, Bazard M C, Gabison E, Bourcier T, Schweitzer C, Labetoulle M - Le Kremlin Bicêtre 33505 11:39 Association between visual function and quality of life in patients with Vogt-Koyanagi-Harada disease YAMAMOTO TAKIUTI J H, Missaka R F, Souto F M, Marchiori B M, Caetano V M, Takiuti J T, Lavezzo M M, Oyamada M K, Hirata C E - Sao Paulo 33506 11:45 Interleukin-33 regulates mitochondrial function in the retinal pigment epithelium maintaining immune homeostasis SCOTT L, Vincent E, Dick A, Theodoropolou S - Bristol 33507 11:51 Intraocular lens surface roughness studied by atomic force microcopy in different environments in vitro KETABI SHADVAR S, Gros-Otero J, Villa-Collar C, Garcia-Gonzalez M, Teus M A - Alcobendas 33508 11:57 Influence of steam and pressure and gamma radiation sterilization on drug loaded intraocular lenses for endophthalmitis prevention PRIOR FILIPE H, Topete A, Saramago B, Serro A P - Lisbon 33509 12:03 Implantation of toric intraocular lens and femtolaser arcuate keratotomy as ways for corneal astigmatism correction at single-stage phacoemulsification MALGIN K - Orenburg 33510 12:09 molecular genetic analysis in three cases with syndromic cataracts DUDAKOVA L, Skalicka P, Magner M, Plevova P, Honzik T, Liskova P - Prague 104

Saturday, October 6 - Second morning session

11:15 - 12:30 | Gallieni 1+2 SIS MBGE - Genetic models to human ocular diseases

Genetic disorders are caused by multifactorial means, involving a combination of genetic and environmental factors. Many human diseases involve eye development, a complex and unique sense organ. For most vision pathologies, there is no satisfatory therapeutic tools. Therefore, there is a great need for vision research and design of cellular and animal models that recapitulate eye disorders. Such models will help studying the normal and pathological molecular pathways but also screening for small com- pounds that could become potential therapeutic tools. This session will bring European experts who design cellular and animal models of retinal and corneal disorders. ASHERY-PADAN R , ABERDAM D 3361 11:15 molecular mechanisms underlying retinal degeneration caused by cilia dysfunction MAY SIMERA H, Patnaik S, Kretschmer V, Schneider S - Mainz

3362 11:33 Inherited retinal dystrophies and regulated protein clearance IVAN C - Pozzuoli (NA)

3363 11:51 stem cell tracking, loss and recovery in the corneal epithelium SHALOM-FEUERSTEIN R - Haifa

3364 12:09 modeling of aniridia-related keratopathy by CRISPR/Cas9 of human limbal epithelial cells and rescue by recombinant PAX6 protein Roux, L - Paris 105

Saturday, October 6 - Noon session

12:30 - 13:45 | Hermes JM FAN Club

Cases with retinal imaging are presented and discussed with a panel. Each case presentation lasts for 10 minutes with 5 minutes for discussion. This session is open to all EVER delegates. Presenters at this session are welcome to bring a powerpoint presentation of a single interesting case on a USB memory key and load it up in the speakers room. www.fan-int.org

VAN SCHOONEVELD M

12:30 - 13:45 | Rhodes 1 SIS EOVS - Scattered light and visual function

Any disturbance to the homogeneity of ocular media will cause a localised change in refractive index, which will consequently alter the optical pathway of incoming light, causing an increase in light scatter or retinal straylight. Forward light scatter origi- nates predominantly in the cornea and the crystalline lens; it’s known to produce veiling glare on the retina, which in turn affects retinal image contrast. Veiling glare is also reported to induce disability glare; haloes; and can adversely affect critical tasks such as driving. There has been an increasing interest in the influence of forward light scatter, particularly since the development of instruments which allow easy measurement of light scatter parameters. This Special Interest Symposium aims to bring together researchers with specific interests in the impact of light scatter on retinal sensitivity, its relationship with intraocular lens glistening, measurement techniques, and will discuss functional effects of scattering versus morphology. We expect the symposium to draw interest from a broad range of vision researchers; including those with interests in retinal image quality, and refractive surgery. NAGRA M , BARBUR J L 3421 12:30 scattered light and retinal sensitivity to contrast BARBUR J L - London 3422 12:40 straylight and the slitlamp image: functional effects of scattering versus morphology VAN DEN BERG T J - Amsterdam

3423 12:50 Is bigger better? Glistenings, forward light scatter and visual performance HULL C, Stanojcic N, Philippaki E, O'Brart D - London

3424 13:00 Comparison between two scatter parameters in a population under age 65 : the C-quant (Oculus) and the HD Analyser (Visiometrics) VAN VERRE H - Halle

3425 13:10 Factors influencing retinal straylight ROZEMA J - Edegem

3426 13:20 Disk halo size as a measurement of scattering and visual function PUELL M, Pérez-Carrasco M, Palomo-álvarez C - Madrid 3427 13:30 refractive error and forward light scatter NAGRA M, Patel M, Barbur J - London 106

Saturday, October 6 - Noon session

12:30 - 13:45 | Rhodes 2 SIS SOPREF - Eyelid and orbital tumors: diagnosis, treatment and biomarkers

LAGIER J

3431 12:30 Lymphoma highlights ROBERT P Y - Limoges

3432 12:39 sebaceous carcinoma highlights FEVRIER E, Lagier J - Nice

3433 12:48 Challenge in squamous cell carcinoma MARTEL A, Lagier J - Nice

3434 12:57 radiotherapy of sebaceous carcinoma in 2018 CLAREN A - Nice

3435 13:06 IgG4 relationship with orbital malignant tumor MOURIAUX F - Rennes

3436 13:15 Challenge in eyelid melanoma combined with conjunctivitis melanoma challenge DELAS J - Nice

3437 13:24 Challenge in fibroblastic/myofibroblastic tumor in child NAHON-ESTEVE S, Lasalle S - Nice

3438 13:33 Outcomes of patients with conjunctival squamous cell carcinoma treated with proton beam therapy Nahon-Esteve S, CAUJOLLE J P - Nice

12:30 - 13:45 | Rhodes 3 JM OOG Ocular Oncology Group II - Uveal melanoma

DESJARDINS L , ZOGRAFOS L 3441 12:30 rapid MR Imaging of Ocular Movement for Radiotherapy Planning JAARSMA-COES M, Van Vught L, Koolstra K, Beenakker J W B - Leiden

3442 12:40 Automated analysis of eye tumor MR-images for an improved treatment determination BEENAKKER J W M, Hassan M K, Shamonin D P, Shahzad R, Webb A, Stoel B C, Luyten G P M - Leiden

3443 12:50 measuring eye deformation under different patient positions using MRI JAARSMA-COES M, Schuurmans M S, Hassan M K M A, Marinkovic M, Luyten G P M, Beenakker J W B - Leiden

3444 13:00 mr-Imaging enables accurate diagnosis and follow-up for vitrectomized eyes in uveal melanoma patients JAARSMA-COES M, Goncalves Ferreira T A, Marinkovic M, Luyten G P M, Beenakker J W M - Leiden

3445 13:10 Local tumourcontrol rate and late complications of fractionated stereotactic radiotherapy in uveal melanoma VAN BEEK J, Van Rij C, Yavuzyigitoglu S, Paridaens D, Naus N, Kiliç E - Rotterdam

3446 13:20 Overall survival after treatment for metastatic uveal melanoma: a systematic review and meta-analysis RANTALA E, Hernberg M, Kivelä T - Helsinki 107

Saturday, October 6 - Noon session

12:30 - 13:45 | Rhodes 4 RF COS - Rapid Fire session

GICQUEL J , SZENTMARY N 34502 12:36 Anti-inflammatory properties of corneal stroma-derived stem cells: Potential as a topical therapy for the ocular surface SIDNEY L, Orozco Morales M L, Marsit N, Mcintosh O, Hopkinson A - Nottingham 34503 12:42 Phenotype-genotype correlation of p.R124S mutation in granular type 1 corneal dystrophy of Tunisian origin FALFOUL Y, Bouyacoub Y, Munier F L, Sayeb M, Ouederni M, Chargui M, El Matri L, Abdelhak S, Cheour M - Tunis 34504 12:48 Keratoendotheliitis Fugax Hereditaria is Caused by a Mutation in the NLRP3 Gene TURUNEN J, Wedenoja J, Repo P, Järvinen R S, Jäntti J, Mörtenhumer S, Riikonen A, Lehesjoki A E, Majander A, Kivelä T - Helsinki 34505 12:54 Non-contact millimeter-field imaging of in vivo corneal cells by full-field OCT MAZLIN V, Xiao P, Grieve K, Sahel J A, Fink M, Boccara C - Paris 34506 13:00 Gender Differences in Symptoms and Signs of Dry Eye Disease in a Norwegian Cohort of Patients TELLEFSEN S, Badian R A, Stojanovic A, Paaske Utheim T, Aas Utheim Ø, Tashbayev B, Raeder S, Chen X - Oslo 34507 13:06 Developement of a safe and biocompatible powder to be reconstituted as keystone for dry eye syndrome treatment Barnouin L, MICHEL A - MIONS 34508 13:12 Ocular surface temperature, blinking rate and corneal sensitivity in young contact lens wearers Pastor-Zaplana J Á, Morales-Villellas M, Monteserín-Rodríguez M, GALLAR J, Acosta M C - San Juan de Alicante 34509 13:18 Orbital biomechanical changes in Graves’ disease and Thyroid eye disease: application of Corvis ST VIEIRA M, Neves A, Carvalheira F, Batista A, Santos M, Sousa J - Leiria 34510 13:24 Effect of intracorneal ring segment implantation on tear film properties in patients with keratoconus SAGRI D, Thabit A, Elalfy M, Hamada S, Goldblum D, Scholl H, Gatzioufas Z - Zurich

12:30 - 13:45 | Gallieni 1+2 Women EVER JM Women in EVER 4

VOTRUBA M , KAWASAKI A 3461 12:30 moving from academia to industry PURSLOW C - Monmouth

3462 12:46 Having it all? TSANGARIDES SA - London

3463 13:02 The long way from basic sciences to patient’s care (and return) D’Esposito F - London

3464 13:18 Women in Vision UK- a movement for gender equality in ophthalmology and vision sciences MOOSAJEE M - London

13:34 Q & A and conclusions & next steps by the moderators 108

Saturday, October 6 - First afternoon session

14:15 - 15:30 | Hermes RF Young investigators' award session I

POURJAVAN S , NERI P

3511 14:15 ACB - Neurogenesis detection in the adult human retina ORTUÑO-LIZARÁN I, Peterson D A, Cuenca N - San Vicente del Raspeig 3512 14:24 eOVS - New analysis of the Farnsworth D-15 test EVANS B, Barbur J, Rodriguez-Carmona M - London 3513 14:33 G - Resveratrol nanoparticles are neuroprotective in vitro suggesting a potential to cure glaucoma and Alzheimer’s disease SHAMSHER E, Davis B, Dev P, Grgic L, Somavarapu S, Guo L, Cordeiro F - London 3514 14:42 G - Peripapillary vascular analysis from optical coherence tomography angiography to differentiate glaucoma and normal eyes MARQUES M, Cabral D, Rodrigues P, Alves S, Valadares J, Barrão S - Lisboa 3515 14:51 rV - A morphological study and expression patterns of iron regulatory proteins in aging Wistar rats retina after iron overload KUMAR P, Nag T C, Velpandian T, Toy T S, Wadhwa S - New Delhi 3516 15:00 rV - The incidence of rhegmatogenous retinal detachment in France from 2010 to 2016: seasonal and geographical variations BEN GHEZALA I, Benzenine E, Mariet A S, Gabrielle P H, Bron A, Quantin C, Creuzot C - Dijon

14:15 - 15:30 | Rhodes 1 G/NSPH - Biomarkers in ophthalmology and beyond SIS

Neurodegenerative disorders present ocular manifestations which could precede general signs and symptoms. Correlation between the eye and the brain has been confirmed by recent advances in ophthalmic technologies. Furthermore, ocular biomarkers have increasingly been used as surrogate indicators of disease activity and treatment response. The aim of this SIS is to generate a multidisciplinary discussion around biomarkers in ophthalmology with a particular focus on: 1. What is the State-of-the-Art 2. New advances in structural biomarkers for ophthalmic and neurological conditions 3. Genetic biomarkers in ophthalmology. NORMANDO E M , CORDEIRO M F 3521 14:15 Biomarkers in glaucoma YAP T - London

3522 14:30 Biomarkers in optic neuritis BARBONI P - Bologna

3523 14:45 structural Biomarkers in neurodegeneration CUNHA J P, Ferreira J, Dias-Santos A - Lisbon

3524 15:00 Genetic biomarkers in ophthalmology VOTRUBA M - Cardiff 3525 15:15 New and emerging ocular biomarkers CORDEIRO M F - London 109

Saturday, October 6 - First afternoon session

14:15 - 15:30 | Rhodes 2 SIS PO - New treatments in eye melanomas

Ocular melanoma have a high tendency to metastasize, and a lack of efficient treatments. It is important to get more insight in the molecular pathways and the immunological characteristics of conjunctival and uveal melanoma in order to develop treatments for metastases. Another option is to prevent the development of melanoma by early treatment of high-risk nevi. Different approaches will be discussed. JAGER M J , MOULIN A 3531 14:15 Treatment targets in conjunctival melanoma MOULIN A - Lausanne

3532 14:27 Immunology of conjunctival and uveal melanoma JAGER M J - Oegstgeest

3533 14:39 Differential diagnosis of intraocular tumors ROMANOWSKA DIXON B - Krakow

3535 14:51 Treatment of uveal melanoma metastases: a surgeon's view CASSOUX N - Paris

3536 15:03 Treatment of uveal melanoma: an oncologist's view PIPERNO-NEUMANN S - Paris

14:15 - 15:30 | Rhodes 3 SIS LC/COS - Customized intraocular lenses – challenges and limitations

Beside the classical spherical lens designs there are aspherical (aberration free and aberration correcting), toric and multifocal IOLs on the market. None of them are really customized to the optical aberration of the cornea, which means that after implantation there are residual optical aberrations left in the eye.Customized intraocular lenses offer the capability to individually correct optical aberrations of the eye. Calculations are performed based on the shape of the corneal front and back surface, the shape of the pupil and standard biometric measures. Optical surfaces are characterized by a global definition or local splines. In general, the potential deterioration of the retinal image performance gains with the degree of customization if customized lenses are not properly positioned in the eye or biometric parameters change over time.In this course we would like to address which preoperative measurements are necessary, the workflow of customized IOL calculation, and the postoperative monitoring in terms of quality check. LANGENBUCHER A , EPPIG T 3541 14:15 The basic concept behind customized IOLs – optical aberrations and correction options LANGENBUCHER A, Schröder S, Schrecker J, Eppig T - Homburg

3542 14:33 Calculation of customized IOLs – from corneal tomography and biometry to the lens shape EPPIG T, Schröder S, Schrecker J, Langenbucher A - Homburg/Saar

3543 14:51 robustness towards position uncertainties – the forgotten factor SCHRÖDER S, Eppig T, Schrecker J, Langenbucher A - Homburg

3544 15:09 First clinical results with customized IOLs SCHRECKER J - Glachau 110

Saturday, October 6 - First afternoon session

14:15 - 15:30 | Rhodes 4 RF RV - Rapid Fire session

POURNARAS J , POURNARAS C 35501 14:15 strain differences in the rat streptozotocin-induced model of diabetic retinopathy JÄÄSKELÄINEN N, Tenhunen A, Thapa R, Ragauskas S, Dunlop T, Ziniauskaite A, Haapaniemi A M, Räsänen H, Kaja S, Kalesnykas G, Cerrada-Gimenez M - Kuopio 35502 14:21 In vivo retinal cells visible without adaptive optics using a novel full-field OCT MAZLIN V, Xiao P, Scholler J, Grieve K, Sahel J A, Fink M, Boccara C - Paris 35503 14:27 Choriocapillaris changes during development of CNV – an OCT Angiography quantitative analysis RODRIGUES C, Cabral D, Coscas F, Pereira T, Cachado F, Geraldes C, Sellam A, Barrão S, Papoila A, Coscas G, Souied E - Lisbon 35504 14:33 Analysis of choroidal structure changes in diabetic patients without diabetic retinopathy: a longitudinal study FIGUEIREDO R, Luís M E, Hipólito Fernandes D, Cunha J P, Alves M, Papoila A L, Abegão Pinto L, Tavares Ferreira J - Coimbra 35505 14:39 retinal neurodegeneration in patients with type 2 diabetes mellitus without diabetic retinopathy MOURA-COELHO N, Alves M, Dias Santos A, Costa L, Oliveira Santos B, Cunha J P, Papoila A L, Abegão Pinto L, Tavares Ferreira J - Lisbon 35506 14:45 Predictive biomarkers in OCT-Angiography of peripheral nonperfusion in retinal venous occlusions REIS CABRAL D, Coscas F, Glacet-Bernard A, Pereira T, Geraldes C, Papoila A, Vila Franca M, Coscas G, Souied E - Lisboa 35507 14:51 Topical Treatment for Ocular Diseases of the Posterior Segment: Non-Invasive Delivery of Large Therapeutics such as Bevacizumab and Ranibizumab DE COGAN F, Slope L, Berwick M, Peacock A, Scott R, Xu H, Chen M - Birmingham 35508 14:57 evaluation of an Artificial Inteligence clinical decision support suite for Diabetic Retinopathy and Age related macular degeneration screening TRANOS P, Karassavidou E, Tsirampidou E, Stavrakas P, Chrissafis C - Thessaloniki 35509 15:03 Development and validation of a risk-prediction nomogram for good functional response one year after treatment with anti-VEGF in naive-Diabetic macular edema GABRIELLE P H, Massin P, Arnould L, Bouche-pillon J, Maupin E, Bron A, Kodjikian L, Creuzot C - Dijon 35510 15:09 Acute endophthalmitis after intravitreal injections of corticosteroids or anti-vascular growth factor agents. A nationwide study in France from 2012 to 2015 BAUDIN F, Benzenine E, Mariet A S, Bron A, Daien V, Korobelnik J F, Quantin C, Creuzot C - Dijon 111

Saturday, October 6 - First afternoon session

14:15 - 15:30 | Gallieni 1+2 RF MBGE - Rapid Fire session

LISKOVA P , GRAW J 3561 14:15 Phenotype in homozygous and heterozygous carriers of BEST1 mutations in autosomal recessive Bestrophinopathy EL MATRI K, Falfoul Y, Habibi I, Turki A, Chebil A, Schorderet D, El Matri L - Tunis 3562 14:21 A possible novel TGFBI mutation Ser591Phe in a Finnish family with lattice corneal dystrophy JAAKKOLA A M, Järventausta P, Repo P, Kivelä T, Turunen J - Helsinki 3563 14:27 The 100,000 Genomes Project and the Western Eye Hospital Experience D'ESPOSITO F, Miodragovic S, Normando E, Bonetti P, Cordeiro M F - London 3564 14:33 Vision-Related and Health-Related Quality of Life in Patients with Giant Cell Arteritis NÍ MHÉALÓID Á, Conway R, Molloy E, Murphy C C - Dublin 3565 14:39 Clinical and Genetic Characteristics of enhanced S-cone syndrome in a Tunisian cohort: experience of the oculogenetic laboratory LR14SP01 FALFOUL Y, Turki A, Habibi I, Hassairi A, El Matri K, Chebil A, Schorderet D, El Matri L - Tunis 3566 14:45 mapping of proteomic profile and effect of the spongy layer in the human amniotic membrane NAZARI HASHEMI P, Bisson A, Chaventre F, Guillou C, Cosette P, Boyer O, Muraine M - Rouen 3567 14:51 Cornea donation for research versus for transplantation: a one year prospective study of acceptance rates in a French University Hospital GARCIN T, Pugniet J L, Peyragrosse T, Barallon M, Rogues F, Acquart S, Thuret G, Gain P - Saint Etienne 3568 14:57 Heritability of corneal curvature and Pentacam topometric indices: a population based study YEKTA A A, Hashemi H, Khabazkhoob M, Heydarian S, Ostadimoghaddam H, Derakhshan A, Heravian J, Azimi Khorasani A, Momeni-Moghaddam H, Yekta R - Mahhad 112

Saturday, October 6 - Second afternoon session

15:30 - 16:45 | Hermes RF Young investigators' award session II

FUCHSLUGER T , BARRAQUER R 3611 15:30 COS - Immunolabeling of nerves by anti-neurofilament and anti-βIII-Tubulin in the different compartments of the human ocular surface HE Z, Lambert V, Forest F, Bergandi F, Garcin T, Perrache C, Gain P, Thuret G - Saint-Etienne 3612 15:39 COS - Clinical signs in dry eye: a multicentric cross-sectional study CANTALAMESSA E, Villani E, Nucci P, Rolando M - Milan 3613 15:48 IM - Treatment of corticosteroid resistant Grave’s orbitopathy with tocilizumab GRIVET D, Perillat N, Gain P, Thuret G - Saint-Etienne 3614 15:57 LC - Prediction of postoperative spherical equivalent after cataract surgery using a machine learning approach DEBELLEMANIERE G, Dubois M, Gatinel D - Paris 3615 16:06 mBGE - Clinical and Genetic Characteristics of Leber Congenital Amaurosis in the Tunisian Population: experience of the oculogenetic laboratory LR14SP01 EL MATRI K, Falfoul Y, Habibi I, Turki A, Hassairi A, Chebil A, Schorderet D, El Matri L - Tunis 3616 16:15 PBP - Retinal ganglion cells loss and caspase 3 activation after ocular hypertension VALIENTE-SORIANO F J, Sánchez-Migallón Carreras M C, Agudo-Barriuso M, Vidal-Sanz M - Murcia 113

Saturday, October 6 - Second afternoon session

15:30 - 16:45 | Rhodes 1 RF G - Rapid Fire session

NORMANDO E , POURJAVAN S 36201 15:30 Diagnostic accuracy of a new thresholding glaucoma screening programme using temporally modulated flicker JINDAL A, Fidalgo B, Ctori I, Tyler C, Lawrenson J - London 36202 15:36 Transconjunctival bleb sutures for post-trabeculectomy hypotony RULE E, Beer F, Manns R, Ambrose I, Walker L, Lockwood A, Kirwan J - Portsmouth

36203 15:42 The Role of the αvβ3 Integrin in Lamina Cribrosa Cells and the Possible Role in Glaucoma Pathogenesis HOPKINS A, Murphy R, Irnaten M, Wallace D, Brennan D, Clarke A, O'Brien C - Dublin 36204 15:48 Intravitreal rituximab for the treatment of ocular lymphoma and glaucoma LOCKWOOD A, Farnworth D, Rainsbury P, Balendra S - Portsmouth 36205 15:54 Peripapillary microvasculature and Lamina cribrosa: is there a role in the diagnosis of primary open-angle glaucoma? RODRIGUES C, Sousa Silva R, Cabral D, Rodrigues P, Marques M, Camacho P, Valadares J, Segurado J, Fernandes J, Barrão S - Lisbon 36206 16:00 results from an international observatory survey on the management of glaucoma treatments and its impact on the ocular surface disease (OSD), an ECOS-G (European Club of Ocular Surface in Glaucoma) initiative KOLKO M, Iliev M E, Benitez Del Castillo J M, Thygesen J, Baudouin C - Glostrup 36207 16:06 Incidence and prevalence of glaucoma in native and immigrant groups living in Denmark HORWITZ A, Klemp M, Torp-Pedersen C, Kolko M - Copenhagen 36208 16:12 Comparing the mid-term efficacy and safety of the Stegmann Canal Expander Canaloplasty with the prolene suture Canaloplasty in cases of open angle glaucoma ADLJU R, Brazitikos I, Stangos A, Mameletzi A, Sunaric Mégevand G - Geneva 36209 16:18 Anatomical position of the raphe in the human retina JANSONIUS N, Schiefer U - Groningen 36210 16:24 effects of acute ocular hypertension on the adult rat retina: in vivo an ex vivo retinal analysis GALLEGO ORTEGA A, Segura-Castro P, Gómez-Serna C, De La Villa P, Di Pierdomenico J, Bernal-Garro J, Villegas-Pérez M P, Valiente-Soriano F J, Vidal-Sanz M - Murcia 36211 16:30 Potential metabolic markers in glaucoma and their regulation in response to hypoxia TIEDEMANN D, VOHRA R, Marie Dalgaard L, Vibæk Jensen J, Hildegaard Bergersen L, Vidiendal Olsen N, Hassel B, Abbas Chaudhry F, Kolko M - Copenhagen 114

Saturday, October 6 - Second afternoon session

15:30 - 16:45 | Rhodes 2 SIS PO - Genetics in uveal melanoma

Uveal melanoma is characterised by a high rate of metastases. The development of metastases is associated with a wide range of tumor characteristics, which include tumor size, chromosome changes and mutations. Mutations in a gene located on chromosome 3, BAP1, are especially associated with a high mutation rate. Prognostication may be based on any of these characteristics, and optimal determinants are being sought.

In addition to somatic mutations in the BAP1 gene, germ-line mutations have been identified. It has been known for a long time that uveal melanoma can occur in families with multiple malignancies. Studies are now ongoing to determine the role of BAP1 germ line mutations in such families. HEEGAARD S , KILIC E 3631 15:30 Occurrence of BAP1 mutations in families LUYTEN G, Chau C, Marinkovic M, Bleeker J C, Jager M J, De Klein A, Van Doorn R, Nielsen M - Leiden

3632 15:42 Analysing the function of BAP1 in uveal melanoma TURUNEN J, Kivelä T - Helsinki

3633 15:54 BAP1 in iris lesions VERDIJK R M - Rotterdam

3634 16:06 mutations as prognostic factor in uveal melanoma KILIC E - Rotterdam

3635 16:18 size and chromosomes in uveal melanoma KIILGAARD J F - Copenhagen

3636 16:30 ethical issues of prognostication in uveal melanoma VAFLARD P, Cassoux N, Mamzer-Bruneel M F, Rodrigues M - Paris

15:30 - 16:45 | Rhodes 3 RF ACB - Rapid Fire session

KAUPPINEN A , KAARNIRANTA K 36401 15:30 Improved wound resolution for Entropion Surgery using a microscope-assisted 8’0’ vicryl suture technique. BALENDRA S, Rainsbury P, Makuloluwe S, Lockwood A, Maclean H - Portsmouth 36402 15:36 effect of Pseudomonas and Acanthamoeba infection upon inflammation produced by human cornea epithelial cells BISEVAC J, Korhonen E, Noer A, Moe C. M, Kaarniranta K, Kauppinen A, Petrovski G - Oslo 36403 15:42 Cenupatide is an effective antiangiogenic in a novel mouse model of rubeosis iridis associated with neovascular glaucoma ANDRE H, Locri F, Aronsson M, Maurizio C, Dal Monte M, Bagnoli P, De Rosa M, Pavone V, Kvanta A - Stockholm 36404 15:48 rab 7 characterization and its regulatory role on autophagy in retinal pigment epithelium cells MYSORE Y, Piippo N, Hyttinen J M T, Kaarniranta K, Kauppinen A - Kuopio 36405 15:54 The role of caspase-8 in inflammasome activation in RPE cells RANTA-AHO S, Piippo N, Korhonen E, Hytti M, Kauppinen A, Kaarniranta K - Kuopio 36406 16:00 Oxidative stress and mitochondrial damage overloads mitophagy in dry age-related macular degeneration like PGC-1α/Nrf-2 knockout mice model SRIDEVI GURUBARAN R, Viiri J, Koskela A, Hyttinen J, Kauppinen A, Urtti A, Szäszujfalusi Felszeghy S, Kaarniranta K - Kuopio 115

Saturday, October 6 - Second afternoon session

15:30 - 16:45 | Rhodes 4 RF PBP - Rapid Fire session

OSBORNE N , VIDAL-SANZ M 3651 15:30 effect of flicker stimulation on retinal and optic nerve head blood flow as measured by Laser Speckle Flowgraphy SCHMIDL D, Fondi K, Bata A, Luft N, Witkowska K, Werkmeister R, Schmetterer L, Garhofer G - Vienna 3652 15:36 evaluation of sex differences in flicker light induced vasodilation and central retinal thickness in healthy young subjects SZEGEDI S, Malin A G, Witkowska K J, Fondi K, Bata A M, Schmidl D, Garhofer G, Schmetterer L - Vienna 3653 15:42 effects of focal light-emitting diode (LED)-induced phototoxicity in the albino rat retina MIRALLES DE IMPERIAL OLLERO J A, Di Phierdomenico J, Gallego-Ortega A, Villegas-Perez M P, Valiente-Soriano F J, Vidal-Sanz M - Murcia 3654 15:48 Unilateral optic nerve axotomy at different distances from the optic disk cause the same course of retinal ganglion cells death GALINDO-ROMERO C, Lucas-Ruiz F, Albadalejo-García V, Ros-Alcobas L, Vidal-Sanz M, Agudo-Barriuso M - Murcia 3655 15:54 Different aetiologies cause distinct patterns of cone degeneration GARCÍA-AYUSO D, Di Pierdomenico J, Martínez-Vacas A, Hadj-Said W, Hernandez-Muñoz D, Marie M, Agudo-Barriuso M, Vidal-Sanz M, Picaud S, Villegas-Pérez M P - Murcia 3656 16:00 microglial cell inhibition improves photorreceptor survival in two animal models of inherited retinal degeneration DI PIERDOMENICO J, García-ayuso D, Agudo-Barriuso M, Vidal-Sanz M, Villegas-Pérez M P - Murcia

15:30 - 16:45 | Gallieni 1+2 JM Update in ophthalmology

FUCHSLUGER T

3661 15:30 ACB - Autophagy hot topic in AMD pathogenesis KAARNIRANTA K - Kuopio

3662 15:40 COS - Cornea & ocular surface SZENTMARY N - Budapest

3663 15:50 G - Updates in Glaucoma LIM K. S - London

3664 16:00 mBGE - how to find out the most frequently cited article in molecular biology, genetics and epidemiology of the eye GRAW J - Neuherberg 116

Saturday, October 6 - Prize Award Ceremony & Closing Remarks

16:45 - 18:00 | Hermes Prize Award PS Prize Award Ceremony & Closing Remarks Ceremony

Agenda

Chair: Rafael Barraquer, President EVER 2019

Introduction of the Award Ceremony by Francesca M. Cordeiro, Programme Secretary

Travel awards presentation by the section chairs

Poster prize presentations by the section chairs

Presentation and report of the scientific sections meetings

Conclusion of the congress by the President 2018 Alain Bron 117 European University Professors EUPO 2018 of Ophthalmology

October 3-4 in NICE, France Retina, Intraocular Inflammation & Uveitis

Course Directors: Prof. Catherine Creuzot-Garcher, University of Dijon, France Prof. Bahram Bodaghi, University of Pierre and Marie Curie, Paris, France

The 2018 EUPO course is the first in a series redesigned to match the topics of the four viva voces that each candidate will face when they take the EBO Diploma Examination to become a FEBO. 2018: Retina, Intraocular Inflammation & Uveitis - Nice, October 3-4, 2018 with EVER 2019: Glaucoma, Cataract & Refractive Surgery - Nice, June 15-16, 2019 with SOE 2020: Refraction, Strabismus, Pediatric Ophthalmology & Neuro-ophthalmology - with EVER 2021: Cornea, External Diseases & Orbit - with SOE For those not planning to take a EBO Diploma Examination, the 2018 EUPO Course provides an update on what is new and current, and thus will help in differential diagnosis and in choosing treatment in their offices and practices.

The redesigned course has a new syllabus based not - Anatomy and imaging techniques only on short lectures, which will highlight what is - What to do when I see…? new after the previous EUPO course on the same topic, - Round table: How do you diagnose these cases? but also on round table discussions that will prepare - How does it work? participants to respond in viva voces. - Round table: How do you treat these cases? - My children cannot see because… - Surgical diseases and special cases - Round table: my job is difficult! 118 European University Professors EUPO 2018 of Ophthalmology

Wednesday, October 3 - EUPO Course

8:00 - 8:30 | Hermes Introduction of the EUPO Course

Introduction EUPO by President Tero KIVELÄ

Introduction EUPO 2018 course by Bahram BODAGHI

8:30 - 9:45 | Hermes EUPO session 1 - Anatomy and imaging techniques

DICK Andrew 8:30 Blood retinal barrier BEHAR-COHEN F - Paris 8:45 Fluorescein angiography and ICG PILOTTO E - Padova 9:00 OCT: from anatomy to imaging MIERE A - Creteil 9:15 OCT angiography STAURENGHI G - Milan 9:30 Immune tolerance and its alteration DICK A - Bristol

09:45 - 10:15 Break

10:15 - 12:00 | Hermes EUPO session 2 - What to do when I see?

KIVELÄ Tero 10:15 Serious retinal detachment MIDENA E - Padova 10:30 Atrophy of the retina CREUZOT C - Dijon 10:45 Detachment of pigment epithelium DELYFER M - Bordeaux 11:00 Black and white dots NERI P - Abu Dhabi 11:15 Vasculitis KHAIRALLAH M - Monastir 11:30 Inflammatory marcular edema JONES N P - Manchester 11:45 Pigmented tumor KIVELÄ T - Helsinki 119 European University Professors EUPO 2018 of Ophthalmology

Wednesday, October 3 - EUPO Course

12:00 - 13:15 | Hermes EUPO Round table 1 - How do you diagnose these cases

BAILLIF Stephanie , BARISANI-ASENBAUER Talin Cases of AMD, DME, DEP, dome shape, myopic choroidal nevascularisation, bruch rupture, VKH, sarcoidosis, Syphilis are discussed. Panel: Stephanie Baillif; Alexandra Miere; Piergiogio Neri; Marie-Noelle.Delyfer; Tero Kivela; Moncef Khairallah

13:15 - 14:15 | Mykonos bar Lunch bags

14:15 - 15:45 | Hermes EUPO session 3 - How does it work?

GRZYBOWSKI Andrzej 14:15 AntiVEGF GRZYBOWSKI A - Olsztyn 14:30 Steroids WILLERMAIN F - Bruxelles 14:45 Laser LARSEN L M - Glostrup 15:00 PDT PARODI Maurizio B - Trieste 15:15 Radiotherapy PARROZZANI R - Padova 15:30 IS and biologics BODAGHI B - Paris

15:45 - 17:15 | Hermes EUPO Round table 2 - How do you diagnose these cases

NERI Piergiorgio Cases : AMD 3 cases, DME 2 cases, DME + ischemic DR, ME due to VO, Ischemic vein occlusion, mac tel, Inflammatory choroidal neovascularization, Behçet’s disease, Birdshot retinochoroidopathy, Acute retinal necrosis syndrome, sympathetic ophthalmia, IRVAN syndrome are discussed. Panel : Piergiorgio Neri ; Maurizio Battaglia Parodi; Bahram Bodaghi; Nicholas Jones; François Willermain; Catherine Creuzot

17:15 - 17:45 | Hermes EUPO Best case reports 120 European University Professors EUPO 2018 of Ophthalmology

Thursday, October 03 - EUPO Course

9:15 - 10:30 | Hermes EUPO session 4 - My children cannot see

AUDO Isabelle 9:15 Inherited disease: from diagnosis to treatment AUDO I - Paris 9:30 Macular edema AUDO I - Paris 9:45 Toxoplasmosis KODJIKIAN L - Lyon 10:00 Exudative diseases DE SMET M D - Mont sur Lausanne 10:15 ROP BREMOND-GIGNAC D - Paris

10:30 - 11:00 Break

11:00 - 11:30 | Hermes EVER lectures

11:30 - 12:15 | Hermes EUPO session 5 - Surgical diseases and miscellaneous

VAN MEURS Jan C 11:30 Vitreomacular interface: new disease or new classification VAN MEURS JC - Rotterdam 11:39 Retinal detachment in myopic patients MEIER P - Leipzig 11:48 Central serous chorioretinopathy and ERD BOUSQUET E - Paris 11:57 Pars planitis MISEROCCHI E - Milano 12:06 Lymphoma TOUITOU V - Paris

12:15 - 12:45 | Hermes EUPO Round table 3 - My job is difficult!

POURNARAS Constantin metastasis, choroidal ischemia, endophthalmitis, serpiginous discussed by the panel: Leonidas Zografos, Moncef Khairallah; Alain Bron; Constantin Pournaras; Frédéric Mouriaux

12:45 - 12:50 | Hermes EUPO Closure

CREUZOT Catherine EVER f www.ever-f.eu European Association for Vision and Eye Research Foundation Ophthalmology Is Our Singular Focus

Protecting the World’s Vision

Our commitment to eye care will always endure. As a specialised ophthalmology company, we are focused on improving ocular health to enrich patients’ lives worldwide. That’s Santen’s Clear Vision for Life.

Discover more at www.santen.com SOE2019 EVER 2018 Programme advert.qxp_Layout 1 25/07/2018 15:54 Page 1

Registration and Abstract Submission Now Open!

Acta Ophthalmologica Official Journal of the Nordic and Dutch Ophthalmological Societies, The European Association for Vision and Eye Research ISI Journal Citation Reports© Ranking: 2017: 12/59 Ophthalmology

Acta Ophthalmologica (formerly Acta Ophthalmologica Scandinavica) Impact Factor: publishes clinical and experimental original articles, reviews, editorials, educational photo essays (Diagnosis and Therapy in Ophthalmology), 3.324 case reports and case series, letters to the editor and doctoral theses.

Why publish in AOS? Visit us online ● Online submission and review at ● Sign up for eTOC alerts, never miss an issue https://mc.manuscriptcentral.com/acta ● Submit an article ● 617,088 downloads in 2017 ● Read a free sample issue ● Indexed in Medline ● Look through the special issues published ● throughout the year Edited By: Option to publish Open Access ● Einar Stefánsson See the most accessed articles for the year

Members of EVER receive FREE online access to Download the app Acta Ophthalmologica as part of your membership. for your iOS device 18-454802

www.wileyonlinelibrary.com/journal/AOS 9 APRIL 28 – MAY 2 | VANCOUVER

Early Registration: Opens by 9 Vision in focus APRIL 28 – MAY 2 | VANCOUVER New Editor as from 2019 H. Scholl, Basel

Early Registration: Opens by

Journal for Translational and Clinical Research

Ophthalmic Research features original papers and reviews reporting on translational and clinical studies in the field of ophthalmology and vision research. The journal emphasizes hypothesis-based clinical and laboratory research with statistically valid results that clearly advance the fields of ophthalmic and vision research. It also aims to provide a record of international clinical research for both researchers and clinicians in ophthalmology. Finally, the transfer of information from fundamental research to clinical research and clinical practice is particularly welcome.

www.karger.com/ore KI18286 Visit therecently Wisepress published Booth and Karger browse books through 126

Presenting first authors

Four digit numbers refer to oral presentations One letter and three digit numbers refer to posters

X X X X X X X X

Day | Timeslot | Hall | Order in session Day | Order in the postersession

ADLJU R: 36208, F008 BLOOM P: 1424 AGUDO-BARRIUSO M: 1743 BODAGHI B: 2144, T069 AHMAD MOUHAMMAD Z: S046 BONET A: S101 AHMED F: 1423 BOWMAN R: 1831 ALARCON-MARTINEZ L: 2651 BOYCHUK I: F114 ALKHALDI S: F113 BREJCHOVA K: S017 ALZAMIL H: S045 BREMOND-GIGNAC D: 2961 AMADIO M: S087 BUCOLO C: S007, S033, S043 AMARIE O: 1863 BUGGAGE R: 33503, T113 AMBRESIN A: 2111 BULLI G: S097 AMBROSE I: F131 BUNOD R: F123 AMEEN S: 1822 BUSHUYEVA N: F096 ANDJELIC S: S105 CALONGE M: 1852 ANDRE H: 36403, S098 CANADAS SUAREZ P: S050, S067 APTE RS: 1611 CANTALAMESSA E: 3612, S037, S039 ARJAMAA O: 3155 CARASQUILLO K: 2952 ARNO G: 3164 CARELLI V: 2361 ARNOULD L: T024 CARRASQUILLO KG: 2754 ARPA C: F060 CASSOUX N: 2643, 2945, 3535 ARRANZ-ROMERA A: 2721 CASTELO-BRANCO M: 1235, F064 ASCASO F: 2152, 2921, S068, T048, T067 CELLINI M: 33310, F111 ASHERY-PADAN R: 2764 Cerrada-Gimenez M: T003 ATILLA H: 2963 CHAMARD C: F021 BALENDRA S: 36401, F124, S081 CHANG YS: T078 BARABINO S: 2526 CHARPENTIER S: F075 BARBONI P: 2362, 3522 CHATZIRALLI I: 3112, T047, T050, T071 BARBUR JL: 3421 CHOI CW: T061 BARNOUIN L: S005, S006 CHRISTODOULOU E: T025, T074 BARTOLOME I: F044, T019, T023 CHRYSOU A: F059 BASKARAN T: F040 CHUNG JK: F024 BAUDIN F: 35510, T065 CHUNG Y: T049 BEENAKKER J: 3442 CINELLI L: 1713 BELMONTE C: 2523 CIPRÉS ALASTUEY M: T044, T046 BEN GHEZALA I: 3516, T080 CLAEYS M: T123 BENNEDJAI A: F054 COCHENER B: 3134 BERNARDES R: 1233, T089 CORDEIRO MF: 1223, 3211, 3525, 3321 BERNER D: 2634 CORTON PEREZ M: 2663 BERNIOLLES J: T088 COSCAS F: 1812, T018 BESINIS D: 1422, 1823 COURRIER E: S042, S080 BEUERMAN R: 1451, 1853 CRAWLEY L: 1821 BHARGAVA A: 1722 CROUZET E: S063, S072, S074 BISEVAC J: 36402, S083 CUENCA N: 1441 BITTON K: S032 CUNHA J: 3523 BLANCO AR: T118 CURCIO C: 2164, 2811 BLANCO R: 1444 CVEKL A: 2761 BLASIAK J: 1252 D’AMICO RICCI G: T016 127

Presenting first authors

D’ANTIN JC: S104 GALLEGO ORTEGA A: 36210, F010 D’ESPOSITO F: 3463, 3563, F125 GARCIA-AYUSO D: 3655, T102 DAAS L: 2133, 2335, 2934 GARCIN T: 3567, F129, S002, S109 DAIEN V: 2965 GARHOFER G: 3123 DAL MONTE M: T104, T105 GARNAVOU-XIROU C: T096 DARUICH-MATET A: F063 GATZIOUFAS Z: 3132 DAVIDSON A: 3161 GAVIN SANCHO A: F066, F082 DAVIS B: 2121, 2724, F047 GEORGIADIS O: 3115 DE BAERE E: 3163 GEORGIOU M: T093 DE BOEVER P: 2125 GIL M: S003 DE COGAN F: 35507, T039 GILOYAN A: 33302, F101 DE GROEF L: 2722 GOCHO K: T094 DE HOZ R: F038 GONZALEZ C: T029, T030, T091 DE LA VILLA P: 1442 GRAJEWSKI L: T079 DE LAEY JJ: 2411 GRAW J: 3664 DEBELLEMANIERE G: 3614, S108 GRIEVE K: 2912 DEFORCE F: F023 GRIMM C: 3154 DELYFER M: 2313 GRIVET D: 3613, T112 DENIS P: F042 GRZYBOWSKI A: 2155, 2922, F115, S103 DESJARDINS L: 2644 GUAGLIANO R: F057 DI PIERDOMENICO J: 3656, T103 GUINDOLET D: S077 DI POLO A: 2322 HADJISTILIANOU T: 2941, 3147, 3148 DICK A: 1311, 2143, 2342 HAMADA S: 3131 DOBROWOLSKI D: 1734 HAMRAH P: 1434 DRAGONI F: S082 HE Z: 3611, S051, S073, S078 DUBIS A: 2914 HERBORT Jr CP: 1461 DUDAKOVA L: 1241, 33510, S114 HIJAZI B: T052 DUPAS B: 2312 HOCHHARD K: F094 ECKSTEIN A: 2743 HOHBERGER B: 2733 EL MATRI K: 3561, 3615, F118, F119, T022 HOPKINS A: 36203, F003 EL MATRI L: F120, F121, T055 HORNER F: T064 ELAHI S: 33502, T111 HORWITZ A: 36207, F007 ELBANY S: T092 HULL C: 3423 EMIN U: S058, S059 HUNTER G: F050 EPPIG T: 2134, 2933, 3542 IBANEZ J: F048 ETIENNE I: T011 IOYLEVA E: F077, F108, F109 EVANS B: 3512, F099 IRSCH K: 1231, 1232, 1234 EVANS R: F088 IVAN C: 3362 FALCIONE A: T095 JAAKKOLA AM: 3562, F122 FALFOUL Y: 34503, 3565, F116, F117, S019 JAARSMA-COES M: 3441, 3443, 3444 FALKNER-RADLER C: 1711 JAASKELAINEN N: 35501, T005 FARES-TAIE L: 2664 JAGER MJ: 3532 FENOLLAND JR: F034 JANSONIUS N: 36209, F009 FERNANDEZ-ROBREDO P: 1443 JEONG S: T063 FERRARI G: 2631, 2512 JIN SW: F027 FERRINGTON DA: 1251, 1751 JINDAL A: 36201, F001 FIGUEIREDO R: 35504, T031 JOLLY J: 2123 FLIESLER S: 2162 JONAS JB: 1741 FLOCKERZI E: 2932 JONES R: S021 FRUSCHELLI M: T059 JORGE L: F076 FUCHSLUGER T: 2633, 2731, 2514 JUENEMANN A: 2734 FUNKE S: 2325 JUNG Yh: F030 GABRIELLE P: 35509, T054 JYLHA A: 1453 GAIN P: S018, S076 KAARNIRANTA K: 1753, S100, 3661 GALINDO-ROMERO C: 2654, 3654, T101 KAJA S: F041 GALLAR J: 1431, 34508, S048, S049 KALESNYKAS G: 1854 128

Presenting first authors

KALTAKJI F: 3146 LIRAVI P: 2635 KANELLOPOULOS J: 3133 LISKOVA P: 1243, 1861, 3162 KANG J: S022 LIU S: T038 KARATSAI E: T058 LLORIA X: F085, F087 KATAYAMA Y: 2511 LOCKWOOD A: 36204, F004 KAUPPINEN A: 1254 LOISELLE A: F014 KESTELYN P: 1463, 2624 LOPEZ SANGROS I: S023, S115 KETABI SHADVAR S: 33507, S055, S106 LUPIDI M: 1814 KHAIRALLAH M: 1462, S035 LUYTEN G: 3631 KHAWAJA A: 2324 LYTVYNCHUK L: 1714 KHIKMATULLIN R: S066 LYU IJ: F055 KIILGAARD JF: 1844, 3635 MACGREGOR C: S060 KILIC E: 3634 MACHOWICZ J: T107 KIM C: T007 MADIGAN M: 3144 KIM EK: F026 MALGIN K: 33509, S112, T060, T082 KIM EW: F083 MAMMADZADA P: F126 KIM JY: T014 MANE V: 2712 KIM KT: T056 MANNS R: F046 KIM YC: T032, T075, T085 MANO S: F053 KIVELÄ T: 1843, 2742, 2946 MANTEL I: 2115 KLAVER C: 2154 MANZAR H: F043 KNOP E: 2751, 2951 MANZONI F: F060 KOH KM: S065 MARCO MONZON S: F058, F097 KOLKO M: 36206, F006 MARQUES M: 3514, F011, F098 KOLOVOS P: T008 MARTINEZ MORALES J: F049 KONTOU E: 3116 MATET A: 2646, 2947 KOSSL J: S015 MAURYA M: T002 KOVACS I: 1432 MAY SIMERA H: 3361 KOZMIK Z: 2762 MAZLIN V: 34505, 35502, S025, T013 KRASTEL H: 33301, F100 MCCARTY C: 1761 KUMAR P: 3515, T006 MCMANUS M: 1222 KUTSYR O: S093 MEIER-GIBBONS F: 3322 KWON J: T012 MEIMON S: 2314, 2915 LABBE A: 3121 MEKKI MB: 2755, 2955 LAGALI N: 1732 MERCIECA K: 1721 LAGIER J: 2744 MERINO D: 2913 LAIGINHAS R: T051 MESSMER EM: 2524 LAMBERT V: S079, S110 MICHAEL R: 2354 LANGBØL M: F036 MICHEL A: 34507, S040 LANGENBUCHER A: 2131, 3541 MIKKELSEN LH: 2647 LANGMANN T: 1744 MIRALLES DE IMPERIAL OLLERO JA: 3653, T099 LAPAJNE L: S016 MODIS L: 2331 LARREA SAMPER JG: F092, F093 MOOSAJEE M: 2916, 3464 LATTA L: 1731 MORGAN I: 2151, 2355 LAWRENSON J: 1763 MOULIN A: 2641, 3531 LAX P: T106 MOURA-COELHO N: 35505, F020, T034, T043 LAZREG S: S047 MOURIAUX F: 2741 LE A: T119 MRAZOVAC D: 33304, F103, S116 LEE G: S113 MUQIT M: 1716 LEE KS: F039 MYSORE Y: 36404, S089 LEE MY: T077 NADAL J: 3142 LEE SC: T083 NAGRA M: 3427 LENAERS G: 2363 NAGYMIHALY R: S090 LEROY B: 1244, 1864 NATTINEN J: 1454 LEVIN L: 2211, 2321 NAU A: 2753, 2954 LIM KS: 3663 NAU C: 2752, 2953 129

Presenting first authors

NAVARRO R: 2353 REZKALLAH A: F016 NAZARI HASHEMI P: 3566, F128 RIBEIRO F: 1723 NERI P: 1464, 2344, 2621 ROBERT M: 2962 NGUYEN A: F091 RODRIGO MJ: 33308, F107, T109, 2513 NI MHEALOID Á: 3564, F130 RODRIGUES C: 35503, 36205, F005, F017, T017 NICOLAISSEN BO: S084 RODRIGUEZ M: S004 NORMANDO EM: 1263, 2122, 2725 ROJAS LOZANO MP: F061, F073, F074 OH WH: F035 ROLANDO M: S031 ORDUNA HOSPITAL E: 33309, F110, T042, T045 ROMANOWSKA DIXON B: 3533 ORTIN-MARTINEZ A: 2652 ROSA A: 1833 ORTUNO-LIZARAN I: 3511, S094 ROSSI EA: 2917 OZER B: S010 ROUATBI A: S117, S118, S119 PANFILOVA A: T062 ROUSSEAU A: 1261, 33504, T114 PANFOLI I: T004 ROUX L: S012, 3364 PAPADAKIS M: 2925 ROUX M: 1862 PAPASTEFANOU V: 3111 ROZEMA J: 2352, 3425 PAPPAS G: 2615, 3313 RULE E: 36202, F002 PAPPELIS K: F018 RYOO N: T081 PAQUES M: 2311, 2911 SAGRI D: 34510, S062 PARIKAKIS E: 3311, S057, T073 SALAZAR JJ: F037 PEBAY A: 1221 SALINAS NAVARRO MA: 2653 PEET D: 3151 SALOBRAR-GARCIA E: 1742, T090 PEREZ CARRASCO MJ: T028 SANCHEZ SAEZ X: S096 PEREZ GARCIA D: F090 SANCHEZ-LOPEZ E: 2723 PERITI F: F068 SATUE M: F069, F070 PERRACHE C: S075 SAUER A: 2964 PETROU P: 3312 SAUNIER V: S071 PINNA A: T116 SCEMLA B: S034 PIPERNO-NEUMANN S: 3536 SCHALENBOURG A: 1841, 2642, 2943 PISANI F: 3153 SCHMETTERER L: 3122 PLAISANCIE J: 2662 SCHMIDL D: 3651, T097, 2112 POLAK A: 2923, F078, F079, F080 SCHRECKER J: 3544 Porteous A: 1421, 1824 SCHRODER S: 3543 POSTOLACHE L: F052 SCHWARTZ S: 1762, 2153, 2924 POURJAVAN S: 2622 SCOTT L: 33506, T117 POURNARAS C: 1811, 2715 SEITZ B: 2332, 2732, 2935 POURNARAS J: 2113, 2613, 3113, 3314 SHALOM-FEUERSTEIN R: 3363 POZO LORENZO FJ: S091 SHAMSHER E: 3513, F045 PRIOR FILIPE H: 1724, 33508, S029, S107 SHERIFF I: 3145 PUECH M: 2713 SHIN K: T040 PUELL M: 33307, 3426, F106, T033 SHORTT A: S041 PULT H: 2525 SIDNEY L: 34502, S014 PURSLOW C: 3461 SILVA M: F086 RAGAUSKAS S: T010 SINHA D: 1752 RAGGE N: 2661 SJÖSTRAND J: T087 RAHAYU S: F081, T035 SKONDRA D: T015 RAMIREZ AI: F089 SKOWRONSKA-KRAWCZYK D: 2763 RAMOS D: S102 SOUBRANE G: 1111 RANTA-AHO S: 36405, S085 SOUSA F: 3141, F065, T070 RANTALA E: 3446 SRIDEVI GURUBARAN R: 36406, S088 RATNARAJAN G: 1262 SRIKANTHA N: F022 REDMOND T: 2124 STACHON T: 2931 REIS CABRAL D: 1815, 35506, F062, T027 STAHL M: F033 REMEIJER L: 1735, 2333 STAPPLER T: 2614 RENAULT D: S069 STATHOPOULOS C: 2711, 2942 REZAEIAN M: T001 STEFANSSON E: 3152 130

Presenting first authors

STERN ME: 1851 VIEIRA M: 34509, S053, T057 STETT A: 1715, 2735 VIESTENZ A: 2611 STOCKMAN M: T122 VILADES E: F071, F072 STODTMEISTER R: F013 VILLANI E: 2521 SUBCZYNSKI W: 2163 VLAYKOVA D: F032 SUGANDA R: 33303, F102 VOHRA R: S095 SULLIVAN DA: 2522 VOLHA Y: T068, T084 SUNARIC MEGEVAND G: 3323 VOTRUBA M: 1832, 2364, 3524 SUNG MS: F067 WAIZEL M: 33306, F105 SUZUKI N: 33311, F112 WALKER L: F019 SZASZUJFALUSI FELSZEGHY S: 1253, S086 WASYLUK J: F025 SZEGEDI S: 3652, T098 WILLERMAIN F: 2142 SZENTMARY N: 2135, 2334, 3662 WILLIAMS P: 2323 TEIXEIRA F: F056 WOWRA B: 1733 TELLEFSEN S: 34506, S036 WYLEGALA A: S099 TENHUNEN A: T108 WYLEGALA E: 2132, S044 TERRENI E: S030 XIROU T: 3114, T076 THAPA R: S008 YAMAMOTO TAKIUTI JH: 33501, 33505, T110, T115 THIEME D: 2632 YANCHENKO S: S064 THIERY T: T086 YAP T: 3521 THOMPSON D: 1834 YEKTA AA: 3568, F127, S054 THURET G: S052, S070 YILDIZ E: S009 TIEDEMANN D: 36211, F012 ZHIOUA BRAHAM I: T020, T021, T026 TIGCHELAAR I: 33305, F104 ZHOU W: F095 TIMONINA A: T003 ZINIAUSKAITE A: S011 TOMKINSON C: T037 ZOGRAFOS L: 1813, 2645, 2714, 2944 TRANOS P: 2612, 35508, T053 ZSOLT NAGY Z: 1433 TRONE MC: S026, S027, S028 TSAKIRIS K: F051 TSANGARIDES S: 3462 TSOKOLAS G: F031, T036 TURUNEN J: 34504, 3632, S020 UTHEIM O: S038 UUSITALO H: 1452, 1855 UWINEZA A: 2161 VAFLARD P: 3636 VAHATUPA M: T009 VALENCA A: S092 VALIENTE-SORIANO FJ: 3616, T100 VAN BEEK J: 3445 VAN CALSTER J: 2141, 2341, 2623 VAN DEN BERG TJ: 2351, 3422 VAN GINDERDEUREN R: 2343 VAN HOEFEN WIJSARD M: 1845 VAN LINT M: F084 VAN SLYCKEN A: T121 VAN VERRE H: 3424 VANCLOOSTER A: T120 VAUDAUX J: 2114 VEGA-ESTRADA A: S024, S056, S061 VEIBY N: T041 VERA LF: F028, F029 VERDIJK RM: 3633 VERDIN H: 1242 VERRECCHIA S: S111 VICENTE A: S013 131

All authors

All authors of abstracts are listed alphabetically

One letter and three digit numbers refer to posters Four or five digit numbers refer to oral presentations The digit numbers marked in bold indicate a first author abstract

Aas Utheim Ø: 34506, S036 Anastasakis A: T096 Abbas Chaudhry F: 36211, F012 Anastasia T: F033 Abdelhak S: 34503, S019 Andjelic S: S105, S016 Abdulghafor M: F091 Andollo N: S004 Abecia E: T042 Andre H: 36403, S098, F126 Abegão Pinto L: 35504, 35505, T031, T043 Andries L: 2722 Aberdam D: S012 Andrieu S: S034 Abraham A: T069 Antosova B: 2762 Abroug N: 1462 Appeltans A: F084 Acha J: T019, T042 Aptel F: F023 Acosta MC: 1431, 34508, S048, S049 Aranda R: S050 Acquart S: 3567, F129 Arjamaa O: 3155 Adam C: F123 Arno G: 3164 Adams D: F123 Arnould L: T024, 35509, T054 Adler CH: S096 Arntz R: S031 Adlju R: 36208, F008 Aronsson M: 36403, S098 Agard E: S111, T092 Arpa C: F060, F057, F068 Agudo-Barriuso M: 1743, 2653, 2654, 3616, 3654, Arranz-Romera A: 2721 3655, 3656, T100, T101, T102, T103 Arruda H: T057 Ahmad Mouhammad Z: S046 Arslanov G: T062 Ahmed F: 1423 Ascaso Puyuelo FJ: T088 Aimadaly M: 2713 Ascaso Puyuelo J: F044, F090, T019, T023 Ainsbury E: 2161 Ascaso F: 2152, 2921, S023, S068, T048, T067 Ajeleti M: T107 Ascaso J: F048, F049, F058, F097, S115 Al Bourgol S: S070, S072, S076, S079, S080 Ashery-Padan R: 2764 Al-Kinani AA: S030 Atilla H: 2963 Al-Shymali O: S024 Aviles-Trigueros M: F037, S091 Alany RG: S030 Avolio A: T001 Alarcón-Martínez L: 2651 Ayuso C: 2663 Albadalejo-García V: 3654, T101 Azimi Khorasani A: 3568, F127 Aldana BI: S095 Badian R: S038 Ali Y: T058 Badian RA: 34506, S036 Alía-González C: T028, T033 Bae HW: F083 Alio J: S024 Bagnoli P: 3153, 36403, S098, T104 Alkhaldi S: F113 Bodaghi B: 2144 Alvarez-Lorenzo C: S029 Balendra S: 36401, F124, S081, 2724, 36204, F004, Alvarez I: 2123 F047 Alves Chaves M: F034 Balikova I: T122 Alves C: F064 Barabino S: 2526 Alves M: 35504, 35505, T031, T043 Barallon M: 3567, F129 Alves S: 3514, F011 Barben M: 3154 Alzamil H: S045 Barber AC: F088 Amadio M: S087, S082 Barboni P: 2362, 3522 Amarie O: 1863 Barbur J: 3421, 3427, 3512, F099 Amato R: T105 Barchitta M: 3147, 3148 Ambresin A: 2111 Barillà D: F057, F060, F068 Ambrose I: F131, 36202, F002, F046, F050 Barnouin L: S005, S006, 34507, S040, S076 Ambrósio AF: 1743, S093, F064 Barrantes I: 2734 Ameen S: 1822 Barrão S: 3514, 35503, 36205, F005, F011, F017, Amirkavei M: S082 T017, T018 Ammous I: T020, T021 Barraquer RI: 2354, S104 132

All authors

Barreau E: F123, S032, S034 Bleeker JC: 3631 Bartolomé I: F058, T042, T067, F044, T019, T023, Bloom P: 1424 T048, S068, S115 Bocca C: 2363 Basílio AL: F020, T034 Boccara C: 2912, 34505, 35502, S025, T013 Baskaran T: F040, F036 Bocchia M: T059 Bata A: 3651, 3652, T097, T098 Bodaghi B: T069, S032 Batista A: 34509, S053 Bográn-Rodríguez HR: S091 Batolome Sese I: T088 Bohacova P: S015 Batsos G: S057, T025, T073, T074 Boia R: 1743 Baudin F: 35510, T065 Bonet A: S101, S092, S102 Baudouin C: 36206, F006, F021 Bonetti P: 3563, F125 Bazard MC: 33504, T114 Bonnin S: 2712 Bazewicz M: T119 Bordereau S: 33504, T114 Beach TG: S096 Bordier L: F075 Beck-Popovic M: 2942 Boscia F: T016, T116 Beenakker JWB: 3441, 3442, 3443, 3444 Bouche-Pillon J: 35509, T054 Beer F: 36202, F002 Bouguila H: S117, S118, S119 Begun X: S046 Boukari M: T020, T021, T026 Bek T: F040 Bourcier T: 33504, T114 Belmonte C: 2523, S049 Bourenane H: F123 Belmonte J: S049 Bourlet T: S080 Ben Ghezala I: 3516, T080 Boutouri E: T096 Ben Selem M: S117, S118, S119 Bouyacoub Y: 34503, S019 Benitez Del Castillo JM: 36206, F006 Boychuk I: F114 Bennedjai A: F054 Boyer O: 3566, F128 Bennis Y: F054 Braz F: F062 Bentaleb Y: F021 Brazitikos I: 36208, F008 Benzenine E: 3516, 35510, T065, T080 Brejchova K: S017 Beraki K: S084 Bremond-Gignac D: 2961, 2962, F054, F063 Bergandi F: 3611, S051 Brennan D: 36203, F003 Bergersen LH: S090, S095 Bridge H: 2123 Bernal-Garro J: 36210, F010 Britchford E: 34501, S001 Bernardes R: 1233, T089, F064, F076 Bron A: 3516, 35509, 35510, T024, T054, T065, T080 Berner D: 2634 Bucolo C: S007, S033, S043 Berniolles J: T088, F044, F049, F097, S068, S115, Buggage R: 33503, T113 T023, T048, T067 Bulli G: S097 Bertone C: F057, F060, F068, T095 Bunod R: F123 Berwick M: 35507, T039 Burgalassi S: S030 Besinis D: 1422, 1823 Burrel S: 33504, T114 Best AL: S032 Bushuyeva N: F096 Beuerman R: 1451, 1853 Butlin M: T001 Bhargava A: 1722 Butskhrikidze T: 2135 Bianchi A: F068 Byström B: S013 Bianchi PE: F057, F060, F068, T095 Cabral D: 1812, 3514, 35503, 36205, F005, F011, Bikbov M: S058, S059, S066 F017, F098, T017, T018 Bikbova G: S058, S059 Cachado F: 35503, T017 Binder S: 1714 Cadena M: F074 Bischoff P: 33301, F100 Caetano VM: 33505, T115 Bisevac J: 36402, S083 Cagini C: 1814 Bisio A: T004 Calonge M: 1852 Bisson A: 3566, F128 Calvas P: 2662, 2663, 2664 Bitton K: S032 Calzia D: T004 Bitza P: T076 Calzoni P: T059 Blanco-Kelly F: 2663 Camacho P: 36205, F005, F017, F062 Blanco AR: T118, S033, S043 Cambazard F: S026 Blasiak J: 1252, S100 Camins A: 2723 133

All authors

Cammalleri M: 3153, T104, T105 Chen E: F042 Campos EC: 33310, F111 Chen M: 35507, S086, T039 Campos F: F053 Chen X: S038 Canadas Suarez P: S050, S067 Chen X: 34506, S036 Canário N: F064, F076 Cheour M: 34503, S019 Cantalamessa E: 3612, S037, S039 Chetoni P: S030 Cao D: 3144 Chhabra R: T037 Carasquillo K: 2754, 2952 Chibante-Pedro J: T051 Cardillo Piccolino F: 1814 Chin CF: F095 Carelli V: 2361 Chipala E: S030 Carretero A: S092, S101, S102 Chistyakova N: T062 Carroll J: T093 Choi CW: T061 Carss KJ: 3164 Chowdhury T: 3145 Carstens J: T079 Chrissafis C: 35508, T053 Carvalheira F: 34509, S053 Christodoulou E: T025, T074 Casini G: T105 Chrysou A: F059 Caspers L: T119 Chun L: T015 Cassiman C: F084 Chung J: T063 Casson R: 3151 Chung JK: F024, S065 Cassoux N: 3636 Chung YR: T049 Castaño Martin B: S055 Ciércoles-Rodríguez M: T028, T033 Castelo-Branco M: 1235, F064, F076, T089 Cinelli L: 1713 Castignoles F: S063, S072 Cinotti E: S026 Castillo J: F058, S115 Ciprés Alastuey M: 33309, F066, F071, F082, F110, Catanzaro M: S087 T045, T044, T046, F072, F092, F093 Catarino C: F085, F086, F087 Cipres M: F069, F070 Catita J: S092, S101, S102 Claeys M: T123 Cattaert T: F023 Clarke A: 36203, F003 Cauquil C: F123 Clarke B: T036 Causse A: F021 Cochener B: 3134, T052, T086 Cave J: F088 Colineaux H: 2662 Cellini M: 33310, F111 Comanita L: 2652 Cepla V: S011 Conceição R: F088 Cerrada-Gimenez M: 35501, T005, T003, T010, T108 Concordet JP: S012 Chae JB: T056 Contreras I: T028, T033 Chamard C: F021 Conway R: 3564, F130 Champiat S: S032 Cordeiro MF: 1223, 3525, 3321, 2121, 2723, 2724, Chan A: F095 3563, F045, F047, F125, 3513 Chang Y: T063 Corton Perez M: 2663 Chang YS: T078 Coscas F: 1812, T018, 1814, 1815, 35503, 35506, Chao De La Barca M: 2363 T017, T027 Charaoui S: S079, S080 Coscas G: 1812, 1814, 35503, 35506, T017, T018, Chargui M: 34503, S019 T027 Charif M: 2363 Cosette P: 3566, F128 Charpentier S: F075, F034 Costa L: 35505, T043 Chassaing N: 2662, 2663, 2664 Cottin Y: T024 Chatziralli I: 3112, T047, T050, T071, T076 Couceiro R: F056 Chatzirallis A: T047, T050, T071 Couret C: S032 Chau C: 3631 Courrier E: S042, S080, S069, S070, S075, S079, Chavan R: T064 S110 Chaventre F: 3566, F128 Couturier A: 2712 Chebbi A: S117, S118, S119 Creuzot-Garcher C: 3516, 35509, 35510, T024, Chebbi Z: T055 T054, T065, T080 Chebil A: 3561, 3565, 3615, F116, F117, F118, F119, Crippa S: 2664 F120, F121, T022, T055 Crisóstomo S: F020 Cheetham ME: 3164 Crouzet E: S063, S072, S074, S002, S018, S070, 134

All authors

S071, S073, S075, S076, S077, S078, S079, S080 Deyou Z: 2761 Ctori I: 36201, F001 Di Pierdomenico J: 3656, T103, 36210, 3653, 3655, Cuello JP: F074 F010, T102, T099 Cuenca N: 1441, 3511, S093, S094, S096, T042, T106 Di Polo A: 2322 Cummins I: 2161 Dias Santos A: 35505, 3523, T043 Cunha JP: 3523, 35504, 35505, T031, T043 Dick A: 33506, T117, 1311, 2143, 2342 Curcio C: 2164, 2811 Dimitriou E: T047, T050 Cvekl A: 2761 Dimov D: F032 D’Amico Ricci G: T016, T116 Dobrodjnova O: 1735 D’Angelo I: S087 Dobrovolny R: S017 D’Antin JC: S104 Dobrowolski D: 1734, 1733 D’Arrigo M: T118 Dollfus H: 2662, 2663 D’Esposito F: 3563, F125, 3463 Dolz M: F075 Da Cruz L: 3115 Dominguez A: F097, S115 Daas L: 2133, 2335, 2934, 2131, 2334, 2932 Dommanget C: S063, S072 Daien V: 3142, 35510, F021, T065, 2965 Donadu MG: T116 Dal Monte M: T104, T105, 3153, 36403, S098 Dorothy Thompson: 1834 Dal N: T062 Dot C: S111, T092 Dalgaard L: F036 Douet JY: S005 Daniszewski M: 1221 Draganova D: T119 Daphan O: S074 Drago F: S007, S033, S043 Daruich-Matet A: F063 Dragoni F: S082 Datta A: F031 Drake P: S067 David P: 2664 Drozdzik M: F032 David S: S091 Dubald M: S003 Davidson A: 3161 Dubis A: 2914, 2916 Davis B: 2121, 2724, F047, 3513, F045, 2723 Dubois M: 3614, S108 De Baere E: 1242, 3163 Dubra A: T093 De Bartolo G: T059 Duch S: F042 De Boever P: 2125 Dudakova L: 1241, 33510, S114, S017 De Cogan F: 35507, T039 Duncan C: 3145 De Groef L: 2722, 2121 Dunlop T: 35501, T005 De Hoz R: F038, 1742, F037, F061, F073, F089, T090 Dupas B: 2312, 2712 De Keizer R: F084 Dutra-Medeiros M: F020, T034 De Klein A: 3631 Dzhelebov D: F032 De Kleine E: F014 Eckstein A: 2743 De Laey JJ: 2411 Edward W: 1733 De La Villa P: 1442, 36210, F010 El Chehab H: T092 De Rosa M: 36403, S098 El Matri K: 3561, 3615, F118, F119, T022, 3565, F116, De Schryver I: T120, T121, T122, T123 F117, F120, F121, T055 De Vin T: F084 El Matri L: F120, F121, T055, 34503, 3561, 3565, 3615, De Zaeytijd J: T122, T123 F116, F117, F118, F119, S019, T022 Deback C: 33504, T114 El-Sehemy A: 2652 Debellemaniere G: 3614, S108 Elahi S: 33502, T111 Deforce F: F023 Elalfy M: 34510, S062 Defrancesco S: 3147, 3148 Elbany S: T092, S111 Degan P: T004 Emin U: S058, S059 Dehoorne J: T121 Enriquez De Salamanca A: 1852 Del Buey MA: S023, S068 Eppig T: 2134, 2933, 3542, 2131, 3541, 3543 Delyfer MN: 2313 Erb C: F042 Denis P: F042, F016 Espina M: 2723 Derakhshan A: 3568, F127 Esposito A: T004 Deshpande SS: F088 Esposti G: 3147, 3148 Desjardins L: 2644 Esser J: 2743 Deumie C: S003 Esteves Marques R: F056 Dev P: 3513, F045 Etienne I: T011 135

All authors

Ettcheto M: 2723 Gabison E: 33504, S077, T114 Etxebarria J: S004 Gabrielle PH: 35509, T054, 3516, T024, T080 Eva R: F088 Gaca-Wysocka M: F115, S103 Evans A: F124 Gaillard MC: 2711, 2942 Evans B: 3512, F099 Gailus-Durner V: 1863 Evans J: 1763 Gain P: S018, S076, 3567, 3611, 3613, F129, S002, Evans R: F088 S026, S027, S028, S042, S051, S052, S063, S069, S070, Exarhopoulos D: T025 S071, S072, S073, S074, S075, S077, S078, S079, S080, Fabius AW: 1845 S109, S110, T112 Falcão-Reis F: T051 Gajda-Derilo B: 2734 Falcão M: T051 Galindo-Romero C: 2654, 3654, T101, 1743 Falcione A: T095 Gallar J: 1431, 34508, S048, S049 Falfoul Y: 34503, 3565, F116, F117, S019, 3561, 3615, Gallego Ortega A: 36210, F010, 3653, T099 F118, F119, F120, F121, T022, T055 Garces A: F048 Falkner-Radler C: 1711, 1714 García -González M: S050, 33507, S055, S106 Fares-Taie L: 2664, 2663 García Martín E: 33309, F066, F069, F070, F071, Farnworth D: 36204, F004 F072, F082, F110, T044, T046, T109, T045, F092, F093 Fawcett J: F088 García-Ayuso D: 3655, T102, 3656, T103 Fenolland JR: F034, F075 García-Benítez N: T028, T033 Ferara N: S074 García-Domínguez JM: F074 Ferguson DR: 2917 Garcia C: F075 Fernandes J: 36205, F005, F017 Garcia ML: 2723 Fernandez-Albarral JA: F037, F038 Garcin T: 3567, F129, S002, S109, 3611, S028, S051, Fernandez-Navarro J: F089 S069, S070, S072, S073, S074, S075, S078 Fernandez-Robredo P: 1443 Garhöfer G: 3123, 3651, 3652, T097, T098, S069 Fernández-Sánchez L: S093 Garnavou-Xirou C: T096, T076 Fernandez I: 1852 Gasc A: 33502, T111 Ferrari G: 2631, 1512 Gatinel D: 3614, S108 Ferreira J: 3523 Gatzioufas Z: 3132, 34510, S062 Ferreras A: F061, F073 Gaudric A: 2712 Ferrigno O: S012 Gauthier AS: S002, S070 Ferrington DA: S086, 1251, 1751 Gavín Sancho A: F066, F082, 33309, F071, F072, Ferster A: T119 F110, T044, T045, T046, F092, F093 Feyen J: T011 Gavin A: 33308, F069, F070, F107 Fidalgo B: 36201, F001 Gedar M: S009 Fidilio A: S007, S043 Geeraerts E: 2722 Figueiredo R: 35504, T031 Gelmi MC: T059 Filip A: S100 Georges G: S003 Filippi L: T104 Georgevsky D: T001 Fink M: 2912, 34505, 35502, S025, T013 Georgiadis O: 3115 Fliesler S: 2162 Georgiou M: T093 Flockerzi E: 2932, 2133, 2335 Georgiou T: T008 Flores R: T034 Geraldes C: 1815, 35503, 35506, T017, T018, T027 Fondi K: 3651, 3652, T097, T098 Gerber S: 2664 Fonseca A: F053 Ghosh A: F041, S008 Forest F: 3611, S051, S052, S063, S072, S073, S074, Giancipoli E: T016 S076, S078 Gil H: S029 Fraile JM: T109 Gil M: S003 Francannet C: 2662, 2663 Gil P: T090 Fries F: 1731, 1732 Gillmann K: 33502, T111 Frigeri A: 3153 Giloyan A: 33302, F101 Fruschelli M: T059, 3147 Giraud JM: F034, F075 Fuchs H: 1863 Gkizis I: T076, T096 Fuchsluger T: 2633, 2731, 2632, 2514 Glacet-Bernard A: 35506, T027 Fujimura N: 2762 Gocho K: T094 Füllen G: 2734 Gofas E: 2915 136

All authors

Goffin L: T119 Hashemi H: 3568, F127, S054 Gojic D: S105 Hassairi A: 3565, 3615, F116, F117, F119, F121, T022, T055 Goldblum D: 34510, S062 Hassan MK: 3442, 3443 Goldenberg A: 2663 Hassel B: 36211, F012 Golzan M: T001 Hawlina M: S016, S105 Gomes T: F020 Haydinger C: 3151 Gómez-Palacios V: T028, T033 He Z: 3611, S051, S073, S078, S002, S052, S070, S075, Gómez-Serna C: 36210, F010 S076, S077, S079, S080 Goncalves Ferreira TA: 3444 Heegaard S: 2647, S046 Gonzalez-Garcia MJ: 1852 Herault Y: 1862 Gonzalez C: T029, T030, T091 Heravian J: 3568, F127, S054 Gosak M: S105 Herbepin P: S002, S070, S071, S075, S079, S080 Goussia A: T074 Herbort Jr CP: 33502, T111, 1461 Govoni S: S087 Hermankova B: S015 Gozzetti A: T059 Hernandez-Muñoz D: 3655, T102 Graham S: T001 Hernberg M: 3446 Grajewski L: T079 Hewitt A: 1221 Graw J: 1863, 3664 Heydarian S: 3568, F127 Gray L: F113 Hijazi B: T052 Greenwood J: 2914 Hildegaard Bergersen L: 36211, F012 Grgic L: 3513, F045 Hipólito Fernandes D: 35504, F020, T031, T034 Grieve K: 2912, 2917, 34505, 35502, S025, T013 Hirata CE: 33501, 33505, T110, T115 Grimm C: 3154 Hirji N: T093 Grivet D: 3613, T112, S026, S109 Ho Wang Yin G: S003 Grolik M: 1734 Hochhard K: F094 Gros-Otero J: 33507, S055, S106 Hoffart L: S003 Grzybowski A: 2155, 2922, F115, S103, F079, F080 Hohberger B: 2733 Guagliano R: F057, F060, F068, T095 Holan V: S015 Gudmundsson J: F126 Honzik T: 1861, 33510, S114 Guenancia C: T024 Hopkins A: 36203, F003 Guerin C: S003 Hopkinson A: 34501, 34502, S001, S014 Guerre A: T086 Horner F: T064 Gueudry J: 33504, T114 Horwitz A: 36207, F007 Guillou C: 3566, F128 Houston S: 2914 Guimarães M: T051 Hrab_ De Angelis M: 1863 Guimond A: 1862 Hull C: 3423 Guindolet D: S077, S075 Hunter G: F050, F046, F131, S060 Guo L: 2121, 2723, 2724, 3513, F045, F047 Hurtado-Ceña FJ: T028, T033 Gupta B: T036 Hussam EC: S111 Gurdita A: 2652 Hwang DJ: T083 Ha KH: T049 Hwang KY: S065 Haapaniemi AM: 35501, T005 Hytti M: 36405, S085 Habibi I: 3561, 3565, 3615, F116, F117, F118, F119, Hyttinen J: 36404, 36406, S088, S089 F120, F121 Ibañez Alperte J: F090 Hadj-Said W: 3655, T102 Ibañez J: F048, F049, F044 Hadjistilianou T: 3147, 3148, T059 Idoate A: F044, T019, T023 Hager T: 2135 Idoipe Corta M: T042 Hakkarainen JJ: 1854, S008, S011, T009 Idoipe M: T109 Hamada S: 3131, 34510, S062 Iliev ME: 36206, F006 Hamed M: 2734 Imshenetskaya T: T068, T084 Hammond C: F043 Ioyleva E: F077, F108, F109 Hamze H: F047 Ip B: 2123 Handayani R: F081 Irnaten M: 36203, F003 Hansen A: 2647 Irsch K: 1231, 1232, 1234 Hardarson S: 3152 Isabel B: F049 Harutyunyan T: 33302, F101 Isabel L: F097 137

All authors

Ivan C: 3362 Kang KT: T032, T075 Iwan S: T035 Kankkunen A: T108 Jaakkola AM: 3562, F122 Kaouel H: T020, T021 Jaarsma-Coes M: 3441, 3443, 3444 Kaplan J: 2662, 2663, 2664 Jääskeläinen N: 35501, T005, T108 Karaa EK: 3145 Jabari M: 2763 Karagiannis D: S057, T073 Jacques Lagier: 2744 Karassavidou E: 35508, T053 Jager MJ: 3532, 3631 Karatsai E: T058 Jandrokovic S: 33304, F103 Kardon R: F091 Jansonius N: 36209, F009, F014, F018, F059 Karlsruher G: F044, F058, F097, S023, S068, S115, Jäntti J: 34504, S020 T023, T048, T067 Jarrin M: 2161 Kartika A: F081 Järventausta P: 3562, F122 Käsmann-Kellner B: 1731, 1732 Järvinen RS: 1843, 34504, S020 KATAYAMA Y: 2511 Järvinen TA: T009 Katsanos A: S055 Javorkova E: S015 Kauppinen A: 1254, 36402, 36404, 36405, 36406, Jayaswal R: S060 S083, S085, S086, S087, S088, S089 Jeannin B: 33502, T111 Kawasaki A: F091 Jensen PK: F040 Kearns V: T038 Jensen PS: F040 Kestelyn P: 1463, 2624 Jeong S: T040, T078, T063 Ketabi Shadvar S: 33507, S055, S106 Jin SW: F027 Khabazkhoob M: 3568, F127, S054 Jindal A: 36201, F001 Khairallah M: 1462, S035 Joana V: F017 Khalimov A: S058, S059 Johanna V: S086 Khatib W: S018 Jolly J: 2123 Khawaja A: 2324 Jonas JB: 1741, 33301, F100 Khikmatullin R: S066 Jones R: S021 Khochtali S: 1462 Jorge A: S056, S061 Khudainazarova V: T062 Jorge L: F076, F064 Kiilgaard JF: 1844, 3635 Judice Relvas L: T119 Kiliç E: 3634, 3445 Juenemann A: 2734 Kim BG: F035 Jun IH: S113 Kim C: T007 Jung YH: F030 Kim CY: F083 Juri Mandic J: S116 Kim DJ: T049 Justice A: S031 Kim DY: T056 Jylhä A: 1453 Kim EK: F026 Kaarniranta K: 1753, S100, 36402, 36404, 36405, Kim EW: F083 36406, S082, S083, S085, S086, S087, S088, S089, 3661 Kim JS: F035 Kabanarou S: T047, T071, T076, T096 Kim JY: T014 Kabanova E: F077, F108 Kim KT: T056 Kadlub N: F054 Kim SA: F083 Kaja S: 35501, T005, F041, 1854, S008, T003, T009, T010 Kim SY: T081 Kalesnykas G: 35501, T005, 1854, S008, S011, T003, Kim TI: S113 T009, T010, F041 Kim Y: F039 Kalitzeos A: T093 Kim YC: T085, T032, T075 Kalligeraki A: 2161 Kirchhübel R: 33301, F100 Kalogerou M: T008 Kirwan J: 36202, F002, F022 Kaltakji First Author F: 3146 Kittipassorn T: 3151 Kamangar F: S103 Kivelä T: 1843, 2742, 2946, 3446, 34504, 3562, 3632, Kameya S: T094 F122, S020 Kanclerz P: 2922 Klaver C: 2154 Kane T: T093 Klemp M: 36207, F007 Kanellopoulos J: 3133 Klopstock T: F085, F086, F087 Kanenobu C: 33501, T110 Klyve P: F042 Kang J: S022 Knop E: 2751, 2951 138

All authors

Kocot E: T107 Lara F: T067 Kodjikian L: 35509, F016, T054, T092 Larrea Samper JG: F092, F093, 33309, F066, F071, Koh KM: S065, S113 F072, F082, F110, T044, T045, T046 Kolarova H: 1861 Larrea G: F069, F070 Kolb F: F054 Larry D: 2761 Kolko M: 36206, F006, 36207, 36211, F007, F012, Latta L: 1731, 1732, 2931 F036, F040, S046, S095, S097 Laucirika G: S067 Kolovos P: T008 Laura Crawley: 1821 Kong M: T083 Laurik-Feuerstein KL: 2334 Kontadakis G: S057 Lavezzo MM: 33501, 33505, T110, T115 Kontomihos L: S057, T073 Lawrenson J: 1763, 36201, F001 Kontou E: 3116, T076 Lax P: T106, S093 Koolstra K: 3441 Lazaro AI: T023 Korhonen E: 36402, 36405, S083, S085 Lazreg S: S047, S042 Korobelnik JF: 35510, T065 Lazzara F: S007, S043 Kort F: T022 Le A: T119 Koskela A: 36406, S086, S088 Leal I: T070 Kossl J: S015 Lee G: S113 Kostic C: 2664 Lee GY: S065 Kouassi Nzoughet J: 2363 Lee K: T049 Kousal B: 1861 Lee KH: F083 Koutropoulou N: T076 Lee KS: F039 Kovacs I: 1432 Lee MY: T077 Kozmik Z: 2762 Lee S: T007, T007 Krajewska M: F025 Lee SC: T083 Kramer WG: S031 Lee SJ: S022 Krasavina M: T062 Lee SK: F055 Krastel H: 33301, F100, 3146 Lee SU: S022 Krause L: T079 Lee SY: F083 Kretschmer V: 3361 Lefebvre P: T119 Krivosheeva M: F108 Lefevere E: 2722 Ksiaa I: 1462 Legout P: S071 Ktena E: S057, T073 Lehalle D: 2662 Kubota D: T094 Lehesjoki AE: 1843, 34504, S020 Kumar P: 3515, T006, T002 Leinonen M: 33305, F104 Kumaran N: T093 Lenaers G: 2363 Kurzawski M: F032 Leroy BP: 1244, 1864, T120, T121, T122, T123 Kutsyr O: S093, T106 Levin L: 2211, 2321 Kvanta A: 36403, F126, S098 Lewin-Kowalik J: T107 Kwon J: T012 Lim DH: F055 Kyriacou K: T008 Lim KS: 3663 Labalette P: 33504, T114 Liravi P: 2635 Labbe A: 3121 Liskova P: 1243, 1861, 3162, 33510, S017, S114 Labetoulle M: 33504, F123, S032, S034, T114 Littink K: 1735 Lagali N: 1732 Litts KM: T093 Laiginhas R: T051 Liu S: T038 Lamard M: T052, T086 Lloria X: F085, F087, F086 Lambert V: S079, S110, 3611, S042, S051, S052, Lob F: F085, F087 S069, S070, S080 Lockwood A: 36204, F004, 36202, 36401, F002, F019, Lambotin C: S034 F022, F046, F050, F131, S060, S081 Langbøl M: F036, F040 Locri F: 3153, 36403, S098 Langenbucher A: 2732, 2131, 3541, 2133, 2134, Loiselle A: F014 2135, 2334, 2335, 2931, 2933, 2934, 3542, 3543 Lomukhina E: T082 Langmann T: 1744 Lopes P: F065 Lanni C: S087 Lopez Galvez MI: T019, T042 Lapajne L: S016 López Sangrós I: F044, T023, S023, S115 139

All authors

Lopez-Cuenca I: T090 Marie Dalgaard L: 36211, F012 Lopez-Miguel A: 1852 Marie M: 3655, T102 Lopez A: T109 Mariet AS: 3516, 35510, T065, T080 López I: F049, F058, T048, T067, S068 Marinkovic M: 3443, 3444, 3631 Lorenz B: 1714 Marino A: T118 Lorenzo Y: S084 Markevich V: T084 Lucas-Ruiz F: 2654, 3654, T101 Marques M: 3514, F011, F098, 36205, F005, F017 Luccarelli SV: S039 Marques R: F053, F065, T070 Lucentini S: S039 Marsh-Armstrong N: 2654 Luft N: 3651, T097 Marsit N: 34502, S014 Luís ME: 35504, T031 Marta CB: S115 Lulli M: T105 Martin K: F088 Lupidi M: 1814 Martinez Ginés M: F074 Luyten G: 3442, 3443, 3444, 3631 Martinez Morales J: F049, F044, F048, F090 Lytvynchuk L: 1711, 1714, S090 Martínez-Vacas A: 3655, T102 Lyu IJ: F055 Martinez T: T109 M Francesca Cordeiro: 3211 Martins A: 1833 Maalej R: T022 Marzano J: T016 Maamouri R: T022 Massin P: 35509, T054 Macgregor C: S060, F022, F050 Mastey R: T093 Machowicz J: T107 Mateo J: T048 Mackiewitcz J: S100 Matet A: 2646, 2947 Maclaren R: 2123 Mateus C: S032 Maclean H: 36401, S081 Mathis T: F016 Madden L: S045 Mattheis S: 2743 Madigan MC: 3144 Maupin E: 35509, T054 Maelle R: T092 Maurin C: S070, S079, S080 Maffia A: F057 Maurizio C: 36403, S098 Magner M: 33510, S114 Maurya M: T002 Mahmood S: T037 May Simera H: 3361 Majander A: 34504, S020 Maycock N: S060 Makhoul D: T119 Mayoral JA: T109 Makuloluwe S: 36401, S081 Mazlin V: 34505, 35502, S025, T013, 2912 Malaguarnera G: 2724, F047 Mazur V: F114 Malek Y: S110 Mccarty C: 1761 Malgin K: 33509, S112, T060, T082 Mcdonald T: T038 Malin AG: 3652, T098 Mcgreal R: 2761 Mameletzi A: 36208, F008 Mcintosh O: 34501, 34502, S001, S014 Mammadzada P: F126 Mcmanus M: 1222 Mammone T: 3151 Meier-Gibbons F: 3322 Mamzer-Bruneel MF: 3636 Meimon S: 2314, 2915 Manchart T: F034, F075 Mekki MB: 2755, 2955 Mane V: 2712 Mendes-Jorge L: S092, S101, S102 Maneu V: S093, T106 Menicacci C: 3148 Manns R: F046, 36202, F002, F050, F131 Mercieca K: 1721 Mano S: F053, 3141, F056, T070 Mering S: 1854, T108 Mantel I: 2115 Merino D: 2913 Mäntysalo T: 33305, F104 Merino ML: S049 Manzar H: F043 Messmer EM: 2524 MANZONI F: F060 Michael R: 2354, S104 Marabelle A: S032 Michaelides M: 3164, T093 Marchiori BM: 33505, T115 Michel A: 34507, S040, S005, S006 Marco Monzon S: F058, F097, T088 Michot JM: S032 Marco S: F044, F049, S023, S068, S115, T023, T048, Mikkelsen LH: 2647 T067 Milano G: F060 Marcovich A: S074 Mili Boussen I: T021 140

All authors

Milla S: 1442 Nau C: 2752, 2953 Minguez E: T067 Naus N: 3445 Miodragovic S: 3563, F125 Navarro M: S092, S101, S102 Miralles De Imperial Ollero JA: 3653, T099 Navarro R: 2353 Missaka RF: 33505, T115 Nazari Hashemi P: 3566, F128 Missel P: F029 Nedelec B: 2664 Mitropoulos P: T071 Neokleous A: T008 Módis L: 2331 Neri P: 1464, 2344, 2621 Moe MC: S083, S084, S090, 36402 Neu F: T123 Mola MG: 3153 Nevalainen T: T108 Moll AC: 1845 Neves A: 34509, S053 Möller S: 2734 Nguyen Huu VA: 2763 Mollerup S: 2647 Nguyen A: F091 Mollica A: S009 Nguyen G: S084 Molloy E: 3564, F130 Ní Mhéalóid Á: 3564, F130 Momeni-Moghaddam H: 3568, F127, S054 Niblock M: 3164 Montés P: F044, F058, F097, S115, T019, T023, T048, Nicchia GP: 3153 T067, T088, S023, S068 Nickerson PE: 2652 Monteserín-Rodríguez M: 34508, S048 Nicolaissen B: S084 Monti D: S030 Nicolaissen BO: S084 Moon BG: T083 Nielsen M: 3631 Moons L: 2722 Noailles A: T106 Moore AT: 3164 Noer A: 36402, S083 Moosajee M: 2916, 3464 Noor A: 2724, F047 Morales-Villellas M: 34508, S048 Nora M: T051 Morgan I: 2151, 2355 Nordström K: 1731 Morin G: 2662 Normando E: 3563, F125 Morita C: 33501, T110 Normando EM: 1263, 2122, 2725, 3563, F125 Mörtenhumer S: 34504, S020 Nostro A: T118 Moulin A: 2641, 3531 Nubourgh I: T119 Moura-Coelho N: 35505, F020, T034, T043 Nucci P: 3612, S037, S039 Mouriaux F: 2741, 33504, T114 Nunes A: T089 Moutinho G: S029 Nunez Do Rio J: 2914 Movahedi K: 2722 O’Brart D: 3423 Mrazovac D: 33304, F103, S116 O’Brien C: 36203, F003 Munier F: 2711, 2942 O’Connor P: S031 Munier FL: 34503, S019 Oh WH: F035 Muñoz Blanco JL: F061, F073 Olafsdottir O: 3152 Muqit M: 1716 Oliveira Rodrigues C: F062 Muraine M: 3566, F128 Oliveira Santos B: 35505, T043 Murphy CC: 3564, F130 Oliveira M: 1833 Murphy R: 36203, F003 Olsen NV: F040 Mysore Y: 36404, S089 Onishchenko E: T062 Nacher V: S092, S101, S102 Orduña Hospital E: 33309, F110, T042, T045, F066, Nadal Nicolas FM: 1743, 2654, 2653 F071, F072, F092, F093, F082, T019, T044, T046 Nadal J: 3142 Orduna E: 33308, F069, F070, F107 Nag TC: 3515, T002, T006 Orozco Morales ML: 34502, S014 Nagra M: 3427 Ortín-Martínez A: 2652 Nagy Z: 1432 Ortuño-Lizarán I: 3511, S094, 1441, S096 Nagymihály R: S090, S046 Oseka M: F025 Nam K: T007, S022 Ostadimoghaddam H: 3568, F127, S054 Narotamo H: 1815, T018 Oudjani N: S110 Naso S: F091 Ouederni M: 34503, S019 Nathalie Cassoux: 2643, 2945, 3535 Oyamada MK: 33501, 33505, T110, T115 Nättinen J: 1454 Özer B: S010, S009 Nau A: 2753, 2954 Paaske Utheim T: 34506, S036 141

All authors

Pahlitzsch M: 2724, F047 Phil W: 2761 Pal B: F033 Philippaki E: 3423 Palomo-Álvarez C: 33307, 3426, F106 Piazza C: S033 Panfilova A: T062 Picard A: F054 Panfoli I: T004 Picaud S: 3655, T102 Papadakis M: 2925 Pierscionek BK: F115, S103 Papastefanou V: 3111 Pietrucha-Dutczak M: T107 Papoila A: 1815, 35503, 35504, 35505, 35506, T017, Piippo N: 36404, 36405, S085, S089 T018, T027, T031, T043 Pillunat LE: F013 Pappas G: 2615, 3313 Pinilla Lozano I: T019, T023, T042, 1441 Pappelis K: F018 Pinna A: T116, T016 Paques M: 2311, 2911, 2912, 2917 Pinto-Fraga FJ: 1852 Pareja Aricó LA: 2354 Pinto F: 3141, F053, F056, F065 Paridaens D: 3445 Piperno-Neumann S: 3536 Parikakis E: 3311, S057, T073, T025, T071, T074 Pisani F: 3153 Park CK: F026, F083 Plaisancié J: 2662, 2663 Park HYL: F026 Plaitano C: F057, F060, F068 Park KH: T081 Platania CBM: S007, S043 Parsa C: F052 Plevova P: 33510, S114 Partanen P: T108 Polak A: 2923, F078, F079, F080 Pasechnikova N: F096 Polling JR: 2154 Passet B: 2664 Polo V: T109 Pastor-Zaplana JÁ: 34508, S048 Popovic Z: T087 Patel M: 3427 Popper A: 1433 Patnaik S: 3361 Porcu T: T016 Pavesio C: T069 Porteous A: 1421, 1824 Pavone V: 36403, S098 Postelmans L: T119 Peacock A: 35507, T039 Postolache L: F052 Pearce EI: S045 Potamiti L: T008 Pearson C: F088 Pourjavan S: 2622 Pebay A: 1221 Pournaras C: 1811, 2715 Pedram Hamrah: 1434 Pournaras JA: 2113, 2613, 3113, 3314 Pedrelli F: T004 Pozo Lorenzo FJ: S091 Pedrosa Domellöf F: F094, S013 Prates-Canelas J: T070 Peet D: 3151 Preto J: T051 Pelen F: F021 Prieto E: T109 Peponis V: S057, T073 Prior Filipe H: 1724, 33508, S029, S107 Perdices Royo L: T019, T042 Prokopiou E: T008 Pereira J: T057 Prost M: F025 Pereira T: 1815, 35503, 35506, F062, T017, T018, T027 Puccetti L: T059 Perez Garcia D: F090, F044, F048, F049 Puech M: 2713 Pérez-Carrasco M: 33307, 3426, F106, T028, T033 Puell M: 33307, 3426, F106, T028, T033 Perez D: F097 Pugniet JL: 3567, F129 Perillat N: 3613, S027, T112 Pult H: 2525 Periti F: F068, F057, F060 Purslow C: 3461 Perrache C: S075, 3611, S002, S051, S063, S070, Puska P: F042 S072, S073, S074, S076, S077, S078, S079, S080 Quantin C: 3516, 35510, T065, T080 Perrot JL: S026 Quellec G: T052, T086 Peterson DA: 3511, S094 Quental H: F064, F076 Petra H: 1861 Quinlan R: 2161 Petricek I: 33304, F103 Quinn AG: F051 Petros Petrou: 3312 Raeder S: 34506, S036, S038 Petrosyan V: 33302, F101 Ragauskas S: 35501, T005, T010, S008, T003 Petrovski G: 36402, S046, S083, S084, S090 Ragge N: 2661, 2662 Peyragrosse T: 3567, F129 Ragkousis A: T096 Pförtner R: 2743 Rahayu S: F081, T035 142

All authors

Rainsbury P: 36204, 36401, F004, S081 Rojas B: F037, F038, F089 Rajendra S Apte: 1611 Rolando M: S031, 3612, S037, S039 Ramírez AI: F089, 1742, F037, F038, F073, T090, F061 Roman Blanco: 1444 Ramirez JM: 1742, F037, F038, F061, F073, F089, Romano-Ruiz P: S004 T090 Romanowska Dixon B: 3533 Ramiro Millan P: T088 Ros-Alcobas L: 3654, T101 Ramiro P: F058, F097 Rosa A: 1833 Ramos D: S102, S092, S101 Rosas J: S049 Ramos P: 2663 Rosini M: S087 Ranta-Aho S: 36405, S085 Rossi EA: 2917 Rantala E: 3446 Rossino MG: T105 Rao V: F041 Rouatbi A: S117, S118, S119 Räsänen H: 35501, T005 Rousseau A: 1261, 33504, T114, F123, S032, S034 Ratnarajan G: 1262 Rousseau B: S034 Ravindran N: 2121, 2723, 2724, F047 Roux L: S012, 3364 Raymond FL: 3164 Roux M: 1862 Rebika H: S069 Rozema J: 2352, 3425 Reddy MA: 3145 Rozet JM: 2663, 2664 Redmond T: 2124 Ruberte J: S092, S101, S102 Regnier A: S005 Ruberto G: T095 Reis Cabral D: 1815, 35506, F062, T027 Rudolph G: F085, F087 Reis A: F064 Rule E: 36202, F002, F019, F046, F131 Rejdak R: 2923 Ryoo NK: T081 Remeijer L: 1735, 2333 Sá Cardoso M: F020 Rémond AL: S032 Sagoo MS: 3145 Renard JP: F034, F075 Sagri D: 34510, S062 Renata Musa I: 33303, F102 Sahel JA: 2912, 2917, 34505, 35502, S025, T013 Renault D: S069, F023, S042, S047, S110 Sahin A: S009, S010 Repo P: 1843, 34504, 3562, F122, S020 Saitakis G: T050 Reynier P: 2363 Sakata VM: 33501, T110 Rezaeian M: T001 Salazar JJ: F037, 1742, F038, F061, F073, F089, T090 Rezkallah A: F016 Salinas-Navarro M: 2653, 2722 Riadh M: S035 Salobrar-García E: 1742, T090, F037, F038, F061, Ribeiro Koch C: S104 F073 Ribeiro F: 1723 Salomone S: S033 Richard Bowman: 1831 Samardzija M: 3154 Riikonen A: 34504, S020 Sanchez Cano A: T042 Rizzo S: 1713 Sanchez Marin JI: F044, T023 Robert M: 2962 Sánchez Sáez X: S096 Robin MC: S005 Sanchez-Cano AI: T019 Rocha L: 2763 Sánchez-López E: 2723 Rodero A: S050 Sánchez-Migallón Carreras MC: 3616, T100 Rodrigo Rey S: S055 Santana I: F064 Rodrigo Sanjuan MJ: 33309, F066, F071, F072, Santiago AR: 1743 F082, F092, F093, F110, T045, T046 Santiago B: F064 Rodrigo MJ: 33308, F107, T109, F069, F070, 2513 Santos-Sousa H: T051 Rodrigues C: 35503, 36205, F005, F017, T017, T018 Santos C: F098 Rodrigues M: 3636 Santos M: 34509, S053, T057 Rodrigues P: 3514, 36205, F005, F011, F017, F062, Saramago B: 33508, S029, S107 F098 Sarangapani R: F028, F029 Rodriguez-Carmona M: 3512, F099 Satué M: 33309, F066, F069, F070, F071, F082, F092, Rodriguez M: S004 F093, F110, T044, T045, F072, T046 Rodrio Sanjuan MJ: T044 Sauer A: 2964 Roels D: 1735 Saunier V: S071, S070 Rogues F: 3567, F129 Sayeb M: 34503, S019 Rojas Lozano MP: F061, F073, F074 Scemla B: S034 143

All authors

Schachar IH: F115, S103 Silva D: S029 Schachar RA: F115, S103 Silva M: F086, F085, F087 Schalenbourg A: 1841, 2642, 2943 Simcoe M: F043 Scheimberg I: 3145 Singh N: T093 Schiefer U: 36209, F009 Sinha D: 1752 Schito A: T004 Siozade Lamoine L: S003 Schlichtenbrede F: 3146 Sisa C: 2724, F047 Schmetterer L: 3122, 3651, 3652, T097, T098 Sjöstrand J: T087 Schmidl D: 3651, T097, 3652, T098, 2112 Skalicka P: 33510, S017, S114 Schneider S: 3361 Skondra D: T015 Scholl H: 34510, S062 Skov J: F042 Scholler J: 2912, 35502, T013 Skowronska-Krawczyk D: 2763 Schollmayer P: S016 Skytt DM: S095, S097 Schorderet D: 3561, 3565, 3615, F116, F117, F118, Slope L: 35507, T039 F119, F120, F121 Smaoui S: T026 Schori C: 3154 Smedowski A: T107 Schrecker J: 3541, 3542, 3543, 3544 Sobol M: F025 Schröder S: 3543, 3541, 3542 Sohn JH: T083 Schubert DW: 2632 Sokratous K: T008 Schuurmans MS: 3443 Somavarapu S: 2724, 3513, F045, F047 Schwartz S: 1762, 2153, 2924 Song SH: T078 Schweitzer C: 33504, T114 Sornsute A: 2724, F047 Scott L: 33506, T117 Soubrane S: 1111 Scott R: 35507, T039 Souied E: 1812, 35503, 35506, T017, T018, T027 Sebastian Funke: 2325 Sousa Silva R: 36205, F005, F017 Segura-Castro P: 36210, F010 Sousa F: 3141, F065, T070, F053 Segurado J: 36205, F005, F017 Sousa H: S029 Seidel D: F113 Sousa J: 34509, S053, T057 Seitz B: 2332, 2732, 2935, 1731, 1732, 2133, 2134, Souto EB: 2723 2135, 2334, 2335, 2931, 2932, 2933, 2934 Souto FM: 33505, T115 Seldon R: F062, F098 Spira-Eppig C: 2134, 2933 Sellam A: 35503, T017 Spoerl E: F013 Sendon D: F034, F075 Sridevi Gurubaran R: 36406, S088 Seo KY: S065 Srikantha N: F022, F124 Serge D: S035 Stachon T: 2931, 1731 Serrano GE: S096 Stachs O: 2734 Serro AP: 33508, S029, S107 Stahl M: F033 Setioadji B: F081 Stahnke T: 2734 Shah P: 2724, F047 Stangos A: 36208, F008 Shahzad R: 3442 Stanojcic N: 3423 Shakir D: F096 Stappler T: 2614 Shalom-Feuerstein R: 3363 Stathopoulos C: 2711, 2942 Shamonin DP: 3442 Stavrakas P: 35508, T053 Shamsher E: 3513, F045, F047 Stefaniotou M: T025, T074 Sheck L: F033 Stefansson E: 3152 Sheldon A: 2123 Stern ME: 1851 Sheriff I: 3145 Stett A: 1715, 2735 Shevchuk N: S059 Stockman M: T122 Shi L: 2334 Stodtmeister R: F013 Shin JA: F030 Stoel BC: 3442 Shin KH: T040 Stojanovic A: 34506, S036 Shortt A: S041 Stroehla H: F013 Sidney L: 34502, S014 Strømgaard K: S097 Sierra Garcia ME: T088 Struckmann S: 2734 Signorini S: T095 Stubbs E: F041 Silva AM: 2723 Subczynski W: 2163 144

All authors

Subias M: T109 Tinelli C: F057, F060, F068 Suganda R: 33303, F102 Titah O: 2955 Sullivan DA: 2522 Todorova MG: 33306, F105 Sunaric Mégevand G: 3323, 36208, F008 Toft-Kehler AK: F036 Sung MS: F067 Toma C: F068 Suzuki N: 33311, F112 Tomkinson C: T037 Svelto M: 3153 Ton HTT: 3144 Sys C: T120, T122, T123 Topete A: 33508, S107 Szäszujfalusi Felszeghy S: 1253, S086, 36406, Torp-Pedersen C: 36207, F007 S088 Tóth G: 2135 Szegedi S: 3652, T098 Touboul D: S071 Szentmáry N: 2135, 2334, 1731, 2131, 2133, 2134, Toy TS: 3515, T006 2335, 2931, 2933, 3662 Tranos P: 2612, 35508, T053 Tacheva T: F032 Traverso CE: T004 Tachibana N: 2652 Traz F: F098 Tack M: T120 Tresserra F: S104 Tadayoni R: 2712 Triviño A: F037, F038, F089 Taibi A: 2955 Trone MC: S026, S027, S028, S042, S052, S063, S072, Takahashi H: T094 S073, S074 Takiuti JT: 33505, T115 Tsai ELS: 2652 Tampucci S: S030 Tsakiris K: F051 Tan E: 2154 Tsamis D: T096 Tarilonte M: 2663 Tsangarides S-A: 3462 Tashbayev B: 34506, S036, S038 Tsilioni A: S057 Taul Brændstrup C: S046 Tsirampidou E: 35508, T053 Tavares Ferreira J: 35504, 35505, F020, T031, T043 Tsokolas G: F031, T036 Taylor S: T058 Turki A: 3561, 3565, 3615, F116, F117, F118, F119, Teixeira F: F056, 3141 F120, F121 Tellefsen S: 34506, S036 Türksever C: 33306, F105 Tenhunen A: 35501, T005, T108, 1854, S008, T003, Turunen J: 1843, 34504, 3632, S020, 3562, F122 T010 Tyler C: 36201, F001 Terai N: F013 Tynninen O: 2742 Terreni E: S030 Tzamos G: F031 Terzidou C: T096 Urcelay JL: F061, F073 Teus M: S067 Urtti A: 36406, S088 Teus MA: 33507, S055, S106 Usai D: T116 Thabit A: 34510, S062 Ushan O: F096 Thapa R: 35501, T005, S008, 1854, T108 Usubov E: S058, S059, S066 Theodora Hadjistilianou: 2941 Utheim O: S038 Theodoropolou S: 33506, T117 Utheim T: 1732, S038 Theodossiadis G: T047, T050 Uusitalo-Järvinen H: T009 Theodossiadis P: T047, T050 Uusitalo H: 1452, 1855, T009 Thibaud M: T092 Uwineza A: 2161 Thieme D: 2632 Vachova V: S017 Thiery T: T086 Vaflard P: 3636 Thomas Lavaud A: F075 Vähätupa M: T009 Thouvenin O: 2912 Vakros G: S021 Thuret G: S052, S070, 3567, 3611, 3613, F129, S002, Valadares J: 3514, 36205, F005, F011 S018, S026, S027, S028, S042, S051, S063, S069, S071, Valença A: S092, S101, S102 S072, S073, S074, S075, S076, S077, S078, S079, S080, Valiente-Soriano FJ: 3616, T100, 36210, 3653, S109, S110, T112 F010, F038, T099 Thygesen J: 36206, F006 Valiokas R: S011 Tideman W: 2154 Van Beek J: 3445 Tiedemann D: 36211, F012, F040, F036 Van Bergen T: T011 Tigchelaar I: 33305, F104 Van Den Berg TJ: 2351, 3422 Timonina A: T003 Van Dijk P: F014 145

All authors

Van Doorn R: 3631 Vlaykova T: F032 Van Ginderdeuren R: 2343 Vohra R: 36211, F012, S095, S097, F040 Van Hoefen Wijsard M: 1845 Volha Y: T068, T084 Van Hove I: 2722 Von Livonius B: F085, F087 Van Laar T: F059 Vontress M: F028 Van Leeuwen FE: 1845 Votruba M: 1832, 2364, 3524 Van Lint M: F084 Vukojevic N: S116 Van Rij C: 3445 Vulpetti A: F068 Van Slycken A: T121 Waagepetersen H: S095 Van Slycken M: T121 Wadhwa S: 3515, T006 Van Verre H: 3424 Wahyu MS: 33303, F102 Van Vught L: 3441 Waizel M: 33306, F105 Van Calster J: 2141, 2341, 2623 Walker L: F019, 36202, F002 Vanclooster A: T120 Wallace D: 36203, F003 Vandelli G: F068 Wallace VA: 2652 Vanderhulst J: T119 Waseem N: 3164 Vandewalle E: F084 Wasyluk J: F025 Varandas G: F062, F098 Watala C: S100 Vasileias D: T096 Wawrzonkowski P: T107 Vaskevich G: T084 Webb A: 3442 Vaudaux J: 2114 Webster AR: 3164 Vega-Estrada A: S024, S056, S061 Wedenoja J: 34504, S020 Veiby N: T041 Weiss SL: S031 Velpandian T: 3515, T006 Werkmeister R: 3651, T097 Vera LF: F028, F029 Weston K: F019 Verdijk RM: 3633 Willermain F: 2142, T119 Verhoeven P: S079, S080 Williams P: 2323 Verjans G: 2333 Winiarczyk M: S100 Verrecchia S: S111, T092 Witek P: T107 Verticchio Vercellin AC: F057, F060 Witkowska K: 3651, 3652, T097, T098 Vibæk Jensen J: 36211, F012, F036 Wojtyniak A: T107 Vicente A: S013, F094 Woo SJ: T081 Vicente C: 1442 Wood J: 3151 Vidal-Sanz M: 1743, 2653, 2654, 3616, 36210, 3653, Wowra B: 1733, 1732, 1734 3654, 3655, 3656, F010, F037, S091, T099, T100, T101, Wylegala A: S099, S044 T102, T103 Wylegala E: 2132, S044, 1732, 1734, 2131 Vidiendal Olsen N: 36211, F012 Xiao P: 2912, 34505, 35502, S025, T013 Vieira L: T034 Xirou T: 3114, T076, T047, T071, T096 Vieira M: 34509, S053, T057 Xu H: 35507, T039 Viestenz A: 2611 Yahiaoui S: 2955 Viiri J: 36406, S082, S088 Yamamoto Takiuti JH: 33501, 33505, T110, T115 Vila Franca M: 35506, T027, T018, 1815, F062 Yamane K: 33311, F112 Viladés Palomar E: 33309, F066, F082, F110, T044, Yanchenko S: S064 T046, F092, F093, T045 Yang E: F033 Vilades E: F071, F072, 33308, F069, F070, F107 Yap T: 3521 Villa-Collar C: 33507, S106 Yavuzyigitoglu S: 3445 Villain M: 3142, F021 Yekta AA: 3568, F127, S054 Villani E: 2521, 3612, S037, S039 Yekta R: 3568, F127, S054 Villega-Perez MP: F038 Yildiz E: S009, S010 Villegas-Pérez MP: 3653, T099, 36210, 3655, 3656, Yilin Z: 2761 F010, T102, T103 Yubero R: T090 Vilotte JL: 2664 Zagrebneva M: T060 Vincent E: 33506, T117 Zajicova A: S015 Virgana R: 33303, F102 Zanetti S: T116 Vispe E: T109 Zarei-Ghanavati S: S054 Vlaykova D: F032 Zasa G: S007 146

All authors

Zaynetdinov A: S066 Zhioua Braham I: T020, T021, T026 Zhioua R: T020, T021, T026 Zhou JH: S012 Zhou L: 1451 Zimak Z: 33304, F103, S116 ZiniauskaitE A: 35501, T005, S011, 1854, T003, T010, S008 ZmorzyNski S: S100 Zografos L: 1813, 2645, 2714, 2944 Zsolt Nagy Z: 1433 147

Authors by country

Algeria...... 3 Armenia...... 2 Australia...... 6 Austria...... 6 Belarus...... 2 Belgium...... 28 Brazil...... 4 British Virgin Islands...... 1 Bulgaria...... 1 Canada...... 6 Croatia...... 3 Cyprus...... 1 Czech Republic...... 9 Denmark...... 15 Finland...... 39 France...... 128 Germany...... 43 Greece...... 23 Hungary...... 5 Iceland...... 1 India...... 3 Indonesia...... 4 Iran...... 3 Ireland...... 4 Israel...... 2 Italy...... 43 Japan...... 3 Norway...... 8 Poland...... 18 Portugal...... 41 Russia...... 12 Singapore...... 4 Slovenia...... 2 South-Korea...... 29 Spain...... 94 Sweden...... 7 Switzerland...... 40 The Netherlands...... 20 Tunisia...... 22 Turkey...... 4 Ukraine...... 2 United Arab Emirates...... 4 United Kingdom...... 93 United States...... 28 EVER 2018 SPONSORS and EXHIBITORS

SILVER SPONSORs CIS SPONSOR

SIS SPONSORS EXHIBITORS WEDNESDAY, OCTOBER 3

08:00 - 17:45 JM EUPO Course 2018 on Retina, Intraocular Inflammation & Uveitis Hermes

HERMES Rhodes 1 Rhodes 2 Rhodes 3 Rhodes 4 Gallieni 1&2

08:30 - 08:45 P Welcome by the President EVER 2018 - BRON A Hermes

08:45 - 09:15 P EVER-Acta Lecture: OCT-A all what we need? - SOUBRANE G Hermes

09:15 - 10:30 EUPO Course 2018 G/ACB - Novel models to study EOVS - Basic principles of MBGE - I have received a mutation ACB - How to study mitochondria G/COS - Ocular surface in on Retina, Intraocular Inflammation glaucomatous neurodegeneration state-of-the-art ophthalmic report for my patient, but i don’t function, structure and clearance? glaucoma – why bother? & Uveitis instrumentation know what it means! KOLKO M - IRSCH K - LISKOVA P - KAARNIRANTA K - NORMANDO EM - JM SIS CORDEIRO MF C BERNARDES R C DUDAKOVA L C BLASIAK J SIS RATNARAJAN G

10:30 - 11:00 SOC Coffee break Exhibition area

11:00 - 11:30 KN EVER Lecture: Ocular Inflammation - delivered by the Past President - DICK A Hermes

11:30 - 12:45 EUPO Course 2018 G/LC - P+p (phaco ‘plus’ procedures) COS - Corneal nerves in health and PBP - Cone photoreception in huma ACB - Proteomics- a tool to find rele- IM - Don’t miss the diagnosis! how on Retina, Intraocular Inflammation - revolutionising glaucoma care disease retina: structure and functional vant biomarkers for ocular diseases, to survive against the worst enemies & Uveitis & closure evaluation of the human fovea drug development and safety in your daily practice BLOOM P - GALLAR J - DE LA VILLA P - UUSITALO H - NERI P - JM SIS AHMED F C KOVACS I SIS VIDAL-SANZ M C BEUERMAN R SIS KHAIRALLAH M

12:45 - 14:00 CIS Lunchtime CIS: Nothing to fear about Demodex - JAMES T Rhodes 2 , O ctober 4 , O ctober 4 14:15 - 14:45 KN Keynote Lecture: An eye on aging and disease - APTE RS Hermes

14:45 - 16:00 RV - Bionic eye - where are we now? G/LC - Simulated ocular COS/ACB - Aniridia-associated PBP - Pathogenic role of the micro- ACB - Crosstalk of mitochondria MBGE - Controversies in surgery - part II keratopathy (aak): from disease glia in neuroretinal diseases and lysosomes in the degeneration epidemiology: beneficial or harmful mechanisms to treatments of rpe effects of nutritional supplements in the prevention of AMD? THUR sday THUR sday LYTVYNCHUK L SUNARIC MEGEVAND G - LAGALI N - RAMIREZ JM - KAARNIRANTA K - GRAW J - SIS SIS PRIOR FILIPE H SIS WYLEGALA E SIS VIDAL-SANZ M SIS UUSITALO H SIS MCCARTY C

16:00 - 17:00 SOC Coffee break Exhibition area

16:00 - 17:00 SOC Coffee with Profs Poster area

16:00 - 17:00 POS Poster session: Retina/Vitreous - Physiology/Biochemistry/Pharmacology - Immunology/Microbiology Poster area

17:00 - 18:15 RV - Oct-angiography biomarkers in G - Laser treatments for glaucoma G - YOS - Landmark papers in PO - Genetic predisposition ACB - Ocular surface as a target for MBGE - Grand rounds in animal & choroidal and retinal disease -old headlines or breaking news? ophthalmology – how to do one! syndromes in ophthalmology drug development human genetics BAILLIF S - CRAWLEY L - JóHANNESSON G KIVELÄ T - UUSITALO H - LEROY B - SIS SOUBRANE G SIS AMEEN S C SIS MOURIAUX F SIS BEUERMAN R SIS GRAW J

18:30 - 19:30 SIS Evening SIS: What does TFOS DEWS II bring to your clinical practice? - ROLANDO M Rhodes 2

08:30 - 09:45 SIS RV - Ischemic ocular diseases: G - Maximising information extrac- COS - Optical imaging techniques for IM - Therapeutic update: biologic LC/RV - New approaches in myopia MBGE/NSPH - Understanding retinal raise the red flag! tion from biological data the cornea and anterior eye segment agents in uveitis diagnosis, prevention and treatment ganglion cell loss — from genes to – pearls and pitfalls disease mechanisms

AMBRESIN A - DAVIS B - SZENTMARY N - VAN CALSTER J - GRZYBOWSKI A - VOTRUBA M - SIS POURNARAS JA SIS NORMANDO EM C WYLEGALA E SIS BODAGHI B SIS ASCASO F SIS YU-WAI-MAN P

09:45 - 10:15 KN Keynote Lecture: The Axon is dead: long live the Axon! - LEVIN L Hermes

10:15 - 10:45 SOC Coffee break Exhibition area

10:45 - 12:00 RV - Laser photocoagulation of G - EVER Obergurgl optic-nerve- COS - Diagnosis and treatment of IM/PO - Uveitis: translational insights LC - Optical and refractive changes LC/MBGE - Cholesterol, oxysterols capillary macro-aneuvrysms in conference symposium 2017 infectious keratitis in the clinical in invasive diagnostics with aging and eye disease retinal vascular diseases practice today DUPAS B - GRUS F - SZENTMARY N - VAN CALSTER J - MICHAEL R - QUINLAN R SIS PAQUES M SIS CROWSTON J C SEITZ B SIS VAN GINDERDEUREN R SIS ROZEMA J SIS

12:00 - 12:30 KN European Ophthalmology Heritage Lecture: A brief history of cataract surgery - DE LAEY JJ Hermes

12:30 - 13:30 CIS Lunchtime CIS: Innovations & Novel Products in Ophthalmology (INPO) Hermes

12:30 - 13:30 SIS COS/MBGE - TFOS DEWS II: Dry Eye redefined - VILLANI E - SULLIVAN DA Rhodes 1

12:30 - 13:30 CIS Lunchtime CIS: GuangDong Ophthalmologist Association (GDOA) Rhodes 3

13:30 - 14:45 RV - Macular interface surgery G/IM - The latest update on uveitic COS - New approaches for unmet PO - Conjunctival tumors PBP/ACB - Modern tools to examine MBGE - New insights in ocular glaucoma needs in anterior segment diseases the retina developmental dysgenesis PAPPAS G - POURJAVAN S - FUCHSLUGER T - DESJARDINS L - VIDAL-SANZ M - CALVAS P - SIS POURNARAS JA SIS NERI P SIS FERRARI G C MOULIN A SIS SALINAS NAVARRO MA SIS ROZET JM

14:45 - 15:45 SOC Coffee break Exhibition area

FRIDAY, O ctober 5 FRIDAY, 14:45 - 15:45 SOC Coffee with Profs Poster area O ctober 5 FRIDAY,

14:45 - 15:45 POS Poster session: Glaucoma - Neuro-ophthalmology/Strabismology/Paediatric/History - Electrophysiology, physiological Optics, Vision Sciences - Molecular Biology/Genetics/Epidemiology Poster area

15:45 - 16:15 Business Meeting Business Meeting Business Meeting Business Meeting Business Meeting Business Meeting BM RV/LC BM G/EOVS BM COS/NSPH BM PO/PBP BM IM/MBGE BM ACB

16:15 - 17:30 RV - Advanced oct and G - Neuroprotection in glaucoma – COS - Translational concepts in PO - Orbital inflammation ACB/COS - Scleral contact lenses: MBGE - Gene regulation in eye oct-angiography in challenging cases challenges and opportunities ophthalmology hands on - fitting, maintenance & development and disease clinical advantages - it´s no magic !

POURNARAS C - DAVIS B - JUENEMANN A - MOURIAUX F - KNOP E CVEKL A - SIS ZOGRAFOS L SIS DE GROEF L SIS SEITZ B C KIVELÄ T SIS SIS KOZMIK Z

17:30 - 18:00 KN Keynote Lecture: Microarchitecture and timeline of geographic atrophy: the x,y,z,t of AMD - CURCIO C Hermes

18:00 - 19:15 RV - Adaptive optics: clinical NSPH - From Francisco de Goya´s COS - Keratoconus – from molec- PO - Intravitreal pharmacotherapy in ACB/COS - Keratoconus in all its NSPH - Understanding ocular applications and beyond eyesight difficulties to famous one- ularbiological background through ocular oncology states under a contact lens anterior dysgenesis phenotype eyed warriors corneal stabilization to keratoplasty genotype PAQUES M - GRZYBOWSKI A - SZENTMARY N - ZOGRAFOS L - KNOP E - BREMOND-GIGNAC D - SIS GRIEVE K SIS ASCASO F SIS SEITZ B SIS DESJARDINS L SIS MEKKI MB SIS ATILLA H

19:15 - 19:45 GA EVER General Assembly Hermes

08:30 - 09:45 RV - Controversies in new technol- G - Ocular imaging in glaucoma COS - Visual rehabilitation in OOG Ocular Oncology Group I - ACB/RV - Functional hypoxia in the MBGE - The role of non-coding ogy for the diagnosis and manage- keratoconus beyond keratoplasty Ocular adnexa, imaging and eye: a role for hypoxia-inducible variants in ocular disease ment of retinal and choroidal disease intraocular tumors factors

PAPASTEFANOU V - GARHOFER G - GATZIOUFAS Z - HEEGAARD S - ANDRE H - LISKOVA P - SIS XIROU T SIS SCHMETTERER L SIS SZENTMARY N JM KIVELÄ T SIS KAUPPINEN A SIS DE BAERE E

09:45- 10:15 KN Ophthalmic Research Lecture: DARC Development and Translation - CORDEIRO MF Hermes

10:15 - 11:15 SOC Coffee break Exhibition area

10:15 - 11:15 POS Poster session: Cornea/Ocular Surface - Anatomy/Cell Biology - Lens and Cataract - Pathology/Oncology Poster area

11:15 - 12:30 RV - Management of proliferative ARVO@EVER - Advances in EOVS - Rapid Fire session OOG Business Meeting IM/LC - Rapid Fire session MBGE - Genetic models to human diabetic retinopathy glaucoma ocular diseases PAPPAS G - CORDEIRO MF - LAWRENSON J - HEEGAARD S PICHI F - NERI P - ASHERY-PADAN R - SIS POURNARAS JA SIS BRON A RF CASTELO-BRANCO M JM RF MICHAEL R - BARRAQUER R SIS ABERDAM D , O ctober 6 , O ctober 6 12:30 - 13:45 FAN Club EOVS - Scattered light and visual SOPREF - Eyelid and orbital tumors: OOG Ocular Oncology Group II - COS - Rapid Fire session Women in EVER function diagnosis, treatment and biomarkers Uveal melanoma VAN SCHOONEVELD M NAGRA M - LAGIER J DESJARDINS L - GICQUEL JJ - VOTRUBA M- JM SIS BARBUR JL SIS JM ZOGRAFOS L RF SZENTMARY N JM KAWASAKI A

13:45 - 14:15 SOC Coffee break Exhibition area day SATUR day SATUR

14:15 - 15:30 Young investigators’ award session I G/NSPH - Biomarkers in PO - New treatments in eye LC/COS - Customized intraocular RV - Rapid Fire session MBGE - Rapid Fire session ophthalmology and beyond melanomas lenses – challenges and limitations POURJAVAN S - NORMANDO EM - JAGER MJ - LANGENBUCHER A - POURNARAS JA - LISKOVA P - RF NERI P SIS CORDEIRO MF SIS MOULIN A SIS EPPIG T RF POURNARAS C RF GRAW J

15:30 - 16:45 Young investigators’ award session II G - Rapid Fire session PO - Genetics in uveal melanoma ACB - Rapid Fire session PBP - Rapid Fire session Update in ophthalmology

FUCHSLUGER T - NORMANDO EM - HEEGAARD S - KAUPPINEN A - OSBORNE N - RF BARRAQUER RI RF POURJAVAN S SIS KILIC E RF KAARNIRANTA K RF VIDAL-SANZ M JM

16:45 - 18:00 P Prize Award Ceremony & Closing Remarks Hermes

BM Business Meeting KN Keynote lecture ACB: Anatomy / Cell Biology MBGE: Molecular Biology / Genetics / Epidemiology

C Course SIS Special Interest Symposium COS: Cornea / Ocular Surface NSPH: Neuro-ophthalmology / Strabismology / Paediatric / History

CIS Industry Sponsored Symposium SOC Social EOVS: Electrophysiology / Physiological Optics / Vision Sciences PBP: Physiology / Biochemistry / Pharmacology

RF Rapid Fire session POS Poster session G: Glaucoma PO: Pathology / Oncology

GA General Assembly P Plenary session IM: Immunology / Microbiology RV: Retina / Vitreous

JM Joint Meeting LC: Lens and Cataract SOPREF: Société Ophtalmologique Plastique Reconstructive et Esthetique Française